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Canonical Wnt signaling is one of the most extensively studied signaling cascades, with 
a multifunctional role in development and disease. Activating mutations in β-catenin, the 
key regulator of this pathway, have been observed in many types of cancer. The general 
hypothesis is that, all these activating mutations in β-catenin affect the protein turnover 
and localization, and thus aberrantly activate the Wnt target genes that are capable of 
modulating multiple aspects of tumourigenesis. Although various residues in β-catenin 
were found to be mutated in different cancer types, a detailed analysis of the individual 
mutations has been lacking so far.   
In this project, firstly I sought to explore the frequency and distribution of mutations in the 
β-catenin gene across different cancer types using the COSMIC (Catalogue of Somatic 
Mutations in Cancer) database. The analysis of the β-catenin mutational spectrum 
revealed a preferential selection of different residues and amino acid substitutions among 
the different cancer types. This specific selectivity of mutations indicated a difference in 
phenotypic effect from different β-catenin mutations. Furthermore, through "saturation 
mutagenesis" of the β-catenin hotspot region (L31-G50) and by generating independent 
clonal cell lines harbouring various substitution mutations at the selected top six β-catenin 
residues through "multiplex targeting", I tried to understand whether or not there exists a 
genotype-phenotype correlation among the β-catenin mutations. Using these 
complementary experimental approaches, I convincingly demonstrated the presence of 
an allele specific β-catenin activity level conferred by these mutational variants, which 
cannot be explained by the current model of β-catenin regulation. 
The results of this study imply a fundamental difference between these mutations, the 
existence of a genotype-phenotype correlation based on β-catenin activity, and 
challenges the prevailing dogma of β-catenin regulation, thus emphasizing the need to 






Genes are functional units of DNA, many of which code for proteins responsible for 
controlling the various functions of a cell. A number of these processes are controlled by 
a coordinated network of protein-protein interaction referred to as signaling pathways. 
Often, genes encoding the proteins of these signaling pathway are susceptible to 
mutations (changes in the DNA sequence) which when remained unrepaired may result 
in various diseases including cancer. Analysis of the DNA sequence of tumour samples 
from different types of cancers have revealed mutations in various genes including the 
gene encoding the β-catenin protein which is an important component of the Wnt 
signaling pathway. 
The current accepted model of β-catenin activity is based on an all or none response 
governed solely by the stability of β-catenin protein. The β-catenin mutations observed in 
many types of cancer are all considered to affect the stability of the protein and have the 
same effect. However my analysis of β-catenin mutations revealed that different tumour 
types have preferential selection of mutations. This preferential selection indicates the 
presence of a specific mutation-effect correlation.  
In this project, I studied this mutation-effect correlation among the β-catenin mutations. 
Our study was made possible by the advanced gene editing technique known as the 
CRISPR/Cas9 system. Using the CRISPR/Cas9 system I was able to change the normal 
β-catenin gene to create the different mutations artificially in the genome of mouse 
embryonic stem cells. By creating the different mutations in the β-catenin gene using the 
CRISPR/Cas9 system and analyzing the activity corresponding to each variant, I was 
able to show the existence of differences in β-catenin activity response among the various 
mutants. In conclusion, this study lays a strong ground work and highlights the 
importance of the variation in functional outcome resulting from the specific mutations in 
the different cancer types in not only understanding their role in process of cancer but 
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Deregulation of cellular signaling is central to the multistep process of tumourigenesis, 
largely resulting from malfunctioning of the key mediators of the circuitry. Studies over 
the years, have revealed the underlying genetic and epigenetic changes in various 
components of the signaling cascades, which lead to the deviation from normal 
physiology, and have also highlighted their crucial role in the acquisition of characteristic 
cellular advantages to cancer cells. The most significant among them being, the gain of 
function and loss of function mutations in 'proto oncogenes' and 'tumour suppressor 
genes', respectively, that code for the major mediator proteins of cellular processes. The 
genetic alterations in these genes are especially crucial for hijacking the multiple 
mechanisms key for neoplastic transformation, including the process of cell proliferation 
and cell death. Characterization of the tumorigenic potential of the aberrant counterparts 
of cellular oncogene and tumour suppressor genes have not only provided key insights 
into the disease pathogenesis, but in addition helped to further understand the role of 
these mediators in the regulation of the molecular mechanism of cellular signaling 
pathways. The advancements in the genome engineering techniques such as the 
Clustered Regularly Interspersed Palindromic Repeat/CRISPR associated protein 9 
(CRISPR/Cas9) system have provided the perfect platform for such investigations. In this 
view, this project is an attempt to understand the genotype-phenotype correlations in the 
oncogenic protein β-catenin, and further envisage the yet unresolved mechanistic details 
governing the β-catenin mediated signal transduction cascade. 
1.2 The Wnt signaling cascade  
The diverse role of Wnt signaling in embryonic development and maintenance of adult 
homeostasis is coordinated by a network of multiple receptors, ligands, phosphokinases, 
phosphatases, secondary metabolites, G proteins and various other proteins 
orchestrating the Wnt mediated signaling cascades. The role of the majority of these 
mediators in Wnt signaling, and their importance in development, have been understood 
through the functional studies of their respective homologues in model systems, including 
Drosophilla, Xenopus laevis, C elegans and Mus musculus.  
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In the year 1982, using the method of proviral tagging, Nusse and collagues identified 
the proviral integration site of mouse mammary tumour virus (MMTV) to be within the Int1 
(int for integration) locus in multiple tumour samples, making Int1 a putative proto-
oncogene activated by viral integration (Nusse and Varmus, 1982). The oncogenic 
activity of Int1 was later confirmed by the tumour initiating effect of Int1 transgene under 
the transcriptional regulation of MMTV (Varmus, 1988). The conservative nature of Int1 
gene allowed identification of Int1 homologue in Drosophilla, that was later mapped to 
the Wingless (Wg) gene responsible for segment polarity (Rijsewijk et al., 1987). To avoid 
confusions in nomenclature, the Int1 and Wg members were named Wnt-for Wingless 
related integration site (Nusse et al., 1991). Wnt is a large gene family consisting of 
variable number of Wnt related genes in different species. In mammals, 19 Wnt related 
genes have been described, expressing the secretory Wnt proteins with distinct 
developmental roles (Garriock et al., 2007). 
The biogenesis of Wnt (Fig 1-1) involves a complex process, including the crucial 
palmitoylation by the membrane bound O-acyltransferase protein porcupine in the 
endoplasmic reticulum (ER) (Kadowaki et al., 1996). This post translational modification 
of Wnt proteins is necessary for both secretion, and its interaction with Frizzled receptor 
(Bazan and de Sauvage, 2009). 
4 
 
           
Figure 1-1: Biogenesis of Wnt. The translated Wnt proteins are modified in the ER by the 
membrane bound porcupine and then transported to the golgi apparatus, where the WIs//Evi act 
as chaperones and assist the transport of the modified Wnt proteins across the golgi to the 
extracellular space.  
Once transported to the golgi apparatus, the lipid modified Wnts are recognized by 
Wntless/Evenness Interupted (WIs/Evi). Acting as chaperones, WIs assist trafficking of 
Wnt proteins across the trans golgi network to the plasma membrane (Port and Basler, 
2010). Binding of various Wnt ligands to its cognate receptor Frizzled, induces the 
activation of both canonical and non-canonical signaling cascades. To date, a diverse 
range of Wnt mediated, β-catenin independent non canonical pathways have been 
described of which the planar cell polarity pathway and the Wnt/Ca2+ have been studied 
extensively.  
The structured organization of the cellular architecture, requires directional alignment or 
polarization for localization of specific components, or performing specified functions, and 
the Wnt mediated planar cell polarity pathway plays a key role in coordinating these 
polarization events. The Wnt ligand, acting through Frizzled receptor, activates various 
downstream components, including Dishevelled (Dsh), which in turn activates the Rho 
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family of small GTPases including Rho and Rac, each of which then activates the ROCK 
and the JNK/P-38 type MAPK, respectively. The coordinated effort of these mediators is 
required for directional alignment of various structures, including hair follicles, sensory 
bristles, actin skeleton organization, and also in migration of dorsal mesodermal cells 
during gastrulation. The Wnt/Ca2+ pathway, acting through the phosphotidyl inositol 
signaling coupled to G-protein, triggers the release of Ca2+ from the ER, and these 
second messengers activate Ca2+/ CaMKII and PKC, which in turn are responsible for 
activating the transcription factors enhancing expression of various genes. The Wnt/Ca2+ 
pathway is known to play an important role at various stages of gastrulation and 
organogenesis (Komiya and Habas, 2008). These non-canonical pathways do not act 
independently and there exists consistent cross talk between the β-catenin mediated 
canonical and non-canonical pathways, specifically the reciprocal interaction between the 
two cascades, involving various different mechanisms have been a subject of 
investigation in multiple contexts during both development and disease (Veeman, 
Axelrod and Moon, 2003; Toyama et al., 2010). 
1.2.1 Wnt/β-catenin mediated signalling 
The canonical β-catenin mediated Wnt signal transduction pathway is one of the most 
extensively studied signaling cascades, with a multifunctional role in development and 
disease (Clevers, 2006). Absent in single cell organisms, the Wnt/β-catenin pathway 
evolved as early as in the sponges and is conserved across metazoa from the lower 
invertebrates to higher mammalian species (Croce, 2008). A large number of mediators 
of this pathway have been attributed with either tumour suppressor or oncogenic 
properties, owing to which, the pathway is subjected to high regulation at various levels, 
thus highlighting the importance of Wnt signaling in maintenance of normal tissue 
homeostasis (Polakis, 2000, 2012).  
Central to the canonical Wnt signaling cascade is the β-catenin protein. Being a 
multifunctional protein, β-catenin is sequestered in different cellular compartments on 
account of the differential roles performed by this protein. In mammals, the proto 
oncogene CTNNB1 encodes for β-catenin protein, and a major portion of the newly 
translated product of this gene associates with the cell membrane, where it acts as an 
adaptor protein, essential for cadherin mediated cell adhesion. The turnover of the 
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remaining pool of cellular and nuclear β-catenin is regulated by canonical Wnt signaling 
(Fig 1-2) (Willert and Nusse, 1998; Brembeck and Rosario, 2006).  
1.2.2 β-catenin in adherens junction 
Immunoprecipitation assays of Ca2+ dependent cell adhesion molecule uvomorulin (E-
cadherin) performed by two groups independently in the 1980s, resulted in co-
precipitation of three other proteins along with uvomorulin (Vestweber and Kemler, 1984; 
Peyrieras, Louvard and Jacob, 1985). Later, in 1989, Rolf Kemler and colleagues found 
these three proteins to be associated with the cytoplasmic domain of uvomorulin, possibly 
linking it to the cytoskeleton, and named them α β and Υ catenins (Catena in Latin 
meaning chain).The α β and γ catenins were found to be structurally related in various 
species, including the mouse, humans and avians, implicating a functional conservation 
across species (Ozawa, Baribault and Kemler, 1989). 
Furthermore, the elucidation of the molecular interaction of the cadherin-catenin complex, 
especially the more extensively studied E-cadherin, β and α-catenin interactions revealed 
that immediately following its synthesis, E cadherin associates with β-catenin through its 
cytoplasmic domain, and this interaction with β-catenin is essential for efficient exit of E-
cadherin from ER to the baso-lateral membrane (Chen, Stewart and Nelson, 1999). 
Following membrane trafficking, the E-cadherin- β-catenin complex interacts with α-
catenin (Hinck et al., 1994). It is well established that α-catenin has binding sites for actin 
(Rimm et al., 1995). However, contrary evidence exists whether or not α-catenin 
physically links the E-cadherin β-catenin complex to actin filaments. Studies have 
suggested the presence of a dynamic interaction of α-catenin with actin filament that is 
mutually exclusive to binding β-catenin, owing to the specificities conferred by the 





Figure 1-2: Canonical Wnt signalling cascade. In the membrane, β-catenin, acts as an adaptor protein essential for cadherin mediated cell 
adhesion. The turnover of the cytosolic and nuclear pool of β-catenin is mostly regulated by canonical Wnt signaling. The current canonical 
Wnt pathway is based on the on and off model, where in the absence of Wnt ligand, β-catenin is sequestered in the destruction complex and 
is sequentially phosphorylated at the serine and threonine residues which in-turn tags it for ubiquitin mediated proteosomal degradation. In the 
absence of β-catenin, the TCF/Lef transcription factors are bound by repressors such as Groucho thus preventing the expression of Wnt target 
genes. Binding of the Wnt ligand to the heterodimeric receptor leads to the stabilization of β-catenin which then translocates to the nucleus 
and interacts with TCF/Lef transcriptional factors activating the expression of Wnt target genes.
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Although the intricate molecular details remain inconclusive, it is widely accepted that the 
core cadherin-catenin complex along with additional catenins, including p120-catenin, 
plakoglobin/γ-catenin, and various other junctional proteins, contribute to the formation 
of adherens junction, conferring cell-cell interaction through reorganization of the actin 
cytoskeleton mediated by α-catenin. The stability of E-cadherin based adherens junction 
is regulated by phosphorylation/dephosphorylation at various residues of the interacting 
proteins, including E-cadherin, β-catenin and p120-catenin (Bertocchi, Rao and Zaidel-
bar, 2012). The phosphorylation especially at the tyrosine residues 142, 489 and 654 in 
the armadillo repeat of β-catenin inhibit the protein-protein interactions with α-catenin and 
E-cadherin, respectively (Roura et al., 1999; Piedra et al., 2003; Winter, Shasby and 
Shasby, 2008). 
1.2.3 β-catenin protein structure 
The characterization of protein structure has helped to deduce the pleiotropic association 
of β-catenin with various components involved in both cell adhesion and signal 
transduction. Biochemical assays studying the crystal structure of β-catenin complexed 
with binding partners including T-cell factor (TCF), inhibitor of β-catenin and TCF (ICAT), 
Beta-trasducin repeat-containing protein-S-phase kinase associated protein 1 (β-TrCP-
Skp1), adenomatous polyposis coli (APC), Axin and E-cadherin, have helped to pinpoint 
exact domains and inter molecular bonding specificities required for protein-protein 
interactions. 
In humans, the CTNNB1 gene (41.02Kb – Ensemble Human GRCh38) consisting of 14 
coding exons is translated into a 781 amino acid product, yielding a primary structure 
composed of three main domains – the NH2 terminal domain, the central armadillo repeat 
domain and the COOH terminal domain (Fig 1-3). The highly conserved central Armadillo 
repeat domain consists of 12 arm repeats, each of approximately 42aa that forms three 
alpha helices linked by short loops (Riggleman, 1989; Huber, Nelson and Weis, 1997). 
The helices of the 12 continuous repeat units form a right handed superhelix, and in 
course a positively charged shallow groove is generated with potential binding surface 
for a number of β-catenin interacting proteins. The positively charged surface of the arm 
repeat domain, specifically the groove of the superhelix, is the predominant binding site 
for a majority of β-catenin partners involved in cell adhesion and Wnt signaling. The 
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binding sites for a large number of these proteins, including E-Cadherin, APC, TCF and 
the Wnt signaling inhibitor ICAT overlap with each other, and hence the interaction of 
these proteins with β-catenin is known to be mutually exclusive (Xu and Kimelman, 2007). 
In addition, the arm repeat domain forms the binding site for various co-activators and 
inhibitors of canonical Wnt signaling, making it a major focal point for interaction with β-
catenin. 
Although the three dimensional crystal structure of arm repeat domain has been studied 
in detail, not much is known about the N and C terminal domains. However, the N and C 
terminal domains are known to be negatively charged. A part of the C-terminal domain 
forms an alpha helix known as helix C, which in turn caps the hydrophobic residues of 
the 12th arm repeat (Xing et al. 2008). The crystal structures obtained from β-catenin 
peptide complexes with β-TrCP have indicated the presence of a short helical structure 
even at the N-terminal domain (Megy et al., 2005). The N-terminal domain DSGφXS motif 
phosphorylated at the two serine residues 33 and 37 is the major recognition and site of 
contact for β-TrCP, which ubiquitinates β-catenin, flagging it for proteosomal degradation 
(Wu, Xu, B. a. Schulman, et al., 2003). In addition, the extended helix present prior to the 
first arm repeat at the distal end of the N terminal domain (residue 118-146) provide 
binding sites for α-catenin (Pokutta and Weis, 2000). 
The exact binding specificities of the C-terminal domain is yet to be resolved, however, 
β-catenin C-terminal domain and Gal4 fusion based artificial reporter systems have 
demonstrated this region to be a transactivation domain. Furthermore, the requirement 
of C-terminal domain in lymphoid enhancer-binding factor 1 (Lef1) mediated signaling by 
in vivo study in Xenopus laevis, complemented these findings, establishing the role of C-
terminal domain as a scaffold domain for binding of transcriptional factors (Wetering et 








Figure 1-3: β-catenin protein domain structure. The N-terminal domain consists of the 
regulatory residues important for β-catenin stabilization and also contains binding site for α-
catenin. The twelve armadillo repeats are the major hub for binding of majority of the interacting 
proteins including E-cadherin, BCL9, Axin, APC and ICAT. The C-terminal domain is known to be 
the transactivation domain of β-catenin. 
1.2.4 On/Off model of Wnt/ β-catenin mediated pathway 
According to the current on and off model of Wnt signaling, the kinase dependent 
ubiquitin mediated proteosomal degradation of β-catenin is the key regulatory event 
governing the stability of β-catenin, which in turn helps in maintaining low cytoplasmic 
level of this major downstream effector (Aberle et al., 1997). In the absence of Wnt 
signaling, the so called destruction complex, consisting of the scaffold protein Axin, the 
APC tumour suppressor protein and the two kinases glycogen synthase kinase3 (GSK3) 
and Casein kinase 1 (CK1), sequesters and phosphorylates β-catenin (Ikeda et al., 1998; 
Kishida et al., 1998; Sakanaka, Weiss and Williams, 1998; Liu et al., 2002). The initial 
phosphorylation of β-catenin by CK1 at residue S45 is the priming event for the 
subsequent GSK3β mediated sequential phosphorylation of residues T41, S37 and S33 
(Fig 1-4) (Liu et al., 2002). The phosphorylation of the two serine residues in the 
consensus degron motif DSGφXS is especially considered to be crucial for the 
recognition and interaction by the F box protein β-TrCP, a component of the E3 ubiquitin 
ligase complex (Hart et al., 1999). This recognition of the doubly phosphorylated motif by 
the WD40 domain of β-TrCP is followed by ubiquitination and proteosomal degradation 
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of β-catenin, and in the absence of nuclear β-catenin, the TCF/Lef interaction with 
repressors such as Groucho/TLE prevents the expression of Wnt target genes, keeping 
the pathway switched off (Hart et al., 1999; Cadigan and Waterman, 2012).  
 
Figure 1-4: Regulation of β-catenin stability by sequential Phosphorylation and β-TrCP 
mediated proteosomal degradation. The initial phosphorylation of S45 by CKI acts as a priming 
event for sequential Phosphorylation of T41, S37 and S33 by GSK3β, forming the recognition site 
for β-TrCP, which then mediates ubiquitin tagging and thus flagging β-catenin for proteosomal 
degradation. 
The canonical Wnt pathway is activated by binding of the secretory Wnt proteins to the 
serpentine (G protein coupled) receptors Frizzled and the single pass LRP5/6 co-
receptors, which belong to the low density lipoprotein receptor family (Macdonald and 
He, 2012). Ligand binding to the heterodimeric receptor induces conformational change 
and phosphorylation of LRPs (Liu et al., 2003; Zeng et al., 2017). The recruitment of the 
effector protein Dsh and the Axin bound destruction complex by the activated receptor is 
known to play a crucial role in mediating β-catenin stability, however, the exact molecular 
mechanisms governing the stability of β-catenin upon activation of the pathway remains 
elusive, and is subject to controversy (Zeng et al., 2017). Various different models have 
been proposed on the mechanism of stabilization of β-catenin, a common theme being 
the inhibition of β-catenin degradation, resulting in its cytosolic accumulation (Gerlach et 
al., 2014). The cytoplasmic β-catenin is then translocated to the nucleus where it 
competes with the Groucho/TLE repressors for TCF/Lef binding site, and on interaction 
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with TCF/Lef, it acts as a transcriptional co-activator, leading to the expression of Wnt 
responsive genes and turning the pathway on (Daniels and Weis, 2005). However, the 
mechanism of shuttling of β-catenin between cytoplasmic and nuclear compartments 
again remains unclear. Reports suggests that, in the absence of a nuclear localization 
signal (NLS), β-catenin directly binds to the nuclear pore complex without the requirement 
for classical transport proteins, such as importin and Ran (Fagotto, Glück and Gumbiner, 
1998; Yokoya et al., 1999).  
The bipartite transcriptional function of TCF/Lef is mediated by binding to various 
activators and co-repressors, acting likely through the chromatin remodeling ability of 
these direct/indirect binding partners. The covalent modifications, especially tinkering the 
acetylation and methylation state of the chromatin, plays a significant role in modulating 
the target gene transcription. Binding of the histone acetyltransferase (HAT) encoding 
proteins CBP/P300 to the C-terminal transactivation domain of β-catenin, results in 
increased acetylation of H3 and H4 subunits of the histone moiety, and enhances the 
transcriptional activation of Wnt target genes (Parker et al., 2008). In addition to covalent 
modification, the Brg1 of the SWI/SNF complex, acting through their intrinsic ATPase 
domain are capable of remodeling the histone (Barker et al., 2001). In addition, H3K4me3 
catalysed by MLL/Set1 family of methyltransferases bound to β-catenin induces an open 
chromatin mark (Sierra et al., 2006) (Wend et al., 2013). The N terminal transactivation 
domain of β-catenin is also known to recruit adaptor protein Bcl9. The Bcl9 protein 
mediates the interaction between Pygopus and β-catenin, and this interaction is known 
to promote transcriptional activation. Studies suggest that Pygo 2 acts as a scaffold 
facilitating RNApol II mediated transcription of Wnt target genes, either indirectly by 
recruitment of the mediator complex, or by direct interaction with the transcription factor 
II D (TFIID) subunit of the basic transcriptional machinery (Carrera et al., 2008; Wright 
and Tjian, 2009). Given the significance of Wnt signaling in a myriad of physiological 
processes, the target genes under direct transcriptional control of canonical Wnt signaling 
are differentially regulated by the coordinated action of the β-catenin interacting nuclear 
transcriptional machinery, thus orchestrating the activation of gene expression in a 
context dependent manner. The list of Wnt target gene is constantly increasing in 
number, and in addition to regulating the expression of proteins that govern the observed 
pleotropic effects of Wnt signaling, few of the mediators of the signaling cascade are 
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themselves targets of Wnt/β-catenin mediated signal transduction. The scaffold protein 
Axin2/Conductin is one such target gene under the control of Wnt signaling, and 
upregulation resulting from increased Wnt activation observed in tumours, is known to 
constitute a negative feedback loop, which in turn represses the Wnt cascade (Lustig et 
al., 2002).  
In addition to the feedback mechanisms, Wnt signaling is modulated by the regulatory 
action of various antagonists and agonists. The six major secreted antagonist including, 
secreted frizzled-related protein (Sfrp), Wnt inhibitory factor 1 (WIF1), Cerebrus, 
Wise/Sclerostin (SOST), insulin- like growth factor-binding protein 4 (IGFBP4) and 
Dickkopf 1 (DKK1), can be classified into two families based on their ability to either 
directly bind to Wnt, or to the Frizzled and LRP5/6 co receptors. In addition to secreted 
antagonists, multiple transmembrane bound proteins including Shisa, Waif1/5T4, APC 
down-regulated 1 (APCDD1) and Tiki1 are also known to negatively regulate Wnt 
signaling. Norrin and R Spondin are two of the well characterized agonist, activating Wnt 
signaling by binding to the Frizzled LRP complex, or the Leucine-rich repeat-containing 
G-protein coupled receptor 4/5 (LGR4/5) receptors, respectively (Kawano, 2003; Cruciat 
and Niehrs, 2013). 
1.3 Wnt signaling in cancer 
Since the initial discovery of oncogenic activation of Int1 by insertion of MMTV, capable 
of initiating mammary tumours and adenocarcinomas in the mouse, several activating 
and loss of function mutations in various components of the Wnt signaling cascade have 
been reported in different cancer types. 
The tumour suppressor gene APC was identified through its ability to induce colorectal 
adenomas (benign polyps) observed in variable numbers ranging from hundreds to 
thousands in familial adenomatous polyposis (FAP) patients. FAP is an inherited 
autosomal dominant disorder, and without surgical intervention the benign condition 
invariably progresses to malignancy. In addition to germline mutations in FAP, APC 
mutations have been frequently observed in sporadic colon cancers (80 percent), and to 
a lesser extent in other cancer types including desmoid, pancreas, stomach, breast and 
other cancer types. Majority of the APC mutations are confined to the 5' carboxy termini 
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with germline mutations distributed across the region, as opposed to somatic mutation 
specifically accumulated in the mutation cluster region (MCR), and most of these 
mutation results in protein truncation (Mori et al., 1992). 
The scaffold protein AXIN, another negative regulator of Wnt signaling has also been 
found to be mutated in various cancer types. Both variants AXIN1 and AXIN2 have been 
found to be mutated in hepatocellular carcinomas (HCC) and hepatoblastomas. The 
detection of loss of heterozygosity (LOH) associated with AXIN1 in HCCs confirms the 
requirement of two-hits, validating its function as a tumour suppressor in these cancers 
(Taniguchi et al., 2002). Mutations in AXIN1/2 have also been reported in colorectal 
cancers (CRCs), and frameshift mutations in the exon 7 of AXIN2 are particularly 
associated with a subset of CRCs with defective mismatch repair (MSI-H) (Liu et al., 
2000). 
Furthermore, the transcriptional regulator TCF4 have been observed to be frequently 
mutated in CRC with defective MMR (Duval, Gayet and Zhou, 1999). In addition to TCF4, 
mutations in transcriptional co-activators such as p300/CBP have also been reported in 
various solid tumours, as well as in certain lymphomas and leukemias (Iyer, Özdag and 
Caldas, 2004). 
1.3.1 N terminal activating mutations in β-catenin – a common 
occurrence in cancer  
The oncogenic potential of β-catenin was initially characterized based on the ability of N-
terminally truncated β-catenin to transform NIH3T3 cells, implicated by the formation of 
transformed foci in a retroviral based complementary DNA (cDNA) library screen that 
identified 8 other novel oncogenes (Whitehead, Kirk and Kay, 1995). Over the years, 
small scale sequencing projects carried out by several independent groups have reported 
mutations in the β-catenin proto oncogene occurring at various frequencies in human 
tumour samples analysed from different tissue types having dominant activating function, 
thus validating the criterion of defining β-catenin as a 'proto-oncogene'.   
The N terminal domain of β-catenin particularly involving the exon 3 region is highly 
susceptible to mutation (Saleem et al., 2017). The N terminal interstitial deletions, 
majority of them involving the exon 3 region, are rare, and have been observed in certain 
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primary colorectal and hepatocellular carcinomas. A low frequency of β-catenin 
truncation mutations in colorectal carcinomas and adenomas was reported by Iwao et al. 
and Murata et al. in two groups of Japanese patients with only around 3 percent of them 
found to be carrying large interstitial deletions in the CTNNB1 gene. The mechanism 
leading to these observed deletion mutations is not clear, but the presence of inverted 
repeats at both ends of the breakage site indicate a possible involvement of somatic 
rearrangement (Iwao et al., 1998; Murata et al., 2000). 
In addition to the interstitial deletion in the exon 3 region, activating β-catenin mutations 
(mostly missense) at various residues have been reported in a number of primary human 
tumours. The exon 3 region consisting the regulatory sequences is known to be the 
mutational hotspot of CTNNB1, and numerous studies based on single strand 
conformation polymorphism and sequencing of the exon 3 region have been successful 
in delineating the precise missense substitutions in various cancer types.  
Although loss of function mutation in APC is the leading cause of colorectal cancers, 
missense mutations at the phosphorylatable S and T residues have been reported in a 
subset of tumours with wild type (WT) APC. The mutual exclusivity of APC and β-catenin 
mutations is attributed to the common outcome of mediating β-catenin stability, leading 
to the TCF dependent transcriptional activation (Sparks et al., 1998). 
Similar activating β-catenin mutations affecting the GSK3β phosphorylation sites are 
observed in hepatocellular carcinoma. In addition, mutations surrounding the 
phosphorylatable S33 residue, particularly the D32 and G34 that are required for ubiquitin 
mediated proteosomal degradation were found to be commonly mutated (Miyoshi et al., 
1998; Omagnolo, Illuart and Nge, 1998; Legoix et al., 1999). A strong correlation between 
nuclear expression and mutation in the β-catenin gene has been observed in these 
tumours (Mao et al., 2001). The β-catenin target gene GLUL, encoding glutamine 
synthetase (GS) is often used as a marker for characterization of β-catenin mutations in 
HCC (Austinat et al., 2008b). In addition, mutations in β-catenin have also been known 
to increase the production of bile and cholestasis and together with GS expression have 




Ovarian tumours especially of the endometroid subtype are particularly susceptible to β-
catenin mutations with frequent nuclear accumulation of the mutant protein. The residues 
D32, S33, G34, S37, T41 and S45 have been reported to be mutated. The combined 
frequency of these activating mutations is around 30 percent in these primary 
endometrioid adenocarcinomas. Although variations exists between different subtypes, 
studies by Gamallo et al., suggests increased nuclear expression of β-catenin to correlate 
with a favourable prognosis (Gamallo et al., 1999). The differential expression by RNase 
protection assay confirmed significant increase in the expression of five candidate target 
genes MMP7, CCND1, CX43, PPAR-δ and ITF2 in a panel of 15 tumour samples with 
deregulated β-catenin (out of which 13 tumours had mutations in the β-catenin 
phosphorylatable S and T residues) compared to 17 tumours with WT β-catenin (Zhai et 
al., 2002). However, the expression of c-myc was unaltered between the two groups. The 
same group also identified FGF9 as a Wnt target gene that was upregulated in ovarian 
endometrioid adenocarcinomas with deregulated β-catenin (Hendrix et al., 2006). 
The earliest identification of the presence of missense mutations in the exon 3 region of 
β-catenin oncogene came from sequencing of a cell line from a melanoma patient, 
confirming the presence of a novel S37F substitution mutation (Robbins et al., 1996). The 
frequency of β-catenin mutations is very low in melanoma, however, a common form of 
skin tumour of the pilomatricoma type are known to harbor activating β-catenin mutations 
at increasingly high rates, present in around 61-75 percent of tumours (Chan et al., 1999; 
Saleem et al., 2017). The residues S33 S37 and T41 are the most commonly mutated 
residues with lower incidence of mutations at adjacent residues, including D32 G34, S47 
and G48. 
Sporadic desmoid tumours are another class of tumours in which increased incidence of 
β-catenin mutations have been reported. Around 70-90 percent of these tumours harbor 
mutations in β-catenin with the majority of the mutations confined to T41 (T41A) and S45 
(S45F and P) residues (Mullen et al. 2013) (Guellec et al., 2012). In an analysis of a panel 
of desmoid tumours, Lazar et al. have reported an increased risk of tumour recurrence in 
patients with S45F mutations, and presence of these mutations could hence act as 
prognostic tool for therapeutic intervention (Lazar et al., 2008). 
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Mutations specifically at residue S45 involving serine to phenylalanine and tyrosine 
residue and in-frame 3 base pair (bp) deletion of residue S45 have been observed in 
patients with Wilms tumour. Furthermore, these activating β-catenin mutations are 
frequently associated with mutations in the WT1 gene (Maiti et al., 2000). 
In addition to the tumour types above, mutations in the regulatory β-catenin residues (and 
adjacent residues) have been observed in cancers including CNS, bone, breast, salivary, 
kidney, adrenal gland, lung, pancreas and various other tumors in differing frequencies. 
Although the differences in the tumourigenic potential of these individual mutations has 
not been clearly established, the general hypothesis is that every activating mutation in-
turn governs the turnover and localization of this central mediator of Wnt pathway, making 
it refractory to regulation and thus activating the Wnt target genes capable of modulating 
multiple aspects of tumourigenesis. Among the target genes are c-myc, CCND1, MMPs, 
VEGF, FGF9, uPAR, PPARδ, AXIN2, all known to play significant roles in various stages 
of the tumourigenic process thus exemplifying the implications of deregulated Wnt 
signaling in cancer. 
1.4 Problems in the current on and off model of canonical 
Wnt signaling 
The widely accepted model of canonical Wnt signaling cascade is based on the activity 
response regulated by the stability of β-catenin protein. However, several evidences 
indicate the current model of β-catenin regulation to be incomplete. The investigation of 
the Wnt mediators, especially the analysis of the mutational spectrum of the APC tumour 
suppressor gene, and the subsequent functional analysis of the Apc allelic series were 
among the defining studies highlighting the drawbacks in the Wnt on and off model. The 
non-random and specific induction of a second hit in the APC tumour suppressor gene 
observed in intestinal tumours was shown to be dependent on the type of existing 
germline mutation. This selection bias was contrary to the random occurrence of the two 
hits proposed by Knudson's two hit theory. Although all the mutation combinations 
resulted in the truncation of APC, these different mutations were proposed to have 
retained residual β-catenin regulatory activity, albeit at varying strengths, determining the 
specificity of mutational selection, as opposed to the complete loss of function leading to 
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a single functional outcome. This mutational selection based on the tumour specific 
requirement known as the 'just right signaling model' provided a link between an optimal 
β-catenin activity level and cancer (Albuquerque et al., 2002).  
Modelling of APC tumour suppressor mutations observed in intestinal tumours and 
functional analysis in in vivo and in vitro systems have provided experimental evidence 
for this proposed model as to how the developing tumours select for an APC mutation 
according to the level of β-catenin activity. Using mouse embryonic stem cells, Kielman 
et al. have shown that the various inactivating mutations in the Apc tumour suppressor 
gene differed in their differentiation potential, determined by the specific β-catenin dosage 
conferred by the allelic variants (Kielman et al., 2002). Additional support to this model 
was provided by in vivo studies of mice tumours; the Apc allele (Apc+/1572T) with lower β-
catenin activity resulted in multifocal mammary tumours as opposed to the increased 
incidence of extra intestinal tumours including cutaneous cyst and desmoid tumours 
observed in Apc+/1638N with lower multiplicity of intestinal tumours. The reduced multiplicity 
of intestinal tumours in these Apc+/1638N mice that had an intermediate level of β-catenin 
activity differed phenotypically from the Apc+/min mice (with a high β-catenin activity) that 
primarily developed intestinal tumours with higher multiplicity (Gaspar et al., 2009). 
Furthermore, crossing the Apc1638N mice with heterozygous β-catenin knockout mice, 
and in effect reducing β-catenin signaling, altered the 1638N phenotype to the 1572T like 
phenotype, resulting in an increased incidence of mammary tumours. This experiment 
provided evidence to support the claim that different β-catenin signaling levels are the 
driving force behind these cancer phenotypes (Bakker et al., 2013).  
In addition to the mutational bias and differential β-catenin downregulating activity of the 
APC mutant allele, few observations suggests a similar genotype-phenotype correlation 
directly associated with mutations in the β-catenin proto-oncogene. The preferential 
selection of S45 mutation in Wilms tumour samples, accounting for about 90 percent of 
the tumours with β-catenin mutations, suggests a selection bias of specific mutations 
similar to those observed for APC tumour suppressor gene. The functional analysis of 
the β-catenin mutations by Provost et al, provided evidence of a differential phenotypic 
response conferred by of the four phosphorylatable residues (Provost et al., 2003). In this 
study, the stable over expression of alanine variants of S45 and T41 residue were found 
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to give rise to a more transformed phenotype in comparison to S37 and S33 variants. 
These results cannot be explained by the current model of regulation of β-catenin stability 
based on the sequential phosphorylation. In this regard, contrary to the sequential 
cascade, it has been shown that in colorectal cancer cells with S45 mutation, the 
phosphorylation of residues T41, S37 and S33 can still take place even in the absence 
of phosphorylation at residue S45 (Wang, Vogelstein and Kinzler, 2003). Taken together, 
these evidences strongly suggests the presence of additional regulatory mechanisms in 
controlling the β-catenin activity that remains to be understood.   
1.5 Gene targeting in mouse embryonic stem cells 
(mESCs) and transgenic technology 
In the 1980s, independent studies by Mario Capecchi and Oliver Smithies, provided the 
first evidence of active homologous recombination (HR) in cultured mammalian cells by 
their ability to replace or insert exogenous DNA sequence into the endogenous loci of 
interest (Smithies et al., 1985; Thomas, Folger and Capecchi, 1986). The most promising 
use of gene targeting was following the successful isolation of mouse embryonic stem 
cells by Evans and colleagues, and discovering that the reintroduction of ES cells into 
blastocyst following in vitro culture produced germline chimeras, opened exciting 
prospects for genetic engineering (Bradley et al., 1984). Gene targeting in mESCs 
followed by the generation of transgenic mice, together provided a perfect tool for 
studying various genetic conditions.  
Initially, targeting approaches based on homologous recombination strategies were 
tested on selectable genes. Particularly, the hypoxanthine-guanine 
phosphoribosyltransferase (Hprt) locus was a common target that allowed for phenotypic 
selection using the cytotoxic chemical 6 thioguanaine (Thomas and Capecchi, 1987). 
Later, polymerase chain reaction (PCR) based screening and enrichment strategies were 
incorporated that could be extended to non-selectable or even non-expressed genes. 
One such enrichment technique was the use of a positive negative strategy (PNS) 
described by Mario Capecchi in 1988, for successful targeting of the hprt and int2 gene 
in mouse ES cells (Capecchi, 1989). Enrichment for selection of targeted recombinants 
against random integration was achieved using neomycin (G418 based positive 
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selection) and herpes simplex virus type-1 – thymidine kinase (HSV1-tk ganciclovir based 
negative selection) selectable markers (Mansour, Thomas and Capecchi, 1988). 
Although these conventional gene targeting strategies had earlier proved to be standard 
tools for genome engineering and numerous knockout transgenic mouse models were 
successfully generated, the irreversible integration of selectable markers and the inability 
to control gene expression resulting in lethal phenotypes (due to presence and 
expression of mutant gene during early stages of development) were the two major 
drawbacks of this system.  
The introduction of conditional targeting using site specific recombinase technology 
based on the activity of recombinase enzyme of bacterial origin including CRE and 
flippase (FLP) have helped to overcome some of the drawbacks of earlier conventional 
targeting strategies. The regulated expression of these enzymes under tissue specific 
promoters along with inducible systems such as tamoxifen inducible oestrogen-LBD-
Cre/flp hybrid or use of inducible promoters such as tetracyclin (Tet) on/off system 
allowed spatio-temporal control of gene expression (Ryding, Sharp and Mullins, 2001).  
1.5.1 Enhanced genome editing using Designer nucleases  
The conventional gene targeting and conditional and inducible genome engineering tools 
are all based on the active HR. The HR mediated repair although provides an error proof 
system for precise in-situ gene manipulation, the low frequency of recombination events 
(1 in 106 – 109 cells) which results in reduced targeting efficiency has been a major 
drawback of experimental systems based on the HR repair pathway. However, deliberate 
introduction of double-strand breaks (DSBs) by I-SceI and other homing endonucleases 
have shown to increase the frequency of HR mediated repair up to a 1000 fold or more 
(Jasin, 1996). Although increased specificity can be achieved by the relatively long 
recognition sequences (14-40bp), the applicability of these homing endonucleases as 
genome engineering tools was significantly reduced due to the complex interaction with 
the target DNA involving 40-50 amino acid chains, making it difficult to modifying the DNA 
modular domain of these proteins.  
The increased targeting efficiency mediated by endonuclease induced DSB directed 
repair mechanisms have led to the characterization of similar customizable nucleases, 
including zinc- finger nucleases (ZFNs), transcription activator like effector nucleases 
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(TALENs) and CRISPR/Cas systems, providing valuable tools for precise editing of 
otherwise difficult to manipulate in-vivo and in-vitro systems. ZFNs are engineered 
nucleases constructed by combining the DNA binding specificity of the eukaryotic 
transcription factors zinc finger proteins (ZFPs) and the nuclease domain of the TypeIIS 
restriction enzyme FokI (Kim, Cha and Chandrasegaran, 1996). Based on the sequence 
of target DNA, the recognition domain of ZFNs can be constructed by modular assembly 
of an array of ZFPs usually consisting of 3-6 DNA binding Cys2His2 zinc finger domains, 
and selecting the appropriate fingers that have been developed for identifying a specific 
nucleotide triplet allows accurate recognition of the region of interest (Wright et al., 2006). 
However, as FokI functions as a dimeric complex incorporating two adjacent recognition 
sequences (Vanamee, Santagata and Aggarwal, 2001), the ZFN must be constructed to 
include two monomeric ZFP arrays recognizing 9/12 bp of target DNA separated by a 
spacer of 5-6 nucleotides between the two inverted recognition sequences. The two ZFP 
arrays (Mani et al 2005) allow appropriate recognition and heterodimerization of the 
nuclease essential for active DSB induction in the spacer region. 
Similar to ZFNs, TALENs have a customizable DNA binding domain again fused to the 
nuclease domain FokI enzyme. The highly conserved TALE are typeIII effectors secreted 
by bacterial plant pathogens of Xanthomonas sps and fuction as trancriptional activators 
of a variety of plant genes. The repeat domain of TALE consist of an array of repeats 
each 33-35 amino acid flanked by additional TALE sequences specifically recognizing a 
single bp of target DNA, and hence the number of repeats in the array corresponds to 
the length of the target DNA recognized (Boch and Bonas, 2010). The specificity of DNA 
recognition of each repeat in an array is conferred by the two hypervariable residues at 
position 12 and 13 often referred to as the repeat variable di-residue (RVD). Modular 
assembly using 4 RVDs each with preferential binding to A,G,T,C using various assembly 
strategies have been described and as FokI functions as a dimer, target specific TALEN 
pair each fused to a FokI monomer allows induction of DSBs (Boch and Bonas, 2010). 
Compared to ZFNs and TALENs which are based on protein-DNA interaction, the 
CRISPR/Cas system is based on the Watson-Crick base pairing rules henceforth making 




1.5.1.1 Genome engineering using CRISPR-Cas9 system 
The term CRISPR was coined by Mojica et al. and Jansen et al. to describe a class 
consisting of an array of direct repeats separated by short spacer sequences (known as 
protospacers in bacteriophages) (Jansen et al., 2002). The presence of these direct 
repeats initially described in 1987 in E. coli was later found to be a common feature in 
the majority of bacterial and archeal strains (Ishino et al., 1987; Mojica, F.J., Díez‐
Villaseñor, C., Soria, E. and Juez, 2000). Absent in eukaryotic genomes, these direct 
repeats and spacers were found to be well conserved, but varied in numbers across 
different strains. Importantly, the newly acquired spacer sequences were found to be 
similar to, and in-fact derived from extrachromosomal DNA such as phage replicons and 
plasmids, implicating the presence of a sequence specific nucleic acid based adaptive 
immunity against bacteriophage (Bolotin et al., 2005;. Mojica et al., 2005; Rodolphe et 
al., 2007). In addition, characterization of CRISPR loci revealed a close association with 
Cas genes that were almost always found located adjacent to these direct repeats, 
signifying a functional relatedness between the two (Jansen et al., 2002). Over two 
decades, genetic and biochemical studies have helped unravel the mechanistic details 
of the CRISPR Cas mediated bacterial immunity. 
The type II CRISPR system from Streptococcus pyogenes is the most extensively 
characterized system that quickly found applicability in genome engineering (Marraffini, 
2016). Initially, the direct repeats together with spacers of the typeII CRISPR loci are 
transcribed into a precursor CRISPR RNA (crRNA) array. After transcription, this pre-
crRNA array associates with its auxiliary partner the trans activating RNA (tracrRNA), and 
directs the RNaseIII dependent processing of the pre crRNA into mature crRNA, 
containing a 20 nucleotide guide and a part of the repeat sequence (by RNase III) 
(Deltcheva et al., 2011). The processed guide then associates with Cas9 protein forming 
an effector complex, and directs the Cas9 to the target locus (protospacer). However, the 
initial recognition of a protospacer adjacent motif (PAM) is crucial for the subsequent 
base pairing and Cas9 mediated induction of a DSB (Sternberg et al., 2014).The 
CRISPR/Cas9 system from S. pyogenes has a 5'NGG PAM requirement with the Cas9 
induced DSB occurring three base pairs upstream of the PAM motif. The detailed 
understanding of the mechanism of this bacterial adaptive immune system has helped to 
engineer programmable Cas9 nucleases that can be used to modulate the endogenous 
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activity of genes in virtually any organism. Using a two component system consisting of 
single guide RNA (sgRNA), designed by fusing crRNA and tracrRNA and a mammalian 
codon optimized Cas9, and only by altering the 20 nucleotide guide sequence, it is now 
possible to direct the Cas9 to the gene of interest in mammalian cells (Fig 1-5) (Jinek et 
al., 2012; Cong et al., 2013; Mali et al., 2013). 
  
Figure 1-5: Schematic representation of Cas9 nucleases guided by sgRNA. The Cas9 
nuclease from Streptococcus pyogenes is directed to the target site by the 20 nt guide oligo within 
the sgRNA followed by Watson Crick base pairing with the target sequence. The Cas9 then 
induces a double strand break 3 bp upstream of the PAM (5'-NGG). 
In addition to the wild type Cas9 nuclease described above, various variants have been 
described. A Cas9 'nickase' version called Cas9n with a point mutation in the D10 residue 
(D10A), rendering the RuvC domain inactive, but retaining the ability to induce single 
strand nicks by the active HNH domain was generated (Jinek et al., 2012). This Cas9n 
mutant, when targeted along with a pair of appropriately spaced offset guide RNA's, each 
directed towards opposite strands of the region of interest, induces a DSB while 
significantly reducing the off-target effects (Ran et al., 2013). The recently described high 
fidelity spCas9-HF1, with four substitutions (N497A,R661A, Q695A/Q926A) is shown to 
be capable of reducing off-target effects, while still maintaining a high degree of specificity 
(Kleinstiver et al., 2016). To overcome the constraints of the stringent requirement for an 
NGG PAM, for Cas9 recognition of target DNA, different variants with altered PAM 
specificities have been generated (Kleinstiver et al., 2015). The orthologues of Cas9 from 
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other bacterial species such as Staphylococcus aureus, Streptococcus thermophiles 
have also been characterized and engineered to recognize alternative PAM sequences, 
to increase the applicability of CRISPR Cas9 system to target a broader spectrum of 
sequences, and the smaller size of these enzymes provide added advantage of efficient 
delivery into in vivo systems by packaging into the adeno- associated virus (AAV)(Cong 
et al., 2013; Ran et al., 2015; Kleinstiver et al., 2015). 
Since its introduction, the RNA guided endonuclease activity of bacterial CRISPR/Cas9 
system has been harnessed in combination with the inherent cellular repair pathway of 
either non-homologous end joining (NHEJ) or homology directed repair (HDR), for the 
introduction of insertions deletions (indel), epitope tagging, or precise point mutations and 
has provided an efficient strategy for genome alteration both in in-vivo and in-vitro 
systems. In addition to gene editing, the CRISPR/Cas9 system can also be used for 
regulated gene expression. The catalytically inactive Cas9, termed dead Cas9 (dCas9- 
D10A/H840A mutant), targeted along with guide RNA is an effective strategy for 
repressing the expression of the known target gene. This strategy termed as CRISPR 
interference (CRISPRi) has been successfully used for gene silencing (Qi et al., 2013). 
The dCas9 fused to effector proteins, such as Kruppel associated box (KRAB) can be 
used to enhance the specificity of efficient transcriptional repression. Similarly, fusion of 
dCas9 to transcriptional activators, such as VP64 can be used for targeted gene 
activation (Maeder et al., 2014). The CRISPR/Cas9 system has also found applicability 
in inducing additional epigenome modifications, by coupling dCas9 to various effector 
proteins for changing the methylation state of the chromatin, and also for histone 
modifications (Huangfu and Raya, 2017). The wide range of applicability, complemented 
with the increasing availability of diverse variants and optimization strategies, has made 
the CRISPR/Cas9 system a robust tool for programming enhanced genome engineering 
strategies that can be tailored to the specific needs. 
1.6 DNA damage and repair response 
The loss of integrity of the macromolecular structure of DNA, a consequence of its 
susceptibility to the various endogenous and exogenous agents capable of inducing wide 
spread repercussions on the robustness of an organism is a common feature observable 
throughout its lifetime. The intrinsic susceptibility of glycosyl bonds to hydrolysis resulting 
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in apurinic sites, sensitivity to hydrolytic deamination (especially the nucleotide bases of 
cytosine and 5 methyl cytosine), oxidative stress induced by endogenous metabolities 
capable of generating various base lesions including transversions, conversions of 
pyrimidine to ring saturated forms, helical distortions, non-enzymatic S-
adenosylmethionine induced DNA methylation, are few of the many DNA lesions caused 
due to endogenous DNA damaging agents (Withers et al., 1993). Physical exogenous 
agents, including ionizing radiation are capable of inducing single and double strand 
breaks and exposure to ultra violet rays is capable of generating pyrimidine dimers with 
increased frequency. In addition, chemical agents such as chemotherapeutic drugs 
acting as either alkylating agents or by forming intra and inter covalent linkages contribute 
to the added genotoxic burden. These exogenous and endogenous DNA damaging 
agents, combined with the errors generated during the intrinsic replicative process, result 
in increased incidence of replicative stress leading to toxic cellular effects. However, each 
of these DNA damages trigger specific DNA damage response (DDR) events to restore 
the integrity and prevent the catastrophic effects of the unrepaired genotoxic lesions. 
Various DDR pathways have been described including, the well-studied mismatch repair, 
nucleotide exchange repair, base excision repair (BER), DNA double strand break repair 
pathways. These DNA repair pathways play a crucial role in maintaining the genomic 
integrity of an organism.  
1.6.1 DSB induced repair mechanisms 
Of the various DNA lesions, DSBs caused by nicks in complementary DNA strands are 
known to be highly genotoxic. The induction of DSB in DNA by extra or intra cellular 
agents triggers the activation of either one of the two major cellular repair pathways, 
namely: the error prone NHEJ, or the high fidelity HDR, both of which help maintain the 
structural integrity of the chromosomes (Pastink, Eeken and Lohman, 2001). The Ku 
mediated canonical NHEJ offers a higher mechanistic flexibility, the independent 
enzymatic activity of the nucleases, polymerases and ligases, in combination with 
iterative processing, contribute to the diverse array of junctional outcomes, including 
insertions, deletions, inversions and direct repeats at the break point. The NHEJ pathway, 
in addition, can operate in any stage of the cell cycle without the requirement of a 
homologous repair template making it a more frequent potentiator of DSB repair. 
However, homologous recombination, the most common form of HDR is functional during 
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the late S/G2 phase of the cell cycle due to the presence of sister chromatid that provides 
a preferred homologous template for HR mediated repair (Lieber, 2010). The resection 
of DNA ends determines the induction of repair by either NHEJ or HR pathways. In the 
case of NHEJ, the binding of the Ku protein prevents excessive end resection whereas 
resection of the 5' end at break point resulting in extended 3' single strand DNA (ssDNA) 
overhangs mediated by the MRN core complex is necessary for HR directed repair. The 
recombinase protein Rad51 assembly onto ssDNA, leads to the formation of a 
nucleoprotein filament that invades the homologous DNA forming the D loop structure. 
The D loop intermediate is then resolved by either synthesis dependent strand annealing 
(SDSA), or second strand capture, resulting in double Holliday junction that can be 
resolved by cross over and non-cross over events (San Fillipo, Sung and Klein, 2008). 
The RNA guided endonuclease activity of bacterial CRISPR/Cas9 system harnessed in 
combination with the inherent cellular repair pathway of either NHEJ or HDR, for the 
introduction of insertions, deletions or precise point mutation has provided an efficient 
strategy for genome alteration (Fig 1-6). 
              
Figure 1-6: Repair pathways induced by double strand breaks. DSBs induced by nucleases 
can either be repaired by NHEJ or HDR. The NHEJ pathway is an error prone mechanism that 
can introduce indels creating a premature stop codon that may result in gene knockout. 




1.7 Aim of my thesis 
The current model of β-catenin activity is based on the stabilization of the protein, which 
in turn is coupled to the kinase dependent sequential phosphorylation of the serine and 
threonine residues. According to this model, the phosphorylation of the S45 residue by 
CK1 acts as a priming event, which leads to the GSK3 mediated phosphorylation of the 
T41, S37 and S33 residues. Once the last two residues have been phosphorylated, a 
docking site for the E3 ubiquitin ligase is formed, and β-catenin is marked for degradation. 
Since this is a sequential cascade, mutations at any of these residues result in the same 
outcome, i.e. the stabilization of β-catenin, and ectopic activation of the pathway. While 
this type of regulation mechanism suggests an equal selection of these mutations in 
tumours, this is not the case in Wilms tumours. In these tumours, mutations in the β-
catenin oncogene are largely biased towards one specific residue, S45, accounting for 
about 90 percent of tumours with β-catenin mutations. This preferential selection of the 
S45 residue implicates the presence of an allele specific phenotype, perhaps offering an 
advantage for this tumour type. Such selection over one specific residue, challenges the 
accepted mechanism, and raises the question as to whether or not there are phenotypic 
differences that these mutations confer.  
A link between an optimal β-catenin activity level and cancer has been previously 
described in intestinal tumours with a “just right signaling model” (Albuquerque et al., 
2002). Furthermore, subsequent  functional analysis of the Apc allelic series by both in 
vitro and in vivo approaches have provided evidence to support the claim that different 
β-catenin signaling levels are the driving force behind the observed cancer phenotypes 
(Kielman et al., 2002; Gaspar et al., 2009; Bakker et al., 2013).  
The evolution of cancers have long been known to follow the Darwinian principles of 
selection. According to this selection paradigm, mutations in cancers are selected for 
their ability to confer the optimal phenotypic advantage to tumour cells. The specific 
selection of the S45 mutation not only imply the presence of such selective force in Wilms’ 
tumours, but suggests that this could also be observed in other tumour types with β-
catenin mutations. The widely accepted current model of β-catenin regulation cannot 
explain how these mutations would lead to different phenotypes, and there must exist 
other, yet to be identified, players in this complex pathway. The weakness of this model 
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has already been exposed by Wang et al, using an S45-mutant colorectal cancer cell line 
to show that T41, S33 and S37 phosphorylation still occurs in the absence of 
phosphorylation at the S45 residue (Wang, Vogelstein and Kinzler, 2003).  
The Wnt/β-catenin mediated pathway, in-spite of being one of the most extensively 
studied signal transduction cascades, still remains a Pandora's Box, and detailed 
characterization of β-catenin, the central switch of the pathway, is especially necessary. 
Over the years, in vivo and in vitro modelling of diseases have not only revealed the 
functional correlation of the genetic consequences, but have also provided deeper 
insights into the mechanism of some of the key regulatory aspects governing the 
signaling circuitry.   
With this in mind, the main aim of my project was to develop an in vitro system to generate 
and analyse all of the mutations observed in the CTNNB1 gene. The compelling evidence 
coming from cancer genetics, and from the literature, suggest an urgent need for this, 
and great advances in genome editing technology in recent times have provided an 
invaluable tool with which to dissect these mutations. Understanding the allele specific 
consequences of each of the different mutations observed in the CTNNB1 gene across 
cancer types will provide a better perspective of the functional and regulatory aspects 
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The revolutionary genetic and evolutionary principles of nineteenth century biologists 
Mendel and Darwin, remain the basis for our understanding of various biological 
processes, including the multistep process of tumourigenesis. The concepts and 
principles of these great visionaries, and their intricate observations, till date, remain to 
be of utmost importance. However, many observations and ideas of these visionaries, 
and their contemporaries remained descriptive, due to the lack of appropriate tools to 
prove their hypotheses. The technological advancements in the 20th century, especially 
in the field of molecular biology, following the seminal discovery of the double helical DNA 
structure by Watson and Crick, hugely complemented these theoretical principles, 
providing the tools to deconstruct the molecular framework and mechanistic details of the 
cellular processing unit.  
The sequencing techniques, including the chemical sequencing introduced by Maxam 
and Gilbert and dideoxy/chain termination method by Fredrick Sanger, played a huge 
role in deciphering the genome at the single nucleotide level (Maxam and Gilbert, 1977; 
Sanger, Nicklen and Coulson, 1977). The availability of the entire genomic sequence for 
a number of organisms following the Human Genome Project, has provided the much 
needed reference sequence that greatly facilitated the detection of the precise genetic 
alterations underlying various anomalies, including cancer. The massively parallel and 
high throughput sequencing techniques have helped in identifying insertions, deletions, 
translocations, point mutations and other recently described phenomena such as 
chromothripsis and kataegis (Stephens et al., 2011; Nik-Zainal et al., 2012). Furthermore, 
sequencing techniques developed for uncovering the epigenetic and transcriptional 
regulation of gene expression, provide a newer dimension to our understanding of the 
cancer genome landscape (Meldrum, Doyle and Tothill, 2011) . 
Taking leverage of these technological advancements, various large scale sequencing 
projects have been initiated to screen patient tumour samples from different cancer types, 
for the genetic, epigenetic and transcriptional variation. A number of completed and 
ongoing projects including the Cancer genome project (CGP) by Welcome trust Sanger 
Institute UK, The Cancer Genome Atlas (TCGA) a joint venture by the National Institutes 
of Health (NIH) and the National Cancer Institute (NCI), The International Cancer 
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Genome Consortium (ICGC), a voluntary and collaborative effort from various countries, 
have all generated massive amounts of data that have been made publicly available 
(Forbes et al., 2009; Campo et al., 2010; Weinstein et al., 2013). In addition, various user 
friendly web based repositories including Catalogue of Somatic Mutations in Cancer 
(COSMIC), cBioPortal, Genomic Data Commons (GDC) dataportal and many such 
interactive platforms provide a comprehensive compilation from these large scale and 
various other smaller independent sequencing projects (Forbes et al., 2008; Cerami et 
al., 2014; Jensen et al., 2017) . 
With regard to β-catenin, various small scale independent sequencing projects have 
reported mutations in the exon 3 region of CTNNB1 in a variety of solid tumours. As 
expected, the four phosphorylatable serine and threonine residues that are known to play 
a significant role in stabilizing the β-catenin protein were found to be the common target 
of mutagenesis in different cancer types. In addition, sequencing studies have also 
revealed mutations at various other residues in the exon 3 region (Polakis, 1999, 2000). 
However, there were no reports on the inclusive analysis of frequency and distribution of 
mutations in the β-catenin gene across various cancer types. Prior to analysis of the 
genotype phenotype correlation of β-catenin mutations, an overview of the mutational 
distribution across cancer types was required. The availability of large scale cancer 
genome data for various cancer types has made this investigation of mutational spectrum 
of β-catenin oncogene possible. Hence, this chapter will provide an overview of the 
mutational spectrum of β-catenin across cancer, compiled from the COSMIC database.  
2.2 Results 
2.2.1 Analysis of mutational spectrum of CTNNB1 across cancer 
types 
COSMIC is a database of somatic mutations frequently observed in human cancers that 
has been extracted from the literature, and from various other large scale cancer genome 
sequencing projects, including CGP and TCGA (Forbes et al., 2010). Mutational data 
from cancer types, each having a minimum of 10 samples harbouring mutations in the 
CTNNB1 gene was compiled from COSMIC.  
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The initial observation of the distribution of various types of mutation in CTNNB1 from the 
COSMIC database showed an increased incidence of missense mutations. Although 
various mechanisms of genetic alteration exists, it has been documented that in a typical 
human tumour, around 90 percent of these mutations in known oncogenes are a result 
of missense changes (Vogelstein et al., 2013).This was also observed for the mutation 
distribution of CTNNB1 from the COSMIC database, with around 89 percent of them 
being missense mutation (Fig 2-1). Given that the majority of the mutations observed 
across the CTNNB1 gene were single nucleotide changes, I considered to analyse only 
these mutations across various cancer types. 
 
Figure 2-1: Distribution of various types of mutation in the CTNNB1 gene. Table and pie 
chart showing the frequency of the different types of mutation observed in CTNNB1 gene. Source: 
COSMIC database.  
The initial tabulation and comparison of frequency distribution between cancers revealed 
mutations in a wide range of target residues across the CTNNB1 gene. The serine and 
threonine residues which are phosphorylated by the destruction complex, were among 
the most frequently mutated residues, contributing to around 70 percent of mutations 
observed in the CTNNB1 gene (Fig 2-2). Of the 4560 CTNNB1 mutations recorded 
across various tumour types from COSMIC database, the highest number of mutations 
were observed at the T41 residue. Mutations at the T41 residue was present in 1135 
tumour samples, and this was closely followed by mutations at the S45 residue that was 
seen in 1092 tumour samples. Next, the two phosphorylatable serine residues S37 and 
S33, which are known to be the key sites for recognition by the ubiquitin ligase complex 
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occupy the third and fourth position, with 515 and 492 tumour samples bearing mutation 
at the S37 and S33 residues, respectively. The presence of mutations at the regulatable 
serine and threonine residues in over 2/3rds of the tumour samples, reflects the 
susceptibility of these residues to mutagenesis, and underlines the functional significance 
of phosphorylatable serine and threonine residues in maintaining the stability of the β-
catenin protein. 
 
Figure 2-2: Distribution of mutation at various residues in across the CTNNB1 gene. Table 
and pie chart showing the frequency of the different mutated residues in the CTNNB1 gene 
compiled from COSMIC database.  
However, the β-catenin mutations were not restricted to these sites. A large number of 
other residues adjacent to the serine and threonine residues, were also found to be 
commonly mutated. Particularly, the two residues D32 and G34, that are present 
immediately adjacent to the phosphorylatable S33 residue were found to be mutated at 
a relatively high frequency. The D32 mutations were seen in 452 tumour samples, and 
317 tumour samples harboured a mutation at the G34 residue. Both D32 and G34 
residues are known to be a part of the β-catenin degron motif, and the observed 
mutations might vary the specificities required for interaction with the E3 ubiquitin ligase 
complex. Furthermore, except for mutations at K335 and G245 residues, the rest of top 
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16 mutated residues were present between residues D32 and G50 in the exon 3 region. 
The residues I35 and H36 (that are also a part of the degron motif) were mutated in a 
considerable number of tumour samples. The mutations at residues P44, T40, K49, A43, 
S47 and G48 were observed in a variety of tumour types, but at a lower frequency. The 
presence of these very many allelic variants of β-catenin across various tumour types, 
observed due to mutations specifically confined to the region between L31 and G50, 
makes this region a mutational hotspot of β-catenin.  
2.2.2 Analysis of the mutation pattern at specific residues across 
different tumour types 
Analysis of the mutations at the hotspot region revealed a preferential selection of 
mutations at different residues among different cancer types (Fig 2-3). For example, the 
cancer types including the central nervous system (CNS) and pancreas are largely biased 
towards mutations at residues S37, S33, D32 and G34, contributing to an overall 97 and 
90 percent of the mutations observed in these tissue types, respectively. Whereas, 
tumours of the soft tissue, specifically selected for mutations at the T41 and S45 residue. 
The mutations at the T41 and S45 residues contributed to 58 and 39 percent of the 
mutations observed in soft tissue tumours, together accounting for 97 percent of the 
mutations in these tumours. The tumours of the soft tissue constitute the highest 
frequency of β-catenin mutations, with 1325 mutated tumour samples, and the major bias 
towards selection of T41 and S45 tumour samples exemplifies the existence of a 
preferential selection of mutation among different tumour types. In addition, other 
examples worth mentioning are the tumours of the adrenal gland and kidney that 
specifically select for mutation at residue S45. This specific selection of a single residue 
attributing to around 79 and 77 percent of the observed mutation in the adrenal gland and 






Figure 2-3: Graph representing the frequency distribution of the top 16+ other mutated 
residues across cancer types. The graphical representation of the CTNNB1 mutation data 
compiled from COSMIC database showing a preferential selection of different residues among 
different cancer types. 
2.2.3 Analysis of the mutational pattern of the amino acid variation 
across different cancer types 
Over the years, mutation data for various genes have focused mainly on the 'residue' 
being mutated, and little or no emphasis is given to the 'amino acid variant' that the 
residue is being mutated to. The overexpression studies for functional analysis of the β-
catenin mutants including S33, S37, T41 and S45 are mostly based on the analysis of 
one or very few amino acid variants of these residues, and all these mutations are often 
generalized to produce the active form of β-catenin (Morin et al., 1997; Provost et al., 



































































































































































































































































































biochemical properties of the 20 amino acids, and differences in their bonding specificities 
for inter and intra molecular interactions, each of these amino acids may vary in their 
functional attributes. This might result in preferential selection of specific amino acids at 
a particular residue among different tumour types. In addition to assessing the mutational 
pattern of the various residues across the exon 3 region, I decided to further analyse the 
amino acid variation at the individual residues across the different cancer types.  
Assessment of the COSMIC database revealed that, indeed for a given residue, different 
tumours showed preferential selection for the amino acid substitution, adding an 
additional layer of complexity. For example, among the 20 available amino acid variants, 
mutations at the T41 residue were largely confined to substitution to alanine and to a 
lesser extent isoleucine. In addition to T41A and T41I substitutions, few tumours also 
selected for T41S, T41N and T41P substitutions. However, except for these five amino 
acid variants, none of the other 15 amino acids were selected for among the various 
tumor samples. Among these T41 missense variants, the soft tissue tumours (99 percent) 
specifically selected T41A substitution, whereas tumours of the pituitary gland (95 
percent) largely selected for T41I substitutions (Fig 2-4). The mutations in the S45 residue 
in kidney cancers were substituted for by multiple amino acid variants including S45Y, 
S45P, S45F, S45C and also by S45 deletion, whereas the S45 mutation observed in soft 
tissue tumours specifically selected for S45F and S45P variants (Fig 2-5). This specific 
selection of different amino acid variants, imposes an additional criterion that must be 




Figure 2-4: Graph representing the frequency distribution of different amino acid 
substitution across cancer types at the residue T41. The graphical representation of the 
CTNNB1 mutation data compiled from COSMIC database showing a preferential selection of 




































































































































































































































































Figure 2-5 : Graph representing the frequency distribution of different amino acid 
substitution across cancer types at the residue S45. The graphical representation of the 
CTNNB1 mutation data compiled from COSMIC database showing a preferential selection of 




































































































































































































































































2.2.4 Assessment of the statistical significance of the observed β-
catenin mutations across different tumour types.  
Before commencing analysis of the biological significance of these mutations, it was 
important to determine if indeed these differences were statistically significant. For the 
purpose of further analysis, I mainly questioned: a) Which of the residues would be good 
candidates for further investigation, b) Which of the amino acid substitutions relating to 
the selected residues would be good candidates for further investigation. Statistical 
assessment was done by Dr. Helen Brown (senior statistician, The Roslin Institute). 
Statistical analysis was done assuming a null hypothesis of no differences in the expected 
proportion of mutations across different cancer types to test; a) Whether or not there are 
significant differences in the proportion of mutation (of a specific residue / amino acid 
substitution) across all the tumour types, and b) Which sites have an overall significant 
difference in mutation (of a specific residue / amino acid substitution) between tumour 
types.  
The top six mutations with an increased frequency among cancer types (T41, S45, S37, 
D32, S33 and G34) also differed in statistically significant (p<0.05) proportions across all 
cancer types (Appendix 1A). Also a significant difference was observed in the spectrum 
of mutations between tumour types (Appendix 1C). For example, tumour types such as 
CNS, pancreas, stomach and endometrium, described earlier were significantly enriched 
for mutations in D32, G34, S33 and S37 residues, whereas kidney, soft tissue and Large 
intestine showed a significant preferential selection for mutation at the S45 residue. 
Mutations at the T41 residue were significantly higher in soft tissue tumours. In addition, 
mutations at various other residues in the hot spot region including I35, H36, T40, A43, 
P44, G48 and K49, although observed in fewer tumour types, were found in significantly 
enriched proportions in the tumours in which they were present.  
Furthermore, analysis of the top six frequently mutated residues revealed statistically 
significant differences in the amino acid substitutions among cancer types (Appendix 1B). 
The T41 missense variants that were observed at differing frequencies, also differed in 
statistically significant proportions. The pituitary tumours were significantly enriched for 
T41I substitution, whereas the tumours of the soft tissue presented a significant 
enrichment for T41A substitution (Appendix 1D). Another mutation noteworthy of mention 
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are those observed in tumours of the salivary gland, the majority of the mutations 
observed in these tumors are T>C transition mutations at the I35 residue, resulting in a 
specific I35T substitution, that were again present in statistically significant proportions. 
The Liver tumours are another tumour type in which the I35 mutations are statistically 
significant. However, the I35 mutations in the liver largely selected for I35S substitution 
and not a single I35T variant was observed. 
This preferential selection of different residues and different amino acid substitutions 
among cancer types, implicate the probable existence of a fundamental difference 
between these mutations, thus validating the importance of understanding the genotype 
phenotype correlation among β-catenin mutations. 
2.3 Discussion 
Oncogenic conversion and deviation from the normal state requires the continuous 
acquisition of various genetic and epigenetic alterations, making the cancer genome 
landscape an evolving hub of mutations capable of providing selective advantages at 
multiple stages of the tumourigenic process. The cellular proto-oncogene required for 
regulated maintenance of the 'master clock of the cellular circuitry' - The cells intrinsic 
growth control machinery, is one of the highly susceptible targets for gaining the 
characteristic cellular advantages attributed to tumours. In the 1970s, viral integration 
was thought to be the major cause of oncogenic activation, however, since then a myriad 
of genetic mechanisms for activation of an oncogene have been described, and can be 
mainly classified into two major groups based on the elicitation of changes in either 
expression levels (regulatory) or structure of an oncoprotein (Pierotti et al. 2003). The 
quantitative changes resulting from multiple mechanisms including translocations and 
viral integration of oncogenes, placing them under ubiquitously expressing promoters, or 
by gene amplification, lead to constitutive gene expression. Furthermore, genetic 
alterations including insertions, deletions and missense mutations, can lead to subtle 
changes in the protein structure, and in addition large inversions and translocations are 
capable of producing a hybrid protein with altered functional role (Botezatu, 2016). 
Besides these genetic changes, epigenetic mechanisms including changes in DNA 
methylation pattern are capable of producing an altered state of oncogene expression 
(Cheung et al., 2009).  
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Detailed analysis of each of these genetic aberrations is of absolute importance not only 
in uncovering the mechanistic significance of the cellular transforming events, but also 
for targeted therapeutic interventions, and great strides in this direction have been made 
in the recent years. The advancements in sequencing platforms have greatly 
complemented the cytogenetic studies in underpinning the nuances of the mutational 
landscapes not limited by the scale of analysis, and account for the availability of tumour 
data at an unprecedented rate.  
Mutations in the proto-oncogene CTNNB1, which encodes for β-catenin have been 
reported in various tumours, however, there is a lack of comprehensive analysis of the β-
catenin mutational pattern in different cancer types. Taking advantage of the available 
tumour data from large scale sequencing projects, I selected one such web based 
repository, the COSMIC database, to analyse the mutational spectrum of CTNNB1 
across various cancer types.  
Non-random distribution of gain of function mutations localized to a particular domain 
referred to as mutational hotspots, exist in RAS, PIK3CA, IDH1 and many other well 
characterized oncogenes, leading to changes in the canonical confirmation of the protein 
and activation (Miller et al., 2015; Baeissa et al., 2017). Small scale sequencing studies 
of human tumours have reported the exon 3 region of CTNNB1 to be the mutational 
hotspot of β-catenin (Polakis, 1999, 2000). Our mutation data of the CTNNB1 gene 
across various cancer types revealed a similar pattern, with the majority of mutations 
localized near the regulatory residues between L31 and G50. The phosphorylatable sites 
were among the most frequently mutated residues, however, mutations were not 
restricted to the regulatory serine and threonine residues but were also observed at the 
surrounding residues making the entire stretch of the exon 3 region a susceptible target 
for mutagenesis. The frequency of mutation was lower at the residues surrounding the 
regulatable serine and threonine sites. Although observed at a lower incidence, these 
mutations may have a crucial role in the tumours in which they are present, and hence 
assessing the phenotypic consequences of each of the allelic variants is necessary. 
Until recently, there were no reports on the detailed analysis of the β-catenin mutational 
spectrum in different types of cancers. However, during the course of my PhD, Çelen et 
al. published a similar analysis of the β-catenin mutational pattern of the top six residues 
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across different cancer types from COSMIC database (Çelen et al., 2015). By performing 
hierarchical clustering, they were able to group the cancer types into two main clusters; 
cluster1 included tumour types that were biased towards mutation at residues D32, S33 
and S37, and with very low frequency of T41 and S45 mutations, and cluster 2 was biased 
towards mutation at T41 and S45 residues. A similar clustering or preferential selection 
of specific residues among different tumour types was observed in our study as well. 
These results suggest that the specific selection mutation confined to one or few 
residues, are a common feature in several cancer types harbouring β-catenin mutations. 
However, based on the current dogma of β-catenin activity, and considering the equal 
probability of occurrence of every observed mutation among different tissues, one would 
hypothesize a random distribution of mutations at the phosphorylatable serine and 
threonine residues across tumour types. This specific selection of mutations among 
different types of cancers, might imply an existence of fundamental difference between 
these mutations.  
Furthermore, as pointed out earlier, little emphasis is placed upon the analysis and 
functional importance of the different amino acid variants, and the majority of the 
phenotypic analysis of the mutant alleles are based on a single amino acid variant. The 
study by Çelen et al, included a brief account on the amino variants observed at the 
residues I35 and H36. However, the detailed analysis of amino acid variants across the 
frequently mutated residues was not performed. Our analysis of the COSMIC database, 
not only includes the mutational spectrum of different cancer types, but also provides 
additional information on the preferential selection of different amino acid substitutions, 
again indicating a selection bias based on functional significance governed by Darwinian 
principles. 
In addition to the Darwinian principle of selection of cancer specific mutations based on 
functional significance, various evidence indicate the presence of differing mutational 
processes contributing to the background mutational rate specific for each of the cancer 
types, to be another important factor that may lead to observed tissue specific mutational 
bias. The differences in the background mutational rate among different cancer types are 
attributed to the differences in sensitivity to endogenous and exogenous agents, and 
mutation inducing mechanisms operative in different tissue types (Pfeifer, 2010; 
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Alexandrov et al., 2013). In this chapter, a basic approach considering no mutational bias 
and assuming equal substitution rates among different cancer types was used while 
calculating the statistical significance of the tissue specific differences in the observed 
spectrum of mutations. However, owing to the importance of the tissue specific mutational 
pattern in determining the overall mutational rates, a detailed bioinformatics analysis was 
later undertaken inclusive of the background substitution rates and will be discussed in 
chapter 4.  
It remains to be understood whether the mutations seen in β-catenin proto-oncogene are 
selected for either based on functional significance, or by the existence of different 
mutation inducing mechanisms in different tissue types, or a combination of both these 
processes. However, it is important to understand the functional consequence of these 
observed mutations, with regard to its role in the tumorigenic process. Moreover, the large 
scale mutational data is of little significance, unless complemented with experimental 
approaches to uncover the underlying genotype-phenotype correlations, which presently 
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The detailed analysis of the COSMIC database revealed a preferential selection of β-
catenin mutations among different cancer types, suggesting a possible fundamental 
difference between these mutations. In order to investigate allele specific consequences 
of the various mutated residues in the β-catenin hotspot region (L31-G50 which cover 93 
percent of the total number of missense mutations observed across the different types of 
cancers), and to explore the functional significance of the individual residues across the 
region of interest, I decided to adopt two complementary approaches.  
In the first approach, I wanted to address our research question by hypothesizing that the 
differences in signaling activity can be a selective pressure that could lead to the 
observed variation in mutations. Recently, it has been shown that “saturation editing” 
combined with CRISPR/Cas9 provides a prospective way to analyse the functional 
significance of every nucleotide/amino acid residue within a short stretch of the genome 
(Findlay et al., 2014). Our analysis of CTNNB1 COSMIC data showed that the majority 
of the mutations are clustered around the conserved phosphorylatable serine and 
threonine residues, making this region a suitable candidate to perform saturation editing. 
Introducing all possible codon substitutions surrounding the phosphorylatable residues 
L31-G50 in a pool of mES cells, which carry a β-catenin activity reporter, allowed us to 
quantify the corresponding β-catenin activity for each substitution at single cell resolution. 
This unbiased approach also allowed us to compare the cancerous and non-cancerous 
mutations in the same region for their effect on β-catenin activity. 
Secondly, I generated mutant mES cell lines using CRISPR/Cas9 technology with 
“multiplex targeting”, and analysed them in vitro for β-catenin activity and the expression 
of the known target genes. For this, I selected the top six statistically significant mutations 
with all the significant amino acid substitution (4-5 amino acid substitution for each 
residue) from the COSMIC database analysis. By analyzing the most frequently mutated 
residues in stable cell lines, I tried to understand the reason for this preferential selection 
and its significance in different tumour types. 
These two approaches adopted to address our research question, multiplex targeting (in 
E14 mES cell line) and saturation editing (in TCF/Lef:H2B-GFP β-catenin activity reporter 
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mES cell line), were both challenging tasks and required a strategic and robust 
experimental set up. Both approaches required a similar system for the generation of 
endogenous mutations, and many strategies were common for both. Hence, in this 
chapter, a detailed view of the various optimization strategies adopted will be provided, 
highlighting their importance in either multiplex targeting, saturation editing, or both. 
3.2 Results 
3.2.1 mCherry pX458 CRISPR nuclease vector construction and 
validation of expression 
Given the large scale nature of our experimental approach, with the requirement of the 
generation of multiple variants, this project would not be feasible using conventional 
targeting approaches. Therefore, I decided to use the CRISPR/Cas9 system due to its 
simplicity in adapting for the target of interest, and increased editing efficiency with the 
aid of endonucleases. Among the various different systems available, I choose to use the 
plasmid based system that contains two main components; the Cas9 and the sgRNA with 
20bp user specific sequence to define the genomic target. A universal CRISPR nuclease 
plasmid (pSpCas9(BB)-2A-GFP- also called pX458)  was generated in Feng Zhang's lab 
that contains all the required components; Cas9, an oligo cloning site to insert the target 
specific 20 bp sequence, and the remainder of the sgRNA scaffold. This vector also has 
a GFP selection cassette, which allows selecting the transfected cells, increasing the 
targeting efficiency (Ran et al., 2013), and I expected to need such enrichment to reach 
the required efficiency for my project. As my reporter cell line was also based on GFP 
expression, for quantification of β-catenin activity in the saturation editing approach, it 
would not be possible to distinguish CRISPR transfected cells from the cells with β-
catenin activity. Therefore, to be able to sort CRISPR transfected cells, I replaced the 
GFP cassette in pSpCas9(BB)-2A-GFP with mCherry, using Gibson assembly. This 
cloning system was developed by Dr. Daniel Gibson, and it is based on having 
overlapping DNA fragments with an enzyme mix containing an exonuclease, DNA 
polymerase and DNA ligase in a single isothermal step (Gibson et al., 2009). Using this 
method, the PCR amplified mCherry fragment (amplified using primers having overlap 
with the vector) was cloned into the CRISPR nuclease (pSpCas9(BB)-2A-(pX458)), that 




Figure 3-1: Cloning of mCherry pX458 vector using Gibson assembly. The GFP pX458 vector was initially digested with EcoRI to remove 
the GFP tag. The mCherry tag was amplified using primers having sequence overlap with the pX458 vector. The overlapping backbone and 
insert fragments were cloned by Gibson assembly. 
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Colony PCR using primers specific for mCherry was performed to select for positive 
clones (Fig 3-2). Next, sequence verification revealed the correct insertion of the mCherry 
fragment in the vector. 
 
Figure 3-2: Colony PCR of mCherry pX458 vector. Agarose gel electrophoresis image of the 
Gibson assembly transformants screened by performing colony PCR using mCherry specific 
primers. PCR positive clones of expected band size (809bp) are indicated by arrows. Hyperladder 
100bp. 
To validate the expression of the mCherry reporter, and also to compare its expression 
to that of the existing GFP CRISPR vector, both vectors were transfected independently 
into E14 cells, and analysed by flow cytometry (Fig 3-3). Wild type E14 cells were used 
as a control to gate the GFP/mCherry negative population. Firstly, to gate the viable 
population from the dead cells, a dot plot of Forward (FSC) vs side scattering (SSC) which 
distinguishes cells based on the size (FSC) and the granularity or cellular complexity 
(SSC) was plotted. The P1 gate represents the viable population of E14 cells (3-1A and 
3-1E). The P1 gate was applied to the rest of the dot plots for analysis of viable cells 
alone. The P3 gate in the FITC-A vs SSC-A dot plot consists of GFP positive population 
which was ~20 percent of the total P1 (viable population) in the GFP pX458 transfected 
cells, validating the expression of GFP reporter, and was negligible in the mCherry pX458 
transfected cells as expected (Fig 3-3B and C). The P2 gate consist of mCherry 
population which was 17 percent of the total P1 population in the mCherry transfected 
cells, and was negligible in the GFP pX458 transfected cells (Fig 3-3F and G). Flow 
cytometric analysis thus confirmed the expression of mCherry, and also the transfection 




Figure 3-3: Validation of GFP and mCherry reporter expression in GFP and mCherry pX458, 
respectively. Flow cytometric analysis of the expression and transfection efficiency of GFP and 
mCherry pX458.  
3.2.2 Design and assembly of various guides targeting the exon 3 
region of β-catenin in GFP px458 and mCherry Px458 
Now that I had the mCherry pX458 vector, the next step was to design CRISPR guide 
sequences. For the purpose of saturation editing, a single guide that cuts in the centre of 
this region was preferred. However, as every guide may vary in their efficiency to induce 
DSB, six guides targeting this region covering the Ctnnb1 mutational hotspot (residue 
L31-G50) were designed to test and select the optimal guide (Fig 3-4). The guides were 
designed using the online CRISPR design tool provided by Zhang lab 
(http://crispr.mit.edu/). All six guides were assembled in both mCherry pX458 and GFP 
51 
 
pX458 using the protocol published by Ran et al. ( Ran et al., 2013). Briefly, a 20 bp guide 
RNA for the target region was ordered as oligos and ligated in to the backbone vector in 
a single reaction of digestion-ligation using BbsI restriction enzyme and quick ligase. The 
reaction was then transformed into Stbl3 competent cells and 3 colonies were randomly 
selected for verification for correct insertion by sequencing. 
 
Figure 3-4: Guides targeting exon 3 region of β-catenin. Sequence view of a part of exon 3 
region of β-catenin with the six selected guides that were assembled into mCherry pX458 and 
GFP pX458. 
3.2.3 Comparison of the editing efficiency (Indel frequency) of the 
mCherry vs GFP PX458 guides 
The efficiency of the 6 guides assembled in both mCherry pX458 and GFP pX458 to 
induce double strand breaks was analysed by performing a T7 endonuclease I (T7E1) 
assay. T7E1 specifically recognizes and cleaves mismatches in heteroduplex DNA, and 
hence is used to identify the presence of mutations. The presence of mutations in the 
CRISPR transfected cells is in turn indicative of the CRISPR editing efficiency, and T7 
assay is routinely used as a preliminary screening strategy for the detection of CRISPR 
editing efficiency. For identifying mutations by T7 assay, initially the PCR product 
covering the region of interest is denatured and reannealed to allow heteroduplex 
formation in the presence of mismatches. On digestion with T7EI that recognizes and 
cleaves the mismatches, presence of mismatches are visible as extra bands on agarose 
gel. 
For the purpose of analysing the editing efficiency of the designed CRISPRs, all the 
guides assembled in the GFP pX458 and mCherry pX458 were transfected into E14 cells 
and FACS sorted 24 hours post transfection. As this is a transient transfection, I had 
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previously tried sorting of transfected cells at various time points and the reporter signal 
was lost over the time course, and I  found that 24 hours post transfection results in 
optimal reporter signal in our experimental system (data not shown).The isolated genomic 
DNA from the sorted population was then used to amplify a 400bp region of exon 3. Next, 
the PCR product was denatured and reannealed to allow heteroduplex formation, 
followed by digestion with T7EI. The presence of mismatches were visible as extra bands 
on agarose gel (Fig 3-5A and B). The intensity of the bands were quantified using ImageJ 
software, and the indel percentage was calculated using the ratio of the cleaved bands 
to the total PCR product (Fig 3-5C). The T7 endonuclease results were comparable in 
both GFP pX458 and mCherry pX458, with slightly better editing efficiency in mCherry 
pX458 vectors. Among the six tested guides it was not possible to modify the PAM of 
guides g5, g35 and g8B. Hence, I selected the remaining three guides (g5, g19 and g9B) 
to test further for their HDR efficiency. The guide g19 was especially a good candidate 
for being in the middle of the region to be edited. In addition to the three guides tested 
here, I also included another guide g6 (2) that had been previously designed and tested 




Figure 3-5: T7 endonuclease I assay.  (A) Agarose gel of T7 endonuclease I assay of guides in 
mCherry pX458. (B) Agarose gel of T7 endonuclease I assay of guides in GFP pX458. (C) Tabular 
column showing the indel percentage of mCherry and GFP pX458. The two lanes for each of the 
6 guides (g3, g5, g8B, g9B, g19, g35) represents undigested (-) and T7 endonuclease I digested 
(+) PCR products. The CRISPR pX458 (either mCherry or GFP, respectively) backbone vector 
only transfected cells (without the guides inserted) were used as controls (c) for T7 assay. 
3.2.4 Generation of PAM mutant cell line  
Studies have suggested β-catenin mutations to be activating, and having a dominant 
effect. The mutation in a single allele is sufficient for the manifestation of the tumourigenic 
potential of this oncogene. Hence, studying the heterozygous condition would be more 
physiologically relevant, therefore I decided to generate heterozygous mutants; i.e. with 
one WT β-catenin allele and one allele harbouring the desired mutation. The initial 
strategy to achieve this, was to generate a cell line with a heterozygous synonymous 
mutation in the PAM region of the selected guide. The PAM sequence is necessary for 
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the recognition and subsequent Cas9 mediated cleavage of the target site, and an intact 
PAM in the targeted clones will result in repeated re-cutting and may lead to additional 
indels, and these NHEJ events would affect the β-catenin activity of that cell. If we could 
generate an allele that is not responsive to the editing guide, this would ensure that in 
every cell the activity is derived from one WT and one mutant allele, making the 
comparison between different cells more reliable. Hence, I initially strategized to generate 
a TCF/Lef:H2B-GFP clone with a heterozygous synonymous mutation in the PAM region.  
In this approach, an ssODN repair template with synonymous mutations in the PAM 
region for four of the selected guides (g5, g19, g6 (2) and g9B) was designed (referred 
as 4mutPAM oligo) (Fig 3-6A). However, as the TCF reporter cells were still being derived 
from the TCF/Lef:H2B-GFP reporter mice in the lab of Kat Hadjantonakis (Memorial 
Sloan-Kettering Cancer Center), I  tested  the targeting efficiency of the 4mutPAM  in E14 
cells along with g19 CRISPR that induces a DSB at the centre of the region of interest. 
The reason for mutating the PAM sites of all these 4 guides was to allow flexibility in the 
future as to which guides I can use in these cells. Although I had tested the editing 
efficiency of these guides, I did not know which one would be best for HDR efficiency. 
We had already known from our concurrent work that although 2 guides may have similar 
editing efficiency, the HDR efficiency can vary greatly. Furthermore, trying to introduce 4 
mutations at the same time, using a guide in the middle, would also give us information 
about the positional effect of the edit to the guides.  
146 clones were tested for correct integration by sequencing. The results showed that 
the editing efficiency of g19 CRISPR was 70 percent with 102 clones repaired by NHEJ 
events. The majority of the indels were very close to the cutting site. A single insertion of 
T nucleotide immediately next to the g19 cutting site was very common, especially among 
the homozygous NHEJ events, and 7 out of 15 clones had this T insertion. The remaining 
homozygous NHEJ events were all deletion of varying lengths. Various different indel 
events were observed among the heterozygous clones repaired by NHEJ, all close to the 
CRISPR cutting site. Although a very good rate of editing was observed, the targeting 
resulted in a very poor frequency of HDR events (Fig 3-6B). Only a single clone was 
homozygous for all the four PAMs and with a HDR of 0.7 percent, and I could not identify 
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any clones targeted correctly in the heterozygous state with a clean WT allele at any of 
the PAM sites I attempted to mutate.   
 
Figure 3-6: ES cell targeting with ssODN repair template using nucleofection method. The 
initial targeting performed using an ssODN (4mutPAM oligo) and g19 CRISPR vector by 
nucleofection method: (A) ssODN repair template with synonymous mutations at PAM sites of 4 
guides. (B) Graph representing the number of sequence analysed Wild type (WT) and mutant 
(NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only) clones. 
3.2.5 Optimisation of HDR efficiency  
3.2.5.1 Small molecule enhancer 
The initial targeting experiment in E14 cells using g19 CRISPR and 4mutPAM oligo using 
nucleofection resulted in a very low percentage of HDR.  Both our experimental 
approaches, generating 5-6 different mutants in a single step via multiplex targeting and 
targeting the 20 residue region for saturation editing, required a much higher efficiency 
than this. Hence, I turned my focus on how to further optimize the HDR efficiency. It has 
been shown that use of small molecule compounds had a potential to increase HDR 
mediated DSB repair mechanism, also with reduced cellular toxicity. One such compound 
SCR7, which is an inhibitor of DNA ligase IV - a key enzyme of canonical NHEJ pathway, 
was shown to promote the frequency of HDR events in both in-vivo and in-vitro systems 
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(Chu et al., 2015; Maruyama et al., 2015). To test this drug, the 4mutPAM oligo (designed 
for saturation editing experiment), an S33Y oligo and ∆S45 oligo were used in 
combination with either g19 or g9B CRISPR in various attempts. 
Targeting of E14 cells was repeated with an ssODN with S33Y point mutation and silent 
PAM mutation (NGG-NGT) (Fig 3-7A), using the nucleofection method, and the cells were 
incubated in 1µM SCR7 containing media for 24hours followed by FACS sorting. The 
analysis of sequencing data for S33Y targeting resulted in a HDR efficiency of 1.2 
percent, which was a two fold increase from the previous targeting experiment (Fig 3-
7B).  
 
Figure 3-7: E14 targeting using DNA ligase IV inhibitor SCR7.  The use of SCR7 in clones 
targeted by nucleofection method. Fig (A) ssODN repair template with S33Y mutation and 
synonymous mutations at PAM (NGG-NGA). (B) Graph representing the number of sequence 
analysed Wild type (WT) and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only) clones. 
In addition to SCR7, another small molecule compound, L755507 was identified in a 
reporter based screening method as having an ability to promote HDR events upon 
induction of DSB by CRISPR/CAS9 system (Yu et al., 2015). To test if this compound 
could promote HDR at our targeting site, again 4mut PAM oligo (designed for saturation 
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editing experiment) along with g19 CRISPR was nucleofected and treated with 5 µM 
L755507 for 24 hours followed by FACS sorting. However, the analysis of sequencing 
results of the targeted clones showed no improvement in the HDR percentage. Only a 
single clone out of 146 clones analysed had a mutation in g19 PAM with 0.7 percent HDR 
efficiency, similar to the targeting observed with nucleofection alone in the absence of the 
compound (Fig 3-8). 
                        
Figure 3-8: E14 targeting using small molecule compound L755507.  The use of L755507 in 
E14 cells targeted by nucleofection method. Graph representing the number of sequence 
analysed Wild type (WT) and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only) clones. 
Even with the use of small molecule compounds, the HDR events at our target site was 
considerably low, and hence it was necessary to attempt different approaches of 
optimization. In the next targeting experiment, a different transfection technique was 
used. Instead of nucleofection, E14s were transfected using lipofectamine with 
suspension cells. The targeting was performed using S33Y oligo and g19 CRISPR along 
with small molecule compound L755507. The analysis of sequencing data revealed a 
drastic improvement in the HDR frequency. The percentage of total HDR events was 
15.6, and except for one clone, all the clones with insertion of PAM mutation also had the 
S33Y mutation. However, the majority of these clones had indels on the other allele and 
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only 2 HDR clones (1S33Y het with PAM het and 1 S33Y hom with PAM hom) out of 115 
(1.7 percent) had no additional NHEJ events (Fig 3-9). 
                      
Figure 3-9: E14 targeting by lipofection in combination with small molecule compound 
L755507. The use of L755507 in cells targeted by lipofection method. Graph representing the 
number of sequence analysed Wild type (WT) and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ 
and HDR only) clones. 
3.2.5.2  E14 targeting using ssODN template with additional mutation in the 
'seed sequence' 
As mentioned previously, the introduction of a synonymous mutation in the PAM 
sequence greatly reduces the chance of re-cutting by Cas9. However, for certain guides, 
introduction of a synonymous mutation in the NGG PAM is not possible, or can only be 
converted to NAG PAM in the targeting template. It has been documented that in addition 
to NGG PAM, SpCas9 has the ability to cleave NAG PAM, albeit with 1/5th the efficiency 
as compared to NGG PAM, thus resulting in additional indels observed along with HDR 
events (Hsu et al., 2013). To test whether an additional mutation in the proximal region 
of the CRISPR binding site reduces the re-cutting of NAG PAM, an ssODN was designed 
with silent mutation in the 19bp of the CRISPR binding site along with PAM mutation in 
g9B CRISPR and S45 deletion (Fig 3-10A). To test this, E14 cells were transfected with 
the ssODN and g9B CRISPR using lipofection and L755507 treatment. Sequencing 
59 
 
analysis revealed 28 percent of clones with HDR and out of the 13 clones that were 
repaired by HDR, 7 clones were homozygous for all the three insertions and without any 
NHEJ events (Fig 3-10B).  
 
Figure 3-10: E14 targeting by using a repair template with additional mutation in the seed 
sequence.  The incorporation of an additional mutation in the 19th bp of CRISPR binding site to 
reduce re-cutting of the NAG PAM. (A) ssODN repair template with S45 deletion, synonymous 
mutation in the PAM (NGG-NAG) and an additional synonymous mutation in the 19th bp of 
CRISPR binding site. (B) Graph representing the number of sequence analysed Wild type (WT) 
and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only clones. 
3.2.5.3 Multiplex targeting using ssODN as repair template 
Applying the above strategies, ssODNs with a synonymous mutation in the PAM region 
and an additional synonymous mutation in the 19th bp of g9B CRISPR binding site and 
the specific mutation (S45 C P Y F) in S45 residue were designed to test how efficient 
multiplex targeting was (Fig 3-11A). The S45 ssODN variants were multiplexed along 
with g9B CRISPR, and transfected into E14 using lipofectamine and L755507, in a single 
transfection. Sequencing analysis revealed an overall HDR percentage of 30, in this first 
attempt of multiplex targeting. However, among the HDR only clones, the frequency of 
homozygous mutants were relatively higher in comparison to the heterozygous mutants 
(Fig 3-11C). Nevertheless, the initial round of multiplex targeting using ssODN was very 
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efficient and we were able to generate all the required S45 mutants. Interestingly among 
the analysed clones there were no compound heterozygous mutant clones which might 
be due to the mitotic recombination events triggered by DSB induction, wherein a DSB in 
the second allele may induce reciprocal crossover with its homologous chromosomes 
that has already been repaired by HDR using the exogenously introduced repair 
template. 
 
Figure 3-11: S45 Multiplex targeting using ssODN as repair template. Multiplex targeting of 
S45 performed in E14 with g9B CRISPR (A) ssODN repair templates of S45 variants with 
synonymous mutation in the PAM (NGG-NAG) and an additional synonymous mutation in the 19th 
bp of CRISPR binding site: (B) Graph representing the number of sequence analysed Wild type 
(WT) and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only clones. (C) Table 
representing the number of homozygous and heterozygous clones acquired for each of the four 
S45 variants. 
Although the initial multiplex targeting of residue S45 using g9B CRISPR that induces a 
DSB 7bp away was successful, the distance between the cutting site and mutation might 
have a significant effect. Based on all our targeting experiments, and testing various 
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guides, we found only two efficient CRISPRs (g9B and g19) in the region of interest that 
were also at a reasonable distance from the desired mutations. The other guides 
including g5 and g6 (2) when used for targeting, had a very low editing efficiency (data 
not shown). Hence, for the purpose of both multiplex targeting and saturation editing, it 
was important to test if we could use these two CRISPRs to generate all mutations in the 
hotspot, using ssODN as template. To test this, we next performed multiplex targeting of 
residue T41 using g19 CRISPR that cuts 10bp away from residue T41 (Fig 3-12A).  
E14 cells were transfected using lipofectamine and L755507 along with g19 CRISPR and 
ssODN variants harbouring mutations at T41, and a synonymous substitution at g19 
PAM. Sequence analysis revealed a reasonable HDR efficiency (17 percent). However, 
out of the 12 clones repaired by HDR, only two clones (<3 percent) harboured mutations 
at both T41 and the PAM region, and the remaining 10 clones had incorporated the PAM 
mutation but not the T41 mutation (Fig 3-12B). This indicated that the distance between 
the cut-site had a significant effect on the introduction of mutations when using ssODN 




Figure 3-12: T41 multiplex using ssODN.  Multiplex targeting of T41 performed in E14 with g19 
CRISPR (A) ssODN repair templates of T41 variants with synonymous mutation in the PAM (NGG-
NGA) (B) Graph representing the number of sequence analysed Wild type (WT) and mutant (NHEJ 
Hom, NHEJ Het, HDR+NHEJ and HDR only clones. 
3.2.6 E14 targeting using vector (TV) with 1Kb homology arms 
Through the targeting's I performed and the other work done in the lab, it became clear 
that, although using ssODN as a template for HDR was efficient if the mutation is very 
close to the cutting site, the efficiency decreased greatly after approximately 8 bp 
distance between the mutation and the cutting site. As I was trying to target a 
considerably larger area than this, I decided to test using a vector with long homology 
arms as an HDR template. Previously, various CRISPR mediated HDR based targeted 
gene editing studies have reported efficient targeting using vectors with homology arms 
500-1000 nucleotide in length (Merkle et al., 2015; Ratz et al., 2015). To test if we can 




3.2.6.1 Cloning of 1Kb Homology arm TV  
To test the efficiency of targeting with a vector as an HDR template in the most time-
efficient way, we changed our focus to the S45 deletion. The reason for this was that, 
from a different project we already had an E14 cell line with a homozygous S45 deletion. 
These cells were also inserted with a V5 tag immediately after the start codon in the exon 
2 region in the endogenous Ctnnb1 gene on both alleles. The V5 tag and S45 deletion 
were introduced using CRISPR/Cas9 mediated gene editing. Briefly, E14 cells were 
transfected using two CRISPRs scg3 (that cuts in exon2 region) and g9B (that cuts in the 
exon3 region) along with HDR vector template with V5 tag and S45 deletion. Using the 
homozygous clone obtained from this targeting, we could amplify both 5’ and 3’ arms, 
and the mutation in one fragment (2.5kb in total), and clone it directly to a vector 
backbone. The genomic DNA isolated from these S45 mutant cells were used as a 
template to amplify the region covering 1kb homology arm on the 5’ side and 3’ end of the 
region of interest. The amplified PCR product was cloned into TOPO 4 vector (Fig 3-13). 
The transformed clones were screened by colony PCR (Fig 3-12B), few PCR positive 
clones were sequenced and one correct vector was selected (to be used as HDR 













Figure 3-13: Schematic representation of cloning of 1Kb homology arm TV. The 2.5kb β-catenin region consisting of V5 tag immediately 
after the start codon in the exon 2 and ∆S45 mutation in exon 3 was amplified using genomic DNA from V5 and ∆S45 homozygous mutant 





Figure 3-14: Colony PCR of 1Kb homology arm TV. Agarose gel electrophoresis image of the 
TOPO cloning transformants screened by performing colony PCR using β-catenin specific primers 
(1Kb F/R). PCR positive clones of expected size (2453bp) are indicated by arrows. Hyperladder 
1Kb. 
3.2.6.2 Targeting using 1Kb Homology arm vector 
E14 cells were transfected with the targeting vector along with two CRISPRS; scg3 
CRISPR (that cuts immediately next to the start codon) and g6 CRISPR (cuts 19bp 
downstream of S45 residue) (Fig 3-15). Using two CRISPRs, the entire region between 
start codon and exon 3 could be deleted, and HDR mediated repair using the 1Kb 
homology arm vector would allow insertion of both V5 tag and S45 mutation. 
The sequencing data revealed HDR events in 12 clones out of 89 (13.5 percent) clones 
analysed (Fig 3-16). The insertion of the V5 tag abolishes the binding site for the scg3 
guide, therefore protecting it against re-cutting and NHEJ. The PAM region (NGG) for g6 
could only be changed to NAG which still had some cutting ability, albeit less efficient. All 
the clones with g6 PAM mutation inserted were also either homozygous or heterozygous 
for S45 deletion, but with additional NHEJ in most of the clones, which shows the 




Figure 3-15: Strategy used for 1Kb homology arm vector targeting. Schematic representation 
of β-catenin WT locus, 1Kb homology arm vector and β-catenin targeted locus. The scg3 CRISPR 
(near start codon) and g6 CRISPR (downstream of S45) were used to delete the region of interest. 
The 1Kb homology arm vector with V5 tag and S45 deletion was used as template for HDR. 
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Figure 3-16: E14 targeting using 1Kb homology arm vector. The use of 1Kb homology arm 
targeting vector to compare the efficiency vs ssODN. Graph representing the number sequence 
analysed Wild type (WT) and mutant (NHEJ Hom, NHEJ Het, HDR+NHEJ and HDR only) clones. 
3.2.7 Generation of β-catenin KO cell line with puDeltatk selection 
cassette 
Our repeated attempts of generating a heterozygous PAM mutant cell line remained 
unsuccessful. It was very important to generate clean heterozygous mutants, but the 
inability to generate a PAM heterozygous mutant cell line, and the caveats of using 
ssODNs as HDR templates for introducing mutations throughout the 20 amino acid 
region,  proved to be two major drawbacks, for both multiplex targeting and saturation 
editing.  
To overcome the above drawbacks, I decided to make the following two changes: 
1) Use vectors as an HDR template – that could overcome the caveats of using 
ssODNs as repair templates. 
2) Instead of using heterozygous PAM mutant cell line, generate a β-catenin KO cell 
line with puDeltatk counter selection cassette – that would provide a system for 
generating clean heterozygous mutants.  
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Conventional targeting approaches based on positive negative selection strategy have 
been successfully adopted in mESCs. The negative selection marker HSV1-tk, in 
combination with various positive selection markers, such as antibiotic resistance gene 
have been widely used (Schwartz et al., 1991; Karreman, 1998). The HSV1-tk is capable 
of phosphorylating nucleoside analogs ganciclovir or FIAU, and incorporation of these 
modified variants during the replicative phase of DNA, terminates the elongation process, 
finally leading to cell death, and hence conferring sensitivity to tk. However, the original 
HSV1-tk caused sterility in male rodents and was a major setback for its use in transgenic 
approaches (Braun et al., 1990). To overcome this drawback, tk was modified at the 
carboxy terminal, to produce a truncated version that allowed successful transmission 
through the male germline. Based on this a novel version of a counter selection cassette, 
by combining the puromycin N acetyltransferase and ∆tk, was described by Chen and 
Bradley. This puro HSV1∆tk fusion protein, under the control of PGK promoter and polyA 
signal from bGh, conferred resistance to puromycin and sensitivity to ganciclovir/FIAU 
(Chen and Bradley, 2000).  
To overcome the drawback of generating clean heterozygous mutants, and given the 
advantages of positive negative selection, we decided to use this counter selection 
strategy to generate heterozygous β-catenin KO cell lines in both E14 and TCF cells. The 
β-catenin allele in these cell lines would be replaced by puDeltatk counter selection 
cassette using CRISPR/Cas9. Various β-catenin knockout conditional mouse models 
with loxp sites flanking either exon 3 and exon 6 or exon 2 and exon 6 of the Ctnnb1 
gene, have been widely used to study the role of β-catenin during development and 
disease (Brault et al., 2001; Huelsken et al., 2001). Taking this into consideration, 
heterozygous β-catenin KO cell lines were generated with a deletion between the exon 2 
and exon 6 regions of the protein. 
Briefly, one of the Ctnnb1 alleles between intron 1 and intron 6 was knocked out and 
replaced by the puDeltatk selection cassette that allows puromycin based positive 
selection of the correctly targeted clone. In the second round of targeting, the puDeltatk 
allele of the β-catenin KO cell line was replaced by β-catenin allele with the desired 
mutation using FIAU negative selection, and this provided us with a robust system for 
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generating heterozygous mutants for both saturation editing and multiplex targeting 
approaches. 
3.2.7.1 Cloning of puDeltatk targeting vector 
For cloning of the puDeltatk targeting vector with β-catenin homology arm, initially a 5.5Kb 
of WT β-catenin region amplified from WT E14 DNA was cloned into PCR 4-TOPO vector, 
using the TOPO TA cloning strategy (Fig 3-17), and sequence verified.  
Next, a Gibson assembly was designed for cloning the puDeltatk targeting vector (Fig 3-
18). Using the 5.5Kb β-catenin TOPO vector as template, primers were designed to 
amplify the entire vector excluding the region between intron1 and intron 6 of β-catenin. 
This would constitute the 5' and 3' β-catenin homology arms of the vector. The puDeltatk 
region was amplified using primers having overlap with the β-catenin region. The two 
amplicons were then gel extracted and cloned using Gibson assembly. The transformed 
clones were screened by restriction digestion using XhoI and XbaI enzymes (Fig 3-19). 
Correctly digested clones were sent for sequencing, and one correct clone was selected 




Figure 3-17: Schematic Representation of cloning of 5.5kb WT β-catenin TOPO vector. The 5.5kb WT β-catenin region was amplified 
using genomic DNA from mESCs. Following amplification, A overhangs were added to the 3'end of the PCR product using taq polymerase 




               
Figure 3-18: Schematic representation of cloning of β-catenin puDeltatk TV. The β-catenin homology arms along with the vector 
backbone were amplified from 5.5kb WT β-catenin TOPO vector. The puDeltatk selection cassette (insert) was amplified using primers having 






Figure 3-19: Restriction Digestion of puDeltatk targeting vector. Agarose gel electrophoresis 
image of Restriction digestion of miniprep DNA from Gibson assembly transformed clones (Lane 
1-12 /12 clones) and controls (Lane 13 and 14 clone 13 and 14) using enzymes XhoI and XbaI 
(2668 and 5623). Control 13 PGK vector and control 14 5.5Kb WT TOPO vector. Hyper ladder 
1Kb. 
3.2.7.2 Designing and cloning of CRISPR guides in intron 1 and intron 6 of 
β-catenin 
In order to knock out the β-catenin allele, two CRISPR guides were designed in each of 
the intron 1 and intron 6 regions of β-catenin, and were cloned into mCherry pX458 vector 
(Fig 3-20A and B) and verified by sequencing. 
 
Figure 3-20: CRISPR guides to Knock-out WT β-catenin.  Two guides each targeting the intron 
1 and intron 6 of β-catenin were designed and cloned into mCherry pX458. (A) Sequence view of 
guides targeting intron 1 of β-catenin. (B) Sequence view of guides targeting intron 6 of β-catenin. 
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3.2.7.3 Targeting of mESCs to generate heterozygous β-catenin KO cell 
line  
Given the advantages of positive negative selection for the generation of clean 
heterozygous β-catenin mutants, we decided to use this strategy for both multiplex 
targeting and the saturation assay. The mESCs, E14 and TCF cells were transfected with 
the puDeltatk targeting vector and intron 1 and intron 6 specific CRISPR guides (Fig 3-
21A) using lipofectamine and L755507. Next day post transfection, the cells were 
trypsinized and plated at various densities in 10cm dishes, 8 hours after which the media 
was replaced with fresh media substituted with positive selection antibiotic puromycin. 
The clones were picked from both E14 and TCF transfections. A PCR based screening 
method was designed to identify the correctly targeted clones and specific primers were 
designed for identifying; A) 5' arm F primer from outside the vector homology arms - to 
avoid amplification of random integration and R primer in β-catenin region – to identify 5' 
end of WT β-catenin allele; B) 3' arm R primer from outside the vector homology arms 
and F primer in β-catenin region – to identify 3' end of WT β-catenin allele; C) 5' arm F 
primer from outside the vector homology arms and R primer in puDeltatk region – to 
identify 5' end of β-catenin KO allele with puDeltatk; D) 3' arm R primer from outside the 
vector homology arms and F primer in puDeltatk region – to identify 3' end of β-catenin 
KO allele with puDeltatk. PCRs were performed for DNA from several clones from both 
E14 and TCF targeting and correctly targeted clones having bands in all 4 PCRs were 
sequenced (Fig 3-21B). The majority of the clones had incorporated the puDeltatk 
selection cassette in one of the alleles. However, among the sequenced clones, I was 
unable to find clones with clean WT allele (due to the biallellic nature of CRISPR activity) 
and since the indels were in the intron region of β-catenin, the chances of the protein 
being affected were very low. Hence one clone each from both E14 and TCF with 
correctly targeted puDeltatk allele and having minimum indels in the intron region were 




Figure 3-21: Targeting strategy for generation of heterozygous β-catenin KO cell line. 
Schematic representation of β-catenin WT locus, puDeltatk targeting vector and puDeltatk 
targeted allele after CRISPR mediated HDR. Coding exons are black boxes and introns are solid 
lines. (B) PCR screening of β-catenin KO cell lines: Agarose gel electrophoresis image of 5' WT, 
3' WT, 5' puDeltatk and 3' puDeltatk of PCR performed for four representative clones. Clones 1,2,3 
were positive for all 4 PCRs whereas clone 4 did not show any band for 5'WT or 3' WT PCRs. 
Similar PCR was done on several clones from both E14 and TCF targeting and few of the rightly 
targeted clones having bands in all 4 PCRs were sequenced. Hyper ladder 1Kb. 
In evidence with homozygous β-catenin deletion having been reported to result in lethal 
phenotypes in vivo, and increased cell death in in vitro culture systems, I observed a 
similar effect of the loss of β-catenin on the viability of ES cells (Haegel et al., 1995) 
(Raggioli et al., 2014). The majority of the targeted cells of both E14 and TCF 
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backgrounds were heterozygous for β-catenin. In addition, heterozygous β-catenin 
knockout E14 cells that were being cultured in normal ES media were especially sensitive 
to loss of β-catenin, and β-catenin expression from a single allele seemed to be 
insufficient in maintaining the integrity of these cells, evident by increased differentiation 
and cell death, and hence needed the support of 2i for continual maintenance in culture. 
However, no loss of viability was observed in heterozygous β-catenin KO TCF cells that 
were already being cultured in media supplemented with 2i. The need for β-catenin in 
maintaining the integrity of ES cells, increased the efficiency in generation of successful 
heterozygous β-catenin KO cell line in our targeting experiment.  
3.2.7.4 Analysis of β-catenin expression in β-catenin KO cell line  
The sequencing results confirmed the KO of one of the β-catenin allele and replacement 
with puDeltatk selection cassette. However, to validate the functional expression of the 
β-catenin WT allele, the total protein was separated by performing SDS polyacrylamide 
gel electrophoresis followed by Western blot of the protein, using pan β-catenin antibody 
and Proliferating Cell Nuclear Antigen (PCNA) as loading control (Fig 3-22A). The β-
catenin KO cell lines of both E14 and TCF cells expressed β-catenin. However, both WT 
and β-catenin KO cell lines showed similar quantities of protein expression. 
In addition to analysis of protein expression by western blot, the β-catenin activity in 
heterozygous β-catenin TCF KO cells was analysed by flow cytometry. The WT TCF cells 
had higher GFP intensity in comparison to β-catenin heterozygous KO TCF cell line 
indicating the reduction in β-catenin activity in the β-catenin heterozygous KO cell line as 




Figure 3-22: Analysis of β-catenin expression in heterozygous KO cell lines. (A) Western 
blot of β-catenin WT and heterozygous KO cell lines: Analysis of protein expression of WT and 
heterozygous KO E14 and TCF cell lines using pan β-catenin antibody indicating β-catenin 
expression in both WT and β-catenin heterozygous KO cell lines. PCNA was used as loading 
control. (B) Flow cytometry analysis of β-catenin activity in WT and heterozygous KO TCF cell 
line: Histograms of WT TCF (TCF control) and heterozygous KO TCF cell line (C2). The GFP 
positive cells are represented in the P3 gate. The heterozygous KO cell line showing lower number 
of GFP+ cells indicating reduced β-catenin activity in comparison to the WT TCF control. The 
GFP+ cells were gated using E14 as negative control.   
3.2.8 Cloning of β-catenin vector with BbsI Restriction site 
To overcome the drawbacks of using an ssODN as HDR template, our second strategy 
was to generate targeting vectors. However, to individually generate 28 vectors for the 
purpose of multiplex targeting and 400 vectors for saturation editing, would have been a 
laborious and time consuming process. To clone all the targeting vectors in an efficient 
way, I decided to take advantage of the Golden gate cloning strategy. Golden gate 
cloning is based on the Type IIS restriction enzymes that cut outside their recognition site 
and allows seamless cloning, with the advantage of performing restriction digestion and 
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ligation in a single step reaction (Engler, Kandzia and Marillonnet, 2008). Type IIS 
restriction enzymes that leave 4bp overhang including BbsI have shown to produce the 
best result. Owing to the advantages of this system, we decided to clone a β-catenin 
backbone vector by inserting a pair of type IIS restriction enzyme BbsI in the region of 
our interest (Fig 3-23). This β-catenin Golden gate vector would later be used as a 
destination vector to clone all the targeting vectors required for both multiplex targeting 
and Saturation editing in a single step (Fig 3-24). 
A Gibson assembly was designed to clone the β-catenin golden gate vector using the 
5.5Kb WT β-catenin TOPO vector as template. However, this template already had a 
BbsI site in the 5' end of β-catenin region, and hence primers were designed such that 
they included a synonymous mutation in BbsI recognition site. In addition, to be able to 
identify the TVs with inserts while cloning the multiple vectors, the region of our interest 
was deleted and replaced with two BbsI sites in the opposite orientation that would allow 
size based separation of positive vectors.  
Using this strategy, both the vector backbone and insert were amplified using 5.5Kb WT 
β-catenin vector. The PCR products were then gel eluted and cloned using Gibson 
assembly protocol. The transformed clones were screened by double digestion using 
BbsI and NotI restriction enzymes (Fig 3-25). Following the preliminary screening, 




                                  
Figure 3-23: Schematic representation of cloning of β-catenin golden gate vector with BbsI sites.  The 5.5Kb WT β-catenin TOPO 
vector was used to amplify both the vector backbone and the insert (with BbsI sites and deleting the region of interest) having short sequence 





Figure 3-24: Schematic representation of cloning of multiplex and saturation TV using golden gate assembly. The β-catenin golden 







Figure 3-25: Restriction digestion of β-catenin Golden gate vector.  (A) Map of β-catenin 
golden gate vector. The β-catenin golden gate vector with BbsI restriction sites was cloned to be 
used as a backbone vector for cloning the TVs for saturation editing and multiplex targeting. (B) 
Agarose gel electrophoresis image of Restriction digestion of miniprep DNA from Gibson 
assembly transformed clones (Lane 1-12) and control (Lane 13) using enzymes BbsI and 
NotI(2482bp and 6820bp). 5.5Kb WT TOPO vector was used as control. Hyperladder 1Kb. 
3.2.9 Preliminary functional analysis of β-catenin mutation 
Another potential problem arose when I analysed the wild type β-catenin reporter cell line 
(refer Fig 3-22B) using flow cytometry. The data showed that the β-catenin activity was 
not uniform in all cells within the population. This could have generated a challenge in 
identifying the potential difference in β-catenin activity in various different mutants. 
Therefore, before the generation of mutant clones using multiplex targeting and 
saturation assay for interpreting the functional significance of β-catenin mutation, it was 
important to conduct a preliminary analysis. The major significance of this experimental 
approach was to test whether or not the difference in β-catenin activity between different 
mutants would be apparent when analysed in a pool of cells, and that the differences in 
activity level was indeed the effect of mutation and not a variation observed due to clonal 
heterogeneity of mESCs. For this purpose, I strategized to use two mutations, S33Y and 
∆S45 mutations, that were being extensively studied in our lab by my mentor and senior 
post doc Derya Ozdemir. The aim was to target the β-catenin reporter cells with either 
S33Y or ∆S45 HDR vectors and analyse them in pools, rather than generating clonal cell 
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lines. To ensure all the cells in the pool analysed were mutant cells, I used fluorescent 
tagging and FACS sorting. The targeting vectors required for this experiment was already 
available in the lab. To generate a pool of heterozygous S33Y cells, I targeted the 
TCF/Lef:H2B-GFP β-catenin reporter cells with wild type β-catenin vector tagged with 
RFP and S33Y vector tagged with BFP. By transfecting the reporter cells with these two 
vectors and selecting for the cells which were double positive for RFP and BFP, I made 
sure to have a heterozygous population (Fig 3-26). This transfection was also done using 
WT-RFP and ∆S45-BFP. As a control, I transfected the cells with WT-RFP and WT-BFP. 
For the targeting, the 2 guide CRISPR system discussed above was used, and this time 
the guides had puromycin selection instead of a fluorescent protein. All these 3 pools of 
cells were analysed by flowcytometry using GFP reporter as a β-catenin activity readout. 
Analysis by flow cytometry indicated a shift in β-catenin activity by both ∆S45 and S33Y 
mutant pool, when compared to WT (Fig 3-28A). The greater shift observed in S33Y peak 
indicated a higher increase in β-catenin activity when compared to ∆S45 mutant pool, 
showing that the mutants differed in their ability to activate β-catenin regardless of the 
clonal variation. 
In order to analyse the mutants in hemizygous state, I repeated the experiment in β-
catenin heterozygous KO TCF cell line (Fig 3-27). The cells were transfected using either 
S33Y BFP, ∆S45 BFP or WT BFP along with two CRISPR guides scg3 and g9B, keeping 
the puDeltatk allele intact. Analysis by flow cytometry of the sorted hemizygous cells also 
showed the similar trend, S33Y giving a higher β-catenin signal than ∆S45 (Fig 3-28B). 
The differences between the populations was more prominent in the hemizygous 
condition when compared to heterozygous condition, probably due to the activity coming 
from the WT allele in the heterozygous state. 
This experiment showed that, although there seem to be some clonal heterogeneity, 
evident from the width of bell shaped peak of the pooled populations, there exists a clear 
difference in the effect of the two mutations on β-catenin activity. In conclusion, the 
differences in the activity conferred by the two mutations in this experiment provided a 
preliminary validation of our hypothesis of the existing genotype-phenotype correlation 




Figure 3-26: Schematic representation of generation of fluorescence tagged heterozygous β-catenin S33Y/∆S45 and WT pool.  The 
TCF cells were transfected with RFP tagged WT β-catenin vector and BFP tagged S33Y/∆ S45/ WT β-catenin vector along with the CRISPR 
guides. The BFP RFP double positive cells were sorted from each of the three targeted population. The sorted cells were then analysed for 




Figure 3-27: Schematic representation of generation of fluorescence tagged hemizygous β-catenin S33Y/∆S45 and WT pool. The 
heterozygous β-catenin KO TCF cells were transfected with BFP tagged S33Y/∆S45/WT β-catenin vector along with the CRISPR guides. The 





Figure 3-28: Flow cytometric analysis of pooled mutant S33Y, ∆S45 and WT TCF clones. (A) 
Histogram of heterozygous S33Y, ∆S45 and WT pooled samples. (B) Histogram of hemizygous 
S33Y, ∆S45 and WT pooled samples. The differences in the observed shift between S33Y, ∆S45 
and WT peaks indicating the existence of genotype phenotype variation with respect to β-catenin 
activity. 
3.3 Discussion 
Over the years, most of the experimental genetic analysis on the activation of oncogenes 
or repression of tumour suppressor activity have relied on either cDNA based 
overexpression, or knockdown studies mediated by RNAi strategy, both these 
approaches have their own limitations. In addition, the conventional gene targeting 
strategies based on HR, although widely used for transgenic technology, falls short in its 
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extended applicability to large scale genome engineering projects. The recently 
developed gene editing techniques, predominantly the CRISPR/Cas9 system, is reported 
to be capable of mediating endogenous genetic manipulations in a range of in vivo and 
in vitro systems, and these RNA guided nucleases have revolutionized the field of genetic 
engineering with implications in a variety of fields, including cancer biology (Sánchez-
Rivera and Jacks, 2015). 
Our goal of understanding the functional significance of the many mutations observed in 
β-catenin would have otherwise been labor intensive and time consuming. However, the 
ease and versatility of the CRISPR/Cas9 system has provided a perfect platform for our 
investigation. Further, the CRISPR/Cas9 system in combination with the two approaches, 
saturation screening and multiplex targeting, will provide a better perspective of 
genotype-phenotype correlations of β-catenin mutations. I decided to use mESCs, E14 
for multiplex targeting and TCF/Lef:H2B-GFP reporter cell line for saturation editing 
approaches. 
The mESCs were selected for the purpose of in vitro analysis of genotype-phenotype 
correlations in β-catenin. ES cells have several advantages - The HDR efficiency of ES 
cells is better in comparison to that observed in somatic cells (Kass et al., 2013); mESCs 
have been studied extensively and are one of the better characterized in-vitro systems; 
in vivo differentiation being one of the functional readouts of β-catenin activity, the mutant 
alleles can be readily used to generate teratomas, and the endogenous mutant cell lines 
of interest can be used directly to generate mouse models. However, this system also 
has certain disadvantages. The Wnt/ β-catenin signaling is one of the major pathways 
governing the 'stemness' of ES cells, and hence β-catenin signaling activity resulting from 
specific mutations may have an impact on self-renewal and differentiation potential of ES 
cells (Merrill, 2012). The preferential selection of specific mutations among different 
cancers point towards a tissue specific selection. However, ES cells may fail to select for 
mutations at particular residues or the mutations that affect the viability of the ES cells 
may simply be lost for further analysis. In spite of these caveats, the potential advantages 
conferred by these cells provided a strong reason for choosing mESCs for in vitro 
modelling of β-catenin mutations. The understanding of β-catenin activity using mESCs 
will be a starting point and will provide a good perspective of the genotype-phenotype 
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correlation of the observed β-catenin mutations, laying a strong foundation for future 
analysis.  
For the purpose of saturation editing and multiplex targeting, design and validation of the 
CRISPR guides to induce strand breaks was necessary. Since different guides may vary 
in their cutting ability, six different guides spanning the region of interest were designed 
and cloned into both the mCherry pX458 and GFP pX458 vectors. The mCherry and GFP 
cassette in the pX458 transfected cells allows selection of transfected cells.  
The analysis of indel percentages of these guides varied between 17 to 35 percent in the 
T7 assay. Although T7 endonuclease I assay is known to be a sensitive approach 
(Vouillot, Thélie and Pollet, 2015), we did not observe a correlation in the indel 
percentages analysed by T7 assay and the number of targeted mutant clones analysed 
by sequencing. The g19 CRISPR which resulted in an indel percentage of 22 percent in 
the T7 assay showed a mutation of greater than 70 percent in the clones analysed by 
sequencing and the g5 CRISPR with a higher indel percentage (30 percent) in T7 assay 
resulted in less than 5 percent of mutation in the clones analysed by sequencing (data 
not shown). These results suggest a need for a more sensitive approach to predict the 
efficiency of guides to induce DSBs until then it is difficult to select guides based on the 
T7 assay alone. 
Although the CRISPR/Cas9 system is a simple and robust technique for genome editing, 
the efficiency of this RNA guided endonuclease for HDR mediated precise gene 
manipulation is significantly limited by the increased frequency of NHEJ events 
(Maruyama et al., 2015). This was observed even in our study, whilst most of the 
CRISPRs were efficient in induction of DSB (as indicated by NHEJ events), the frequency 
of HDR still remained poor. The initial targeting experiments for generation of a 
heterozygous PAM mutant allele resulted in very low HDR events and we did not succeed 
in generating a heterozygous PAM mutant clone in our initial attempt. The low HDR 
events observed at our target site would result in reduced efficiency for our multiplex 
targeting approach. For the purpose of multiplex targeting, we required a higher HDR 
frequency, and hence further optimization was required to improve the HDR events. In 
this regard, various approaches to reduce the inherent NHEJ mechanism and to increase 
the HDR frequency have provided promising results. One such compound SCR7 
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interacts with the DNA binding site of DNA ligase IV, a key enzyme in canonical NHEJ 
pathway, was shown to significantly reduce the NHEJ and subsequently increased the 
HDR events (Chu et al., 2015; Maruyama et al., 2015). The use of this compound, 
although increased the HDR events to a small extent, but the frequency of HDR was still 
reasonably low for our purpose of multiplex targeting. However, the drug was used at the 
same concentration (1µM) that was shown to be optimal in MelJuSo, DC2.4 cells and I 
did not optimize the concentration for our cell line, which might be the reason for the lack 
of significant increase in HDR frequency in our experimental set up. Further optimization 
of the drug concentration in E14 cells would be required to draw conclusions on the 
efficacy of this DNA ligase IV inhibitor in increasing HDR events at our target site.   
In addition to SCR7, another small molecule compound, L755507, was identified in a 
reporter based screening method as having an ability to promote HDR events upon 
induction of DSB by the CRISPR/CAS9 system. The screen involved around 4000 small 
molecule compounds, whose biological activity had been well characterized, and among 
all the compounds L755507, a β adrenergic receptor agonist, yielded a 3 fold increase in 
large insertions and 9 fold increase in point mutations (Yu et al., 2015). The use of this 
small molecule compound in combination with lipofection resulted in a drastic increase in 
the HDR frequency. Although the authors used the electroporation method for L755507, 
our results with the same drug previously used with nucleofection did not result in 
increase of HDR. Our main aim was to improve the HDR frequency and as these 
experiments are time consuming, in most of our targeting experiments I had pooled 
different strategies for optimization. Since the combination of L755507 with lipofection 
had yielded similar HDR frequency in repeated targeting experiments, I decided to 
continue to use this approach. However, an experimental set up with appropriate controls 
for comparison of nucleofection vs lipofection in the presence and absence of the drug 
would provide conclusive results.  
Previous gene editing studies have shown the successful use of short single stranded 
oligodinucleotides (ssODN) especially for insertion of point mutations and with an 
efficiency comparable to that of using targeting vectors with long homology arm (Soldner 
et al., 2011). In addition, ssODNs with a length of 70bp have been shown to achieve an 
optimal frequency of HDR (Yang et al., 2013). The CRISPR based targeting experiments 
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for introduction of short inserts and point mutations using ssODN have been done 
successfully in our lab. However, the only paper on saturation screening uses a plasmid 
with long homology arms, and hence it was decided to test the efficiency of using a 
targeting vector as HDR template (Findlay et al., 2014). The ∆S45 targeting vector with 
1Kb arm resulted in a good frequency of HDR percentage.  
It is well established that, the insertion of a synonymous mutation in the NGG PAM while 
designing a repair template reduces the guide mediated recognition and re-cutting by 
Cas9. However, in certain cases it is not possible to introduce a silent substitution in the 
PAM sequence for many guides, or can only be substituted to an NAG PAM in the 
targeting template. It has been reported that in addition to NGG PAM, SpCas9 has the 
ability to cleave NAG PAM, albeit with 1/5th the efficiency compared to NGG PAM, thus 
resulting in additional indels observed along with HDR events (Hsu et al., 2013). To 
overcome the re-cutting of NAG PAM, a template was designed with introduction of an 
additional silent mutation in the 19thbp of the g9B CRISPR binding site. Various studies 
on off- target effect have proposed the region consisting of 8-10 nucleotides proximal to 
the PAM sequence (known as the seed sequence) with requirement of high specificity 
and mismatches in this region are less tolerated and resulted in reduced Cas9 activity 
(Hsu et al., 2013; Anderson et al., 2015). In agreement with this, our final strategic 
approach of designing a template with introduction of an additional silent mutation in the 
seed sequence greatly reduced the chances of re-cutting by Cas9. This strategy of 
introduction of a synonymous mutation in one or a couple of nucleotide positions in the 
seed sequence prevented re-cutting of the NAG PAM to a great extent and yielded a 
large number HDR only clones.  
The initial multiplex targeting of residue S45, incorporating the various optimized 
strategies resulted in successful generation of both homozygous and heterozygous 
mutants. However, multiplex targeting at the T41 residue did not result in successful 
generation of the required T41 variants/mutants although the HDR efficiency was 
reasonable and 17 percent of the clones had incorporated the PAM mutation but only 3 
percent of the clones had both T41 and PAM mutations. This may be attributed to the 
distance between CRISPR cut site and the mutation being incorporated. However, the 
previous S33Y targeting with g19 CRISPR that cuts 12bp away had yielded a HDR 
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percentage of 15.6 and all the clones, except one clone, had incorporated both PAM and 
S33Y mutations with the distance between PAM and S33Y being 6bp. In the case of the 
T41 residue, although the distance between the cut site and T41 is 10bp, the distance 
between PAM and T41 was 15bp. From these results, it can be speculated that the 
presence of two close mutations have better chances of both being incorporated when 
compared to T41 mutations where the distance between PAM and T41 mutation is slightly 
large, hence the PAM is being repaired but without the T41 residue mutation. These 
results can be attributed to the process of template switching, a common feature in SDSA 
(Synthesis dependent strand annealing, a repair mechanism widely used when ssODN 
acts as repair template). In support with our observation Paix et al have shown that the 
presence of mutation every 3 or 6bp reduces template switching in comparison to 
mutations 12bp apart where increased template switching was observed  (Paix et al., 
2017). 
In addition, other factors may contribute to the observed variation in HDR frequency even 
within a short stretch of locus, for instance purine and pyrimidine rich regions have known 
to favour HDR, and the region surrounding S45 being extremely purine rich and with g9B 
inducing a DSB very close to this region, probably results in higher HDR percentage 
observed. Reports have suggested the heterozygous mutation is favored when increased 
distance between CRISPR cut site and homozygous when the CRISPR cut site is closer 
(Paquet et al., 2016), similarly the distance between the S45 and g9B being the shortest 
may have contributed to the increased homozygous mutants in S45 targeting as 
compared to either S33Y targeting or T41 multiplex, both having higher number of 
heterozygous mutants. These results implicate the existence of multiple factors that 
contribute  to the observed differences in HDR based editing rates, especially when using 
ssODN as repair templates, thus highlighting the importance of carefully designed 
templates and guides for need based enhancement  of targeting efficiency.  
However, with only two efficient CRISPRs in the region of interest, and the increased 
variability in HDR outcome when using ssODN as repair templates, proved to be the 
major limitations, creating bottlenecks in our experimental progress for both multiplex 
targeting and saturation editing. Although few of the drawbacks of using ssODN as repair 
template could be overcome by using vector based HDR template, and a good HDR 
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efficiency was observed with 1Kb homology arm vectors, it was still difficult to generate 
clean heterozygous mutants, without NHEJ on the other allele. Moreover, our strategy of 
generation of PAM mutant cell line remained unsuccessful, requiring the need for a new 
strategy. Using a haploid cell line, or knocking out one of the WT allele in diploids, and 
studying the mutations in a hemizygous condition would have been two other possibilities, 
that could substitute for PAM mutant cell line. However, I decided to continue to analyse 
heterozygous mutants by generating a heterozygous β-catenin KO cell line with puDeltatk 
counter selection cassette. This positive negative counter selection strategy, along with 
the use of vectors as HDR template was our best chance at generating clean 
heterozygous mutants. For this purpose, β-catenin KO heterozygous cell lines were 
generated in both E14 and TCF cells. In addition, a β-catenin destination vector with BbsI 
site was cloned that could be used as backbone for efficient Golden gate based cloning 
of all the vectors for both multiplex targeting and saturation editing.  
As proof of principle, to test whether or not different mutations resulted in differences in 
β-catenin activity, a preliminary experiment performed using pooled S45 and S33Y 
mutants in TCF cell line showed differences in activity of the two mutants, providing initial 
evidence of the genotype- phenotype correlation. 
In conclusion, every targeting experiment as discussed in this chapter, although time 
consuming, provided valuable insights, and helped us design the best possible strategies 
and tools for enhancing the targeting efficiency at the region of our interest. Furthermore, 
the preliminary validation of our hypothesis provided a strong basis for our 




























The directed evolution experiments are frequently adopted in the field of protein/enzyme 
engineering. These experiments are based on the creation of a mutant library 
encompassing a diverse array of amino acid variants, followed by iterative selection and 
high throughput screening for assessing the fitness of the biocatalyst, providing an 
efficient system for selection of mutants with the desired or novel catalytic activities 
(Cobb, Chao and Zhao, 2013). Not limited to protein engineering, these strategies have 
also found applicability in evolutionary analysis of proteins, deciphering metabolic 
pathways, and are further expandable to genome wide level. Adapting similar 
approaches, recently it has been shown that saturation editing combined with the 
CRISPR/Cas9 provides a prospective way to analyse the functional significance of every 
nucleotide/amino acid residue within a short stretch of the endogenous loci of interest 
(Findlay et al., 2014). Given the diversity in the mutational landscapes of the cancer 
genome, CRISPR/Cas9 mediated saturation editing offers a simple tool for induction of 
multiple genetic variations to create a mutant library in a single large scale assay. 
Moreover, the availability of high throughput sequencing platforms provide perfect 
complementary screening approaches for such large scale strategies, and together with 
a detectable phenotypic assay, provide a robust means of determining the precise 
functional consequence of every variant in the generated mutant library. 
Given that a majority of the cancer mutations in the β-catenin oncogene are clustered 
around the conserved phosphorylatable serine and threonine residues, with a defined 
mutational hotspot in the exon 3 region, makes this region of Ctnnb1 a suitable candidate 
to perform saturation editing. Functional analysis of β-catenin activity based on the 
TCF/Lef reporter system, allowing quantification of β-catenin activity at single cell 
resolution through FACS, provided an elegant screening approach for phenotypic 
assesment. The mES cell line with the TCF/Lef:H2B-GFP reporter required for this 
experiment was derived for us in the lab of Kat Hadjantonakis (Memorial Sloan-Kettering 
Cancer Center), from the blastocysts of a well-established reporter mouse model (Ferrer-
Vaquer et al., 2010). As discussed before, in order to mimic the β-catenin mutations in 
cancer as closely as possible, the targeting strategy was based on generating 
heterozygous mutations. 400 substitutions, targeting a 20 amino acid region (residues 
L31-G50), were randomly generated in 200 million reporter cells, which was then divided 
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into 6 segments according to the intensity of the reporter activity. Deep sequencing of 
each individual segment, permit correlating the specific β-catenin activity range to the 
precise mutation the cells carried (Fig 4-1). This chapter will discuss the experimental set 
up and the analysis of the saturation editing. 
 
Figure 4-1: Schematic representation of the experimental design of saturation editing 
assay. CRISPR/Cas9 system coupled with saturation editing to be used to induce all possible 




4.2.1 Cloning of saturation HDR vector library 
4.2.1.1  Optimization of various cloning strategies 
As shown in the previous chapter, ensuring similar efficiency of HDR at each residue 
within the saturation region forced the use of plasmid as an HDR template. The need for 
400 TVs required a more sophisticated cloning approach than the conventional methods. 
Golden gate system proved to be a very efficient method for cloning, and involved having 
a template vector with two type IIS restriction enzyme forming a cloning site. Therefore, 
the first step was to generate a β-catenin backbone vector with two type IIS restriction 
enzyme BbsI site around the region to be targeted along with homology arms. The 
generation of this vector was discussed in chapter 3. In order to find the most efficient 
way of generating the insert with the correct overhangs for the BbsI sites, we tested 3 
strategies.   
Firstly, two complementary strands (182bp) with BbsI sites were ordered separately and 
then phosphorylated, annealed and cloned. This approach was adapted from the sgRNA 
cloning which worked with 100 percent efficiency. However, this approach failed to yield 
any transformants, probably due to the length of the strands giving rise to internal base 
pairing or hairpin loop formation, and not allowing perfect complementary base pairing 
between the two strands. Secondly, a PCR based approach was attempted whereby 
ssODNs including a BbsI site were amplified using high fidelity DNA polymerase that was 
later digested and ligated into the backbone vector. This approach had a cloning 
efficiency of over 85 percent (Fig 4-2A). However, the most efficient and easiest approach 
that allowed single step cloning was by ordering double stranded (ds) oligos with BbsI 
sites that when directly digested along with the destination vector followed by ligation, 
resulted in 100 percent cloning efficiency (Fig 4-2B). This was the most convenient and 





Figure 4-2: Colony PCR of ssODN PCR vs ds oligo based approach optimized for cloning 
of Saturation TVs. Different approaches were taken for the generation of ds oligos, and tested 
for cloning (efficiency) into the designation vector. A) Agarose gel electrophoresis image of colony 
PCR of TVs cloned by generating ds amplicon by oligo PCR based approach yielding an efficiency 
of over 85%. Except for two clones (lane 7 and 9) all clones (lane 1 to lane 16) show the expected 
band size. Lane 17 and 18 are + and –controls. B) Agarose gel electrophoresis image of the colony 
PCR of TVs cloned by ordering synthetically generated ds oligos yielding 100% cloning efficiency. 
All clones (Lane 1 to lane 28) show an expected band size. Lane 29 and 30 are – and + control.  
4.2.1.2 Design of ds oligo 
The ds oligo library to generate the TVs was designed so that, it included all the amino 
acid (20) variants between residues L31 and G50 in the β-catenin hot spot region. Each 
of the ds oligos also included 3 synonymous mutations downstream of residue G50 that 
could be used as a handle PCR to be able to amplify only the edited alleles for deep 
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sequencing. In addition, 2 synonymous mutations were included to disrupt the PAM 
sequence (of g9B β-catenin guide) and to prevent re-cutting. Although, the plan was to 
use guides specific for the puromycin selection cassette and keep the WT β-catenin 
intact, including these mutations gave us the flexibility to use the same TVs in the future 
and target the WT β-catenin allele to generate hemizygous mutations.  
4.2.1.3 Cloning of the ds oligo for generation of TV library 
The 400 ds oligo library was synthesized by Twist Biosciences and cloned into the β-
catenin backbone vector as a pool using the golden gate strategy, as described 
previously. Colony PCR revealed a 100 percent cloning efficiency. Individual colonies 
were picked and analysed by sequencing to confirm the presence of the inserts in the 




Figure 4-3: Colony PCR image of 100% efficient cloning of Saturation TVs using ds oligo 
based approach. Agarose gel electrophoresis image of colony PCR of TVs cloned by ordering 
synthetically generated ds oligos yielding 100 percent cloning efficiency. All clones (Lane 1 to 46 
and lane 48 to 94) show the expected band size. Lanes 47 and 95 are – controls and lanes 48 
and 96 are + controls. The positive clones were sequenced and TVs with desired mutations were 




4.2.2 Design and cloning of guides targeting puDeltatk selection 
cassette 
For the replacement of the selection cassette with a β-catenin allele harbouring the 
desired mutation, two guides were designed for each of the 5' and 3' regions of the 
puDeltatk selection cassette (Fig 4-4). The guides were designed within the selection 
cassette, or spanning the boundary between β-catenin and the selection cassette, such 
that they would induce a DSB only within the knock out allele, and hence keeping the WT 
β-catenin allele intact. The designed guides were cloned into mCherry pX458 and the 
insertion was confirmed by sequencing. 
 
Figure 4-4: Schematic representation of generation of heterozygous β-catenin mutant cell 
lines. Guides were specifically designed targeting bGh polyA and PGK regions of the puDeltatk 
selection cassette. The β-catenin heterozygous KO cell line was targeted with these guides along 
with the HDR vector library followed by treatment with FIAU negative selection. This allowed the 
replacement of puDeltatk selection cassette with β-catenin with specific mutation in the exon 3 hot 
spot region, providing a successful strategy for the generation of β-catenin heterozygous mutant 




4.2.3 Optimizing PCR strategies for deep sequencing 
Deep sequencing by the MiSeq sequencing platform required the amplicon size to be 
around 200-300bp. However, to avoid amplification of random integration of the TV, a 
two-step PCR approach was taken. First PCR was a long range PCR, with forward primer 
being in the β-catenin sequence outside the homology arm, and the reverse primer 
spanning the 3 nucleotide substitution downstream of residue G50 I placed to serve as a 
mutant allele specific amplification. This 3.2 kb amplicon was then used as a template to 
amplify the shorter second PCR product, which included the barcodes for the MiSeq 
sequencing. Various strategies were incorporated to avoid false amplification. For the 
purpose of optimization, a mock transfection was performed using the CRISPR guides 
and TV library. As negative controls, untransfected cells and cells transfected only with 
the TV library (excluding CRISPR guides) was used to detect any false amplification. The 
genomic DNA isolated from all three transfections was used to amplify 3.2 kb PCR 
product. To avoid the contamination with any residual TV library, which might have been 
still present in the cells, the PCR product was gel eluted. This product was then used as 
a template for the second shorter PCR. The first PCR worked as expected, giving a band 
only in the cells transfected with the guides and the library. Even though there were no 
visible bands, the gel elution was performed on the negative controls as well, using the 
correct band size as guidance. Although I expected a band only in the samples 
transfected with CRISPR guides and TV library, the shorter PCR yielded false positive 
amplicons in the library-only and the untransfected controls, in several attempts. I 
assumed this could only be a result of general DNA contamination, as the TV library was 
considerably larger in size than 3.2 kb where the gel elution was performed. As even very 
small amounts of DNA carried over either from buffers in gel tanks or other sources, 
would result in false amplification, I decided to run each sample in a different tank. The  
gel tanks, combs, and the gel trays were all soaked in 5M NaOH O/N, washed thoroughly 
to remove any residual DNA next day, and filled with fresh buffer. The gel eluted PCR 
product was also treated with DpnI restriction enzyme to remove any residual TV coming 
with the buffer, and in addition, all PCRs were performed in T/C hoods. As a result, the 
false positive amplification was visibly reduced and I was able to reduce amplification 





Figure 4-5: PCR optimization strategies to overcome false positive amplification.  Agarose 
gel image of the second PCR performed on sample transfected with TV and CRISPR guide, TV 
only transfected and untransfected control. A) PCR products all run in the same gel- Strong PCR 
bands observed in all three samples B) PCR products run in separate cleaned tanks- Specific 
amplification observed only from DNA transfected with TV and CRISPR guide. 
4.2.4 Saturation Assay 
4.2.4.1 Selection of time frame for culturing TCF reporter cells in normal 
ES media 
The TCF reporter cells could only be cultured in normal media for a short period, and 
prolonged passaging in normal media resulted in a change in morphology and 
proliferation. Therefore, I had to maintain the cells in R2i media which contains a GSK 
inhibitor activating the Wnt pathway. As this would interfere with phenotyping the mutant 
cells, I tested how long it takes for β-catenin activity to reduce after the removal of R2i 
media. As shown in the flow cytometry analysis in figure 4-6, there was considerable 
reduction in the levels of β-catenin activity even after overnight culture in normal media. 
I observed that culturing the TCF reporter cells in normal ES media for a short duration 
of 2-3 days had little effect on the morphology and they could still be maintained in an 
undifferentiated state. Based on these observations I decided that culturing the reporter 
cells for 2-3 days was optimal for both reduction of β-catenin activity levels and 
maintaining their morphology. 
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Figure 4-6: Flow cytometry analysis of β-catenin activity of TCF cells cultured in normal ES 
media. (A) E14 cells used as control to gate the GFP negative population. (B) TCF reporter cells 
cultured in R2i media. (C) TCF cells cultured overnight in normal ES media. (D) TCF cells cultured 
in ES media for three days. TCF cells cultured overnight in normal ES media already showed a 
considerable reduction β-catenin activity levels compared to the TCF cells cultured in R2i mediand 
culturing in normal ES media for three days resulted in a further reduction of β-catenin activity.  
4.2.4.2 Saturation editing and FACS sorting 
On day1, 200X106 β-catenin heterozygous KO TCF cells were transfected with the HDR 
vector library and CRISPR guides targeting the selection cassette. On the third day post 
transfection, the R2i media was replaced with normal ES media supplemented with FIAU 
for negative selection. A control plate with untransfected β-catenin KO TCF cells was also 
placed on FIAU negative selection, to ensure the cell death took place before I started 
the FACS analysis. Flow cytometric analysis on the fifth day post transfection showed a 
shift in the intensity spectrum of the saturation edited mutant pool in comparison with the 
untransfected TCF WT and β-catenin heterozygous KO TCF control cell lines (Fig 4-7). 
Following flow cytometric analysis, the saturation edited mutant pool was divided into 7 
segments of varying intensity, and cells were sorted from each segment. 
The sorting strategy of the saturation edited mutant pool was carefully designed based 
on the various mock experiments, and also the previous functional analysis using the 
S33Y and ∆S45 mutants (discussed in chapter 3 section x). Using E14 as control, I set 
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the P1 and P2 gates to sort the GFP negative population. Next, considering that many of 
the mutant population may be similar to the WT GFP signal, the P3 gate was set, which 
was the range of GFP occupied by majority of WT TCF population. Many mutants might 
be capable of increasing the β-catenin activity levels, however, as seen in our preliminary 
experiment with ∆S45 and S33Y, the intensity of signal may vary among the different 
mutants (refer chapter 3 Figure 3-28A). The S45 heterozygous mutant pool resulted in 
lower and medium levels of increase in β-catenin activity, taking this into consideration, I 
set the P4 and P5 gate to represent this range of activity. Finally, based on the 
observation that the S33Y heterozygous mutant population mainly selected for higher 
increase in activity, I set the P6 and P7 gates to sort for cells with higher increase in 
activity levels. 
However, due to technical reasons the cells from P1 gate could not be sorted, and hence 





Figure 4-7: Flow cytometric analysis for sorting cells from different intensity segments of 
the saturation edited mutant pool. (A)Flow cytrometric analysis of untransfected TCF WT cell 
line. (B) Flow cytrometric analysis of untransfected β-catenin heterozygous KO TCF cell line (C) 
Flow cytrometric analysis of saturation edited mutant pool. Flow cytometric analysis shows a shift 
in GFP expression in the saturation edited mutant pool (on day 5) in comparison with the 
untransfected WT TCF and β-catenin heterozygous KO TCF cell lines. Cells from each of the 
segments P2-P7 were sorted for genotypic assessment by deep sequencing. 
To be able to account for the variation in the experimental set up, the experiment was 
repeated a second time independently using the above described protocol and 
parameters, and cells were similarly sorted from the 6 gates (P2_2 to P2_7). In addition 
to the 6 sorted gates, a small sample of cells (pool) was collected before sorting from 
both experiments (pool_1 and pool_2). The cell numbers sorted from both the 
experiments are given in table 4-1.  
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Segment Replicate1 cell numbers Replicate2 cell numbers 
P2 200,000 200,000 
P3 200,000 200,000 
P4 200,000 200,000 
P5 80,000 1,130,000 
P6 445,427 942,000 
P7 8,309 11,641 
Table 4-1: Number of cells sorted from different segments of replicate1 and replicate2 
4.2.4.3 DNA processing and Deep-sequencing 
Following cell sorting, the DNA was immediately extracted using Qiagen DNeasy kit. 
Taking the precautionary measures to avoid false amplification as detailed in section 
4.2.3, the PCRs were performed. Briefly, the first round 3.2 Kb PCR (with handle specific 
R primer and F primer outside the homology arm) was gel eluted, followed by DpnI 
digestion. The DpnI digested first PCR was used as template to perform a second round 
of handle specific PCR with Illumina barcoded primers. These PCRs were performed for 
all the 14 samples (samples P2-P7 and the pooled sample from both replicates). 
As the ds oligos to generate the targeting vectors was received and cloned as a pool, it 
was important to sequence this library alone itself, to see what the plasmid distribution 
within the library was. For this purpose the TV library used in transfections of the 
independent replicates (plasmid_1 and plasmid_2) was used as template and the short 
handle specific PCR was performed using the Illumina barcoded primers.  
Following amplification, all 16 samples were quantitated using qubit, the samples were 
then pooled in equimolar quantity and finally the integrity of the DNA pool was assessed 
using a bioanalyser. The pooled library was submitted to Edinburgh genomics, and a 
paired end sequencing (200bp read1 and 100bp read2) was performed using the Illumina 




4.2.4.4 Processing and analysis of deep sequencing data 
The processing of raw sequencing data and analysis was done by Martijn Kelder PhD 
student in Andrew Wood's lab, IGMM, University of Edinburgh. Initially, a quick quality 
check of the raw sequencing data (FastQ format) was performed using FastQC, which 
gives an overview of various parameters including per sequence quality score, sequence 
length distribution, total sequences etc for each of the sequenced samples. Next, as the 
forward and reverse reads were respectively, 200nt and 100nt in length, the forward 
reads were stripped down to 100nt using Python. 
Reads were then trimmed for adapter sequences (<1 percent of reads) using Trimgalore 
and aligned to the reference sequence using BowTie2. As the amplicons were designed 
to specifically amplify the HDR edited cells, the handle and PAM mutations being 
common in all the 16 samples, a β-catenin WT sequence (GRCh38) with handle and 
PAM mutation was used as a reference to map the reads. The mapping of the reads from 
each of the 16 samples to the β-catenin reference sequence showed a very high 
percentage of alignment (Table 4-2), with over 98-99 percent of reads from each of the 
samples being correctly aligned to the reference sequence. These results not only 
indicated a good sequencing run, but also shows how good the quality of the library that 
we provided was, and highlights the strength of our design approach and robustness of 
the implemented strategies in determining the quality of the project outcome. 
Following the alignment of the reads, the forward and reverse reads were merged into a 
single 100nt contig using Python. Only contigs without indels and with consensus 
between forward and reverse read for each position were passed on for further analysis. 








Sample Number of aligned pairs Percentage of aligned pairs 
p2_1 709521 98.74% 
p3_1 733891 98.73% 
p4_1 729201 98.75% 
p5_1 613649 98.89% 
p6_1 640743 98.90% 
p7_1 585110 99.17% 
Plasmid_1 658587 98.69% 
pool_2 736914 98.64% 
p2_2 851189 98.28% 
p3_2 679890 98.74% 
p4_2 728792 98.58% 
p5_2 695346 98.96% 
p6_2 604142 98.94% 
p7_2 582289 99.11% 
Plasmid_2 596072 98.71% 
pool_1 789250 98.71% 
Table 4-2: The number and percentage of aligned pairs of deep sequencing data for each 
of the 18 samples.  
4.2.4.5 Correlation between replicates 
As this experiment was repeated twice to be able to account for any variation in the 
experimental set up, we tested how these two replicates correlated for each segment. A 
very high correlation was observed between the replicates, with most of them having R 
values in the range of 0.7-0.99 (Fig 4-8). The very low measurable variation between the 
replicates confirmed that these results were highly reproducible. The slightly lower R 
value (0.653) for the replicates from the P7 gate was probably due to the lower cell 
numbers, however, the correlation was still high enough to draw conclusive evidence of 




Figure 4-8: Correlation between replicates.  A correlation analysis was performed for comparing 
the reproducibility between the samples P2 to P7 from replicates 1 and 2. 
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A very high correlation was obtained between the pool and plasmid library (R=0.93), 
confirming no bias in the rate of incorporation of the different variants (Fig 4-9). In 
addition, the histograms of the amino acid variants across L31 to G50 from the pooled 
sample shows a similar profile as that of the plasmid library, validating the efficient and 
equally weighted incorporation of the substituents, reflecting an un-biased HDR editing 
rate across the target site. As seen in Figure 4-9B and C, there was good representation 
of each residue in the plasmid library except for K49 and G50, similar to that observed in 
the pool sample. This could be an artifact the way the DNA synthesis was done by Twist 
and because of this low incorporation, these 2 residues were later removed from the 
analysis. The substitutions within each residue also seemed to be well distributed and 







Figure 4-9: Comparison between pool and plasmid sample.  (A) Correlation plot of plasmid vs 
pool and (B) Histogram of proportion of amino acid variants across the target site in the plasmid 
sample (C) Histogram of the proportion of the incorporated amino acid variants across the target 
site in the pool sample 
4.2.4.6  Combined overview of P2-P7 from both replicates normalized to 
pool 
Although each residue and each substitution were well represented in both the library 
and the pool, there was still some variation. In order to eliminate the effect of this variation 
from our analysis, I decided to normalize the values from each gate to the pool. This way, 
the differences we found between each mutation could not be due to being 
under/overrepresented in the plasmid or any small difference in HDR efficiency across 
the region.  
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As the replicates for each segment showed good correlation, the normalized values of 
the two independent replicates were combined for further analysis.  
Comparison of the line graphs between the P2 (segment with the lowest activity) and P7 
(segment with the highest activity) populations reveals the variation in the activity levels 
by the different residues (Fig 4-10). The most frequently mutated residues from the 
COSMIC database analysis including the phosphoylatable S and T residues 33,37,41,45 
and residues D32 and G34, showed clear difference in the activity levels across the 
segments. While the rest of the amino acid variants across the target site were largely 
present in the lower intensity segments P2-P4 which also represents the activity range of 
the WT TCF cells.  
            
Figure 4-10: Line graph of the overall β-catenin activity of residues L31-G48 across the 
different segments of the sorted population. 
As expected the top six residues were underrepresented in the low expressing segments 
(P2 and P3), and were prominently present in the high expressing segments (P6 and P7) 
(Fig 4-11). Furthermore, the proportion of the substituted amino acid variants differed 
across the segments for each of these 6 residues, which is the first sign of each residue 
having a different β-catenin activity (Fig 4-12). While in the P4 segment, the number of 
total S45 mutants were significantly higher than S37, the opposite trend was observed in 
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S45 residue. A trend similar to that of S45 was observed for the T41 variants, which could 
also be seen increasing in the P4 segment. The highest proportion of S45 variants were 
present in the P5 segments and decreases in P6 and P7, with only a handful of S45 
variants being selected for in the P7 segment. The proportion of T41 variants increase 
through P4 and P5, with the highest levels in P6 and reducing in P7. A linear increase in 
the proportion of S37 variants can be observed, with the highest proportion in the P7 
segment and with majority of the variants capable of increased activity. The S33 variants 
follow a similar trend as S37, with a linear increase in proportion, however the overall 
proportion of S33 variants was considerably lower than that of S37. Further, the activity 
of D32 and G34 residues increase in the P5 and P6 segments and dips in the P7 
segment. In addition to D32 and G34, a similar increase in the proportion of amino acid 
variants was observed for residue I35, especially in the P5 segment, and slightly reducing 
in the P6 and P7 segments. This enrichment in specific amino acid variants of residues 
across the hot spot region in different segments of the sorted population indicates the 
capability of different mutants to confer different activity levels.  
            
Figure 4-11: Line graph of the overall β-catenin activity of residues D32 S33 G34 S37 T41 

































Figure 4-12: Analysis of the different segments of sorted population. (A-F) Histograms of the 
segments P2-P7 representing the proportion of the amino acid variants for each of the residues 
across the hotspot region. Each colour block represents a different amino acid variation. 
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4.2.4.7 Assigned value heat map 
To statistically predict whether the activity levels of each amino acid variant (for each of 
the 18 residues from L31-G48) changes across the six segments of the intensity 
spectrum, regression analysis was performed. This analysis was done by Helen Brown 
(senior statistician, The Roslin Institute).  
The p values, slope and SE of slope were calculated. Both p value and slope give a 
measure of the change in activity for each amino acid variant across the six segments. 
The normalized values of the two independent replicates were separately used to 
calculate the p values, to test if the observed change is significant. The slope (m) is a 
measure of the 'rate of change' in activity for each of the amino acid variants across the 
six segments.  
The individual m values of the amino acid variants were assigned as their overall activity 
across the six segments (hereafter referred to as the mutational effect). A heat map of 
the mutational effect of the different amino acid variants across L31-G48 residue was 
plotted (Fig 4-13). The assigned value heat map gives a clear indication of the differential 
mutational effect among the amino acid variants. The mutational effect of the amino acid 
variants for of majority of the residues across the target site remain low or unaltered, with 
enrichment observed especially among the amino acid variants at the top 6 residues. 
Similar to our previous observations, among the top 6 residues, the highest mutational 
effect were conferred by the S37 variants and the S45 variants are among those 
conferring a lower mutational effect. In addition to the top six residues, few of the amino 
acid variants at the residue I35 also show enrichment in the observed mutational effect. 
The mutational effect of synonymous substitutions i.e. D32D, S33S, G34G etc, was 
almost always zero across all the residues, which in itself validated the rate of change of 
activity scores obtained by regression analysis.  
This regression analysis was important, not only in assigning a single score for the β-
catenin activity levels for each amino acid variants across the six segment, but also 
provided a statistically significant validation of the observed differential activity among the 




Figure 4-13: Regression analysis of the β-catenin activity across the target region. A 
heatmap of the mutational effect was plotted to analyse the differential activity among the mutants. 
4.2.4.8 Analysis of β-catenin mutational effect for the mutations observed 
across different cancer types 
In Chapter 2, I had tabulated the mutational spectrum for each tumour type using the 
COSMIC database. In order to establish how the mutations found in a particular cancer 
type aligned with the mutational scores from the regression analysis, the mutation 
frequency vs mutational effect graph was plotted for each cancer. These graphs were 
made by Deepti Vipin in Anagha Joshi's group in The Roslin Institutute. 
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The mutations observed in the tumours of the parathyroid, prostrate, testis, urinary tract 
and oesophagus, specifically select for medium to higher range of mutational effect (Fig 
4-14 A-E). In none of these tumour types are there any mutations with lower effect, which 
suggests a preferential requirement an increased β-catenin activity among these tumour 
types.  
Contrary to the selection of mutations with an increased mutational effect observed in the 
above tumour types, the mutations selected for in the salivary gland yield a very low 
mutational effect (Fig 4-14 F). The β-catenin mutation in the salivary gland are confined 
to two residues, I35 and T41.I35T is the most frequently occurring mutation, followed by 
a lower incidence of T41P mutations, and both these mutations contribute to a very low 
mutational effect. 
Next, the tumour types could be categorized into those having mutations of both lower 
and medium to higher mutational effect. Such a pattern was observed in the tumours of 
bone, biliary tract, CNS, lungs, ovaries, pancreas, pituitary, small intestine and breast 
(Fig 4-14 G-0). However, very few mutations that contribute to a lower effect could be 
observed in these tumour types and were present at a very low frequency when 
compared to the mutations that yield a medium to higher activity level. A similar pattern 
of mutations of both lower and medium to higher effect was seen even in the tumours 
stomach, however, these tumours had a slightly larger number of mutations that 
contribute to the lower mutational effect (Fig 4-14 P). The tumours of the thyroid and 
hematopoietic and lymphoid tumours although they had mutations of both lower and 
medium to higher mutational effect, in these tumours the mutations that contribute to the 
lower mutational effect outnumber those that yield a medium to higher effect (Fig 4-14 Q-
R). 
The tumours of the endometrium, large intestine, liver, skin and soft tissue, had very a 
wide spectrum of β-catenin mutations with varied mutational effect giving a scattered 
pattern (Fig 4-14 S-W). The large intestine and soft tissue, although they had a scattered 
pattern with multiple mutations of different mutational effect, the two mutations S45F and 
T41A giving a medium to higher effect occurred at an increased frequency in both these 
tumour types, especially prominent in the tumours of the soft tissue. The mutations in the 
kidney and adrenal gland tumours had a similar varied mutational effect, however, the 
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number of different mutations observed were lower in this tumour type (Fig 4-14 X-Y). 
Also, the kidney and adrenal gland had a higher frequency of S45P and S45F mutations. 
These two mutations present at an increased frequency, especially among the adrenal 
gland tumours, conferred a medium mutational effect. The distinct pattern of mutational 
effect conferred by the observed spectrum of mutations across the different types of 
tumours, indicates the presence of an activity based selection mechanism to be one of 
the major factor contributing to tumour type specific mutational bias. 
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Figure 4-14: Analysis of β-catenin mutational effect for the mutations observed across 
different cancer types. Graphs A-Y represents the mutational effect (m value) vs frequency of 
mutations observed for each of the different tumour types compiled from COSMIC database.
130 
 
4.2.4.9 Analysis of the Background mutational rate 
In addition to selection of mutations based on their functional significance, the differences 
in the sensitivity to endogenous and exogenous agents, and mutational processes, have 
been known to contribute to a distinct tumour type specific mutational signature. The 
preferential selection of G to T transversion in the p53 tumour suppressor gene is 
commonly observed in lung cancers associated with smokers (Pfeifer et al., 2002). The 
AFB1-N7-Gua, the primary adduct formed by the reaction of the aflatoxin B1 with 
guanine, predominantly results in a specific G-T transversion in liver tumours, in patients 
with increased exposure to this fungal metabolite (Aguilar, Hussain and Cerutti, 1993). 
Similarly, the C to T transitions of the dipyrimidine residues and CC-TT double base 
change in the p53 gene are a distinct feature in Ultraviolet B (UVB) induced tumours of 
the skin (Brash et al., 1991). In addition to the environmental mutagens, several other 
endogenous processes are also capable of leaving a distinct fingerprint in the cancer 
genome. The cytosine deaminase activity of the APOBEC enzymes is the source of the 
mutations observed in the helical domain of PIK3CA gene across various cancer types 
(Henderson et al., 2014). The mutations in the mismatch repair genes are also associated 
with specific mutational signature. Included among these, are mutations in MUTYH gene 
that codes for the DNA glycosylase involved in BER, which are known to result in 
increased proportion of 8-oxoguanine induced G-T transversion, in various oncogenes 
and tumour suppressors in CRCs (Viel et al., 2017). With evidence of various mutational 
processes in contributing to the tissue specific mutational bias, in the recent years, more 
and more studies are beginning to focus on the analysis of background mutational profile, 
to be able to categorize tumour types based on the mutational signatures. 
It was thus important for us to analyse the background mutational rate, to understand 
how much of the difference observed in the β-catenin mutational pattern is due to the 
underlying differences in the mutational processes that different cancers with β-catenin 
mutations are exposed to. The analysis of the background mutational rate was performed 
by Ailith Ewing in Colin Semple's group in IGMM. The whole genome (or exome) 
sequencing data for samples with β-catenin mutations were collected from the TCGA 
database. However, except for liver and endometrial tumours, the number of tumour 
samples with whole genome sequencing data for other tumor types was sparse, hence 
the analysis was done only on these two tumour types. 
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The likelihood of a given amino acid substitution within the β-catenin hotspot region  was 
calculated for liver and endometrial tumours using whole exome sequencing data from 
the TCGA project (described in detail in the materials and methods section). The 
mutational likelihood was then plotted against the previously calculated regression score 
(mutational effect), also taking into account the relative incidence of the mutational 
variants (depicted by the circle size).  
The majority of β-catenin mutations selected for in both tumour types are typically those 
having a higher likelihood, and contributing to medium to higher mutational effect (Fig 4-
15A and B). Although mutations with high likelihood and lower mutational effect can be 
seen in both the tumours, their incidence is much lower than those that yield an increase 
in the mutational effect. Comparison of both the tumour types indicate that specific 
mutations selectively happen in each of these tumour types despite having a high 
likelihood of occurrence. For example, the 36HP mutation is observed at a relatively high 
frequency in the liver, when compared to the endometrium, where no incidence of H36P 
mutation has been recorded (from sequencing data obtained from TCGA database), 
although the likelihood of occurrence of 36HP is high in both these tumour types. 
Likewise, specific mutations having a similar likelihood of occurrence in both these tumors 
do not always happen at a similar frequency in the two tumours. For example the 41TA 
mutation have similar likelihood of occurrence, but are observed at a higher frequency in 
the tumours of the liver compared to the endometrium, indicating a tissue specific 
selection bias based on functional significance. 
Overall, these results indicate that both background mutational profile and the β-catenin 
activity are essential forces that together contribute to the specificity of the observed 
mutational pattern in the liver and endometrial tumours. Although the likelihood of the 
occurrence of a given mutation plays an important role in determining the presence of 
these mutations, selectivity based on tumour specific functional significance seemed to 
be a much more dominant force in determining the distinct mutational spectrum observed 








Figure 4-15: Analysis of the background mutational rate. Graphs representing the likelihood 
of amino acid substitution vs the corresponding regression score (effect) and also taking into 




The complexity of the cancer genome landscape is defined by a variety of mutations, 
often leaving a distinct imprint specific to the particular tissue/organ in which they are 
observed. The spectrum of mutations in a particular cancer type may be a result of 
various selection processes. Two of the well documented selection principles include A) 
selectivity based on the specific activity conferred by the variant, particularly of those 
increasing the fitness and in the process providing a specific tumorigenic advantage to 
the clonal population – in accordance with the Darwinian evolutionary principles or B) the 
susceptibility to exogenous and endogenous agents/processes producing a specific 
background mutational signature. These two principles either on their own or in 
combination have been known to be the major contributors of the mutational bias 
observed across different cancer types. 
Having observed a strong preferential selection of specific residues and amino acid 
substitutions in the mutational spectrum of CTNNB1 across various tumour types, firstly 
I sought to explore if different β-catenin activity levels can be the Darwinian force to select 
for specific mutations by performing a saturation mutagenesis screen. The highest 
frequency of mutations was observed between the residues L31-G50 in the exon 3 region 
of β-catenin, and hence I choose to perform a saturation mutagenesis screen of this entire 
stretch of 20 residue region of the β-catenin mutational hotspot. 
The TCF/Lef:H2B-GFP reporter mESC was the cell line of choice as it allowed 
quantitation of β-catenin activity at single cell resolution, which meant that we could easily 
FACS sort the cells into different segments of the activity spectrum, and this would 
provide an efficient system to assess the allele specific activity of the β-catenin variants. 
These cells were derived from blastocysts cultured in R2i and were sent to us after being 
cultured in the same media for a few passages. Since the presence of GSK3β inhibitor 
in the R2i media would interfere in phenotyping the mutant cells, I tried to ween them off 
from R2i to normal ES media. Even after culturing on feeders and weening them of R2i 
by gradual reduction of 2i, these cells still failed to adopt to normal ES media conditions 
evident by increased differentiation and cell death when cultured for over a week. 
However, I observed that the cells could keep their morphology intact and maintained an 
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undifferentiated state when cultured normal media for 2-3 days, and this short time scale 
was also sufficient for reduction of β-catenin activity.  
It was further necessary to carry out this screen in heterozygous condition by targeting 
only one allele and keeping the other allele as WT. This was important, not only to 
maintain physiological relevant scenario, but as the screen is based on NGS of pooled 
cells, and with CRISPR being biallelic, it is not possible to differentiate clean 
heterozygous mutants from compound heterozygous mutants with indel on the other 
allele. Furthermore, the presence of indel in one of the alleles may alter the phenotypic 
response of the specific missense allelic variant. For this purpose, as discussed in 
chapter 3, I tried to initially generate a PAM mutant heterozygous cell line but even after 
several attempts I was unable to generate this cell line. In addition, our initial strategy of 
using ssODN as HDR repair template also remained unsuccessful. However the targeting 
approach based on positive negative selection strategy puDeltatk selection along with 
the HDR vector library that was designed to overcome these drawbacks proved to be 
very successful.  
The analysis of each of the six segments of the sorted population provided the initial 
evidence of the allele specific variation in β-catenin activity. As expected, the serine and 
threonine residues that govern the regulation of the phosphorylation dependent 
stabilization of β-catenin were among those having a maximum impact on the TCF 
mediated β-catenin activity. The overall increase in β-catenin activity by the amino acid 
variants of the priming S45 residue was lower in comparison to the other residues in the 
sequential cascade. These results already contradict the current dogma of β-catenin 
activity based on the sequential phosphorylation. Previously, it has been shown that a 
colorectal cancer cell line with endogenous S45 mutation (S45F) had  phosphorylated 
T41/S37/S33 pool in the absence of S45 phosphorylation showing, S45 priming is not 
essential for GSK3 mediated phosphorylation of residues T41,S37 and S33 (Wang, 
Vogelstein and Kinzler, 2003). These observations may suggest S45 priming dependent 
sequential phosphorylation model of β-catenin regulation is not sufficient to explain this 
complex pathway.   
In addition to the S45 residue, the overall β-catenin activity also varied among the T41, 
S37 and S33 mutants. The S37 mutants showed the highest overall increase in β-catenin 
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activity. The overall β-catenin activity conferred by the S33 variants also follow a similar 
trend as S37 mutants. The phosphorylation of both S37 and S33 residues are known to 
be important for the recognition by E3 ubiquitin ligase which might be the reason for the 
observed effect (Hart et al., 1999). However the proportion of the S33 variants in the high 
activity segments was much lower than that observed for S37 mutants which indicate that 
the two residues might be differently regulated. In addition to the phosphorylatable 
residues, the D32 and G34 variants are also capable of increasing the β-catenin activity. 
The D32 and G34 residues are also known to be a part of the degron motif and the 
observed effect of mutations at these residues underscores their significance in 
regulation of β-catenin activity. 
Furthermore, for each of these six residues, there exists variation in the proportion of 
amino acid variants across the different segments, indicating that not all amino acid 
variants are capable of increasing β-catenin activity to a similar extent. The 
phosphorylatable S33, S37, S45 and T41 residues when mutated to S33T, S37T, S45T 
and T41S, respectively, fail to increase the β-catenin activity suggesting that the serine 
and threonine residues are interchangeable at these sites. The aspartic (D) and glutamic 
acid (E) due to their structural resemblance to phosphoserine and phosphothreonine are 
often used as their phosphometics. However, except for S33E, the substitution of 
phosphorylatable S and T residues with D or E did not mimic the WT β-catenin activity 
levels in our screen. In addition, variable increase in activity levels were observed among 
the amino acid variants for a specific residue. For example, among the T41 variants the 
T41P had the highest frequency in the P4 segment, whereas majority of the residues 
were seen to have higher frequencies either in the P5 or P6 segments, and the T41I, 
T41A (also the most frequently observed T41 variants in our COSMIC analysis) are 
among the only few variants with highest frequency in the P7 segment. This variability in 
TCF dependent β-catenin activity among the amino acid substituents was observed for 
all the four phosphorylatable residues and also for residues D32 and G34. The observed 
differential activity response by the amino acid variants, however, cannot be explained 
based on the current knowledge of β-catenin regulation and will need to be further 
investigated by performing biochemical and structural analysis of these variants on their 
own and also in the combination with their interacting partners.   
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The structural analysis of the β-catenin degron motif predicted that any hydrophobic 
residue can be tolerated at position I35 and any residue can be tolerated at residue H36 
(Wu et al., 2003). A similar observation was made from our screen with majority of the 
hydrophobic residues seem to be well tolerated at the residue I35 in comparison to the 
hydrophilic residues (with the exception of asparagine and glycine where opposite trend 
was seen). Similarly, at the residue H36 any nonsynonymous mutation was tolerated 
except proline. H36 substitution to proline was the only non-synonymous substitution 
giving an increased β-catenin activity and incidentally among the H36 mutations 
observed in various cancer types, H36P substitution was most commonly selected for 
especially among the tumours of the liver. However among all the H36 variants how 
proline alone is capable of increasing the β-catenin activity remains to be understood.  
The graphs of the regression vs the frequency of mutations for each of the individual 
tumour types obtained from COSMIC database showed a distinct pattern of activity levels 
for each of the tumour types. The mutations observed in majority of the tumours were not 
confined to a single activity level but instead selected for different activity ranging from 
low, mid to high levels. The genotype-phenotype study of liver tumours by Rebouissou et 
al have provided evidence of a similar selection of mutations based on activity levels 
(Rebouissou et al 2016). In this study, the HCC were seen to particularly select for 
mutations with medium or low activity levels, compared to HCAs wherein a selection of 
mutations with a lower or medium activity was preferred. The mutations of lower activity 
when present in HCCs, almost always had an additional mechanism (either LOH, 
duplication of allele or an additional β-catenin activating mutation) leading to higher 
activity levels. In addition, different β-catenin mutations were seen to associate with 
mutations in specific genes. In HCAs, the mutation at residue T41 was observed to be 
frequently associated with mutations in the IL6ST gene. However, the β-catenin S45 
mutations were mutually exclusive to these JAK/STAT activating IL6ST mutations. A 
similar association of specific genetic alterations is observed in Wilm's tumour, where the 
inactivating WT1 mutations are found to co-occur with mutations at S45 residue of β-
catenin (Maiti et al., 2000). These studies indicate that many factors including the 
requirement of specific activity levels by tumour sub types, additional genetic alterations 
producing an increased activity level, preferential selection of certain β-catenin activity 
level together in association with specific genetic alterations producing a synergistic effect 
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may contribute to the selection of specific activity levels, and provide a possible 
explanation for the selection of a distinct pattern of low, mid and higher mutational effect 
observed in our study for the majority of the tumour types. 
In addition to analyzing the selection of mutation based on activity levels, it was also 
important to understand the contribution of the background mutational profile in the 
observed preferential selection of the different β-catenin mutations in the hotspot region. 
Increased exposure to environmental mutagens such as tobacco smoke, UV rays, fungal 
metabolite aflatoxin and other endogenous processes including the cytosine deaminase 
activity of the APOBEC enzymes, transcriptional strand bias DNA mismatch repair genes 
have all been known to account for the tumour type specific mutational signature. Besides 
saturation mutagenesis screen, we also performed an analysis of the background 
mutational rate of β-catenin. The investigation of the likelihood of amino acid substitution 
in the β-catenin hotspot region was however limited to the liver and endometrial tumour 
types, due to the unavailability of good sample size of whole exome sequencing data in 
the TCGA database for the other tumour types. The analysis of mutational likelihood, 
together with the corresponding regression score of the various amino acid substitutions 
in the β-catenin hotspot region, and also taking into consideration the relative frequency 
of occurrence for liver and endometrial tumours suggests that, although the background 
mutational rate does contribute to the presence of the mutation, the selectivity based on 
tissue specific functional significance might play a more dominant role in contributing to 
the observed mutational bias for the two analysed tumour types. These results further 
signifies the genotype-phenotype correlation of the β-catenin mutations to be a major 

























5.1  Introduction  
The analysis of COSMIC database revealed mutations at various residues in the exon 3 
region of CTNNB1 gene, and also further selection of different amino acid variants among 
different tumours. The saturation editing of exon 3 region of β-catenin provided insights 
into the existing genotype-phenotype variations among the various mutations, and as a 
complementary approach, we decided to generate clonal cell lines of the known 
mutations observed in cancers that would allow in-depth functional analysis. However, 
as it is not possible to study all of the observed mutations in great detail, we selected to 
study the top six mutations and the subsequent amino acid substitutions observed at a 
high frequency (that were also statistically significant) across various cancer types. In this 
second approach, heterozygous β-catenin mutant cell lines were generated to 
understand the genotype-phenotype correlation among these observed mutations.   
The variability in HDR frequency, and the generation of heterozygous mutants using 
ssODN as repair template, as evident by the differences in editing rates in the initial round 
of multiplex targeting, required the need for a new strategy. The puDeltatk counter 
selection strategy in combination with vector based HDR template proved to be a 
successful combination for saturation editing assay, therefore, the same strategy was 
adopted for the generation of heterozygous β-catenin mutant cell lines. For this purpose, 
as detailed in chapter 3, a heterozygous β-catenin KO E14 cell line with puDeltatk counter 
selection cassette and a β-catenin golden gate destination vector was generated. In this 
chapter, a detailed view of the cloning of 26 targeting vectors followed by multiplex 
targeting in E14 β-catenin KO cell line will be provided. Using this approach, cell lines 
harbouring the top 6 statistically significant residues with all the significant amino acid 
substitution (4̴-5 amino acid substitution for each residue) were generated. The β-catenin 
activity in these mutant cell lines was measured by transfection of luciferase reporter 
constructs (TOPflash/FOPflash luciferase reporter). In addition, the differential gene 
expression in these mutant cell lines were further analysed by Taqman assay to 




5.2  Results 
5.2.1 Cloning of multiplex Targeting vectors 
The targeting vectors (TVs) for multiplex targeting were generated using the same β-
catenin backbone vector that was previously used for cloning of the TVs for saturation 
editing assay. Double stranded (ds) oligos with BbsI site and the desired mutation were 
ordered as separate pools for each of the six residues. Six sets of cloning was performed, 
and the transformants were preliminary screened by colony PCR. Since the β-catenin 
backbone vector had the region of interest deleted, the successfully cloned vectors would 
reintroduce the insert, and could be easily identified based on size difference of the 
amplicon. The PCR positive clones were sequenced by Sanger sequencing. One correct 
clone for each mutation was selected and maxiprep plasmid isolation was individually 
done for of each of the 26 multiplex targeting vectors. 
5.2.2 Generation of heterozygous β-catenin mutant clones by 
multiplex targeting 
Endogenous heterozygous mutants were generated for the various β-catenin mutations 
observed at a high frequency and statistically significant proportions across cancer types. 
Six sets of targeting was performed, wherein CRISPRs targeting the puDeltatk selection 
cassette and the HDR templates with all the selected amino acid variants for a particular 
residue were transfected into the heterozygous β-catenin KO E14 clone. For example, 
for residue T41, HDR vector templates having T41A, T41I, T41P, T41S and T41N 
substitutions were transfected along with the CRISPR/Cas9 guide vectors in a single 
experiment (Fig 5-1). Since the heterozygous β-catenin KO clone was being cultured in 
R2i media, the transfections were carried out in R2i media. Next day post transfection, 
the cells were trypsinised and plated in 10cm dishes in normal ES media and 8hours 
later, the media was supplemented  with FIAU negative selection analogue. Following 
ten days of culture, when visible colonies appeared, 200 clones were picked for each 
targeting, and once confluent each plate was split into two plates. One plate was frozen 




The sequencing of the clones revealed over 80 percent efficiency in targeting. The 
strategy of using positive negative selection in combination with CRISPR Cas9 and vector 
based HDR template once again proved to be a successful combination for generating 
the various mutant clones with high efficiency. 
 
Figure 5-1: Schematic representation of the experimental design for generation of mutant 
cell lines by multiplex targeting.  The CRISPR/Cas9 system combined with multiplex targeting 
to be used to induce mutations at the chosen top six residues along with the corresponding 
substitutions in the endogenous β-catenin gene.  
In order to ensure that the effects we see is not due to the clonal variation but the effect 
of the mutation, I decided to analyse the clones in triplicates (3X26 mutants = 78 cell 
lines). Three clones for each of the mutations was started up in 24 well culture plates, 
expanded and frozen down, and DNA was isolated and re-sequenced for confirmation of 
mutation (Fig 5-2). After confirmation of mutants, cells were started up and plated for 












Figure 5-2: Sequence validation of heterozygous β-catenin mutations. (A-F) Representative 
image of the sequence analysis of the amino acid variants for each of the six residues. 
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5.2.3 Luciferase assay of E14 multiplex clones 
Reporter gene assays based on luciferase system are commonly used to analyse gene 
expression and the strength of transcriptional regulatory elements such as promoters and 
enhancers. Such luciferase based systems have also been adapted to measure the 
Wnt/β-catenin activity. Currently, the most sensitive assay is the 
Super8XTOPflash/Super8XFOPflash which was generated in the Moon lab. These 
vectors are the modified versions of the pTOPflash and pFOPflash reporter constructs 
which were originally developed in Hans Clevers lab. The Super8XTOPflash vector 
construct consists of 7 sets of TCF/Lef DNA binding elements, upstream of a minimal TA 
viral promoter, which drive the expression of firefly luciferase enzyme and provides a 
sensitive and efficient approach for quantification of β-catenin activity. As a control, the 
Super8XFOPflash vector was generated in which these TCF/Lef binding sites were 
mutated. I decided to use this well establish system to compare β-catenin activity in 
different mutants. 
Transient transfections were performed, where the Super8xTOPflash and FOPflash 
vectors were co-transfected with renilla luciferase construct. The signal generated from 
Renilla luciferase system was used as an internal vector control to normalize the signal 
for the cell numbers in each well. The transfections were performed in triplicates and the 
signal was measured 36 hours post transfection. Simultaneously, an additional set of 
transfections were performed for each mutant cell line to be used for treatment with 
DKK1.The Wnt pathway antagonist DKK1 acts by binding to the LRP6 co-receptor 
keeping the pathway turned off. Since the mutants generated were heterozygous, 
treatment with DKK1 would prevent any ligand binding and potentially abrogate the 
activity of WT allele, and provide evidence if the mutant allele is capable of constitutionally 
activating the pathway. The concentration of DKK1 for optimal suppression of WT 
endogenous β-catenin activity in E14 was previously optimized in the lab.  
Six sets of luciferase assay were performed, with each set involving all the variants of a 
particular residue. In each plate, WT E14 cell line was used as a control, to make the 
comparison of each plate possible. As expected, both the cells transfected with the 
Super8x FOP flash and the untransfected controls gave very low luciferase signal. For 
comparison of the TOP signal from different mutant residues, the fold change was 
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calculated by taking the combined average (TOP/Renilla) of the independent clones, 
each normalized to WT E14 values from that particular experimental data set, and then 
plotted on a single graph (Fig 5-3). The β-catenin activity of the mutant clones differed 
when compared to the levels of WT E14, with certain clones of S37 and T41 mutants 
reaching over 800 fold increase in β-catenin activity. With the exception of T41S mutants, 
whose activity was similar to that of the WT E14 control, every other mutant had higher 
β-catenin activity levels. Furthermore, the range of β-catenin activity differed between the 
residues and also for the different amino acid variants for a given residue, clearly 
indicating the presence of a genotype-phenotype correlation among β-catenin mutants. 
The S37 residue showed the highest increase in activity levels along with few variants of 
T41 residue. This was followed by D32, G34 and S33; and S45 variants, which exhibited 
much lower increase in activity compared to the S37 mutants. Statistical analysis was 
done by performing one way ANOVA. This was followed by multiple comparison by 
Tukeys post ad hoc test, wherein a pairwise comparison of the 26 variants with one 
another and with E14 control was performed. Among the 351 possible combination, 
statistically significant differences (p<0.05) was observed between over half (180 pairs) 
of the compared pairs (Appendix 2A). The differences in β-catenin activity between the 
various amino acid variants for a given residue was significant, especially among T41 





Figure 5-3: Analysis of β-catenin activity by Luciferase assay. Luciferase assay was 
performed for analysis of β-catenin activity among the various amino acid variants across the top 
six residues generated by multiplex targeting. Six sets of luciferase assay was performed and the 
TOP values were normalized to the E14 WT control. The values of the triplicate clones were 
combined and the average of the normalized TOP values were plotted for each of the mutant. 
Statistical analysis was done by performing one way ANOVA followed by multiple comparison by 
Tukeys post ad hoc test (Refer Appendix 2A). Renilla was used as internal vector control. 
Next, the analysis of luciferase results from DKK1 treatment resulted in considerable 
reduction in the endogenous β-catenin activity in the WT E14 untreated control cell line 
in comparison to DKK1 treated samples (Fig 5-4).  
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Figure 5-4: Luciferase analysis of WT E14.  The β-catenin activity of the WT E14 cell were 
measured following treatment with Wnt antagonist DKK1. The luciferase measurements are from 
the 6 experiments performed for analysis of β-catenin activity of the amino acid variants for each 
of the 6 residues, in each case WT E14 was used as control. Error bars represent SD. 
However, the effect of DKK1 varied across the mutant clones, and the independent 
clones for a particular mutation also showed differences in their response to DKK1. 
Hence, the activity of the independent clones for a particular mutation were not combined 
and the results are shown separately and in independent graphs. The fold change was 
calculated by normalizing the values (TOP/Renilla) of each clone to the WT E14 control. 
As observed in the graphs, clonal variation in response to DKK1 treatment was evident 
in G34, S33 and S45 mutants, with few clones showing slightly decreased activity, and 
few other clones showing increased activity even among the independent clones for a 
particular mutation (Fig 5-5B, C and F). However D32 (except for one of the clone), S37 
and T41 I and A mutants showed consistently higher levels of β-catenin activity in 
response to DKK1 treatment (DKK1+) in comparison to their respective untreated 
controls (DKK-) (Fig 5-5A,D and E). The increase in the β-catenin activity, was more 
prominent especially among the S37 clones, where more than double the β-catenin 





























Figure 5-5: Luciferase analysis of DKK1 treated cell lines.  The β-catenin activity of the various mutant clones was measured following 
treatment with Wnt antagonist DKK1. The relative Luciferase results of the DKK1 (+DKK1) treated samples were compared with the untreated 
control (-DKK1). In each case WT E14 was used as control. The error bars represent SD.
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5.2.4 Comparison of luciferase with regression saturation data   
In order to see if the luciferase data supported the results from the regression analysis of 
the saturation editing, I plotted regression values of these top 6 residues we used in 
multiplex targeting. As shown in figure 5-6, the activity levels measured by luciferase 
based system resembled the regression analysis in chapter 4, providing a convincing 
validation of the observed results. 
                                             
                                            
Figure 5-6: Comparison of luciferase with saturation data for multiplex clones. (A) β-catenin 
activity of the top six residues (E14 clones) generated by multiplex targeting, analysed using 
luciferase assay. (B) β-catenin activity of the top six residues (TCF clones) generated by 
saturation assay, analysed by the TCF reporter activity. 
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5.2.5 Taqman assay of E14 multiplex clones 
The onset of gastrulation marks the specification of germ layers and involves various 
cellular transforming events characterized by spatio-temporal regulation in gene 
expression. The Wnt pathway is one of the important signaling cascades that plays an 
essential role in controlling a number of characteristic transition events of gastrulation 
including the β-catenin dependent direct/indirect regulation of multiple genes involved in 
the differentiation of the ectoderm, endoderm and mesoderm lineages. In addition, β-
catenin is known to be essential for maintaining the pluripotency of ES cells. In this view, 
the various β-catenin mutant cell lines generated by multiplex targeting were analysed 
for the expression of few of the differentiation markers and genes involved in pluripotency 
network by performing Taqman assay.  
T/ Brachyury is a pan early stage mesodermal marker associated with the induction of 
EMT, and exhibits localised expression at the primitive streak and later in the notochord 
near the posterior/caudal end of the embryo. Brachyury expression is also known to be 
associated with induction of EMT. Similar to its role observed in embryonic development, 
Brachyury expression in mESCs has been reported to correlate with its in-vivo functions, 
with increased expression observed in differentiated mesenchymal like cells at the 
leading edge of EMT (Turner et al., 2014). Taqman analysis of T expression showed 
heterogenous expression among the β-catenin mutants (Fig 5-7A). Although there exists 
clonal variation, overall comparison of expression indicated the S37 mutants having 
higher expression in comparison to the other residues and the control, possibly indicating 
a more mesenchymal like phenotype. T/Brachyury was identified as a target of Wnt/β-
catenin signalling (Arnold et al., 2000), and closely correlates with the β-catenin activity 
analysed by luciferase assay.  
The T box protein Tbx3 that promotes mesendoderm specification and is also important 
for maintaining pluripotency of mESCs, and the homeobox protein Cdx1 known for its 
role in axial/vertebral patterning with expression later localized to intestinal endoderm, 
are both known to be direct transcriptional targets of canonical Wnt signaling 
(Subramanian, Meyer and Gruss, 1995; Silberg et al., 2000; Pilon et al., 2007; Renard et 
al., 2007; Weidgang et al., 2013; Russell et al., 2015). Both these transcriptional targets 
displayed heterogeneous expression across the various mutants, with comparatively 
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lower expression along the S37, T41 and S45 residues (Fig 5-7 B and C). The binding of 
TCF/β-catenin to the Cdx1 promoter mediated by Wnt stimulation is shown to induce its 
expression (Lickert et al., 2000). However the S37 T41I/A clones with increased TCF 
based reporter activity do not show a corresponding induction in Cdx1 expression.  
Furthermore, the expression of Fgf5, a marker for neural precursor that is expressed in 
the embryonic ectoderm was higher in T41S clones compared to the rest of the mutants, 
indicating a possibly differentiated clonal population (Fig 5-7D)(Hébert, Boyle and Martin, 
1991). Gata4, a known marker of yolk sac endoderm and later known for its role in in the 
specification and differentiation of cardiac lineage, once again showed variable 
expression (Stefanovic and Christoffels, 2015). However, the canonical Wnt β-catenin 
signaling negatively regulates the expression of Gata transcription factors imparting an 
antagonistic effect on cardiogenesis (Afouda et al., 2008). A similar reciprocal correlation 
between β-catenin activity and Gata4 expression was observed in some of the mutant 
clones, with higher transcript levels observed for clones of T41S and S45C variants that 
were among the mutants with the lowest TCF reporter activity (Fig 5-7E).  
The classic pluripotency markers Pou5f1 (encoding Oct4) and Nanog showed 
considerable but heterogeneous expression among all the mutant clones in comparison 
with the WT control (Fig 5-7F and G). In addition, the transcript levels of Klf2, another 
gene known to be involved in pluripotency also fluctuated among the mutants (Fig 5-7H). 
Finally, Cdh1 (encoding E-cadherin) expression was slightly higher in D32 and S33 
mutants compared to the other mutants and control (Fig 5-7I). Although there exists 
heterogeneity in expression, overall, the results of Taqman analysis indicate the presence 




























Figure 5-7: Taqman analysis of mRNA expression for markers of differentiation and pluripotency genes. (A-I) The multiplex clones 
were analysed for differential gene expression of selected markers. Triplicate (in some cases duplicate) clones were analysed for the various 
amino acid variants across the top six residues. The mRNA expression of the target gene was obtained by normalizing it to the relative 




Mutations in the β-catenin protoncogene have long been studied in various tumours. 
However, generation of in vitro endogenous mutant cell lines has been a laborious task, 
hindering the possibilities of functional analysis of the various observed genetic 
anomalies. The advancements in gene editing techniques, and the ease of manipulating 
the endogenous loci with CRISPR/Cas9 system, provided us the opportunity to obtain a 
preliminary overview of the phenotypic consequences of few of the β-catenin mutations 
chosen from our analysis of COSMIC database.  
One of the many advantages of using the CRISPR/Cas9 system is the convenience of 
combinatorial editing of multiple loci, or as in our case multiplex editing of a single locus 
of interest. However, some targeting strategies still require the use of large targeting 
vectors instead of single stranded short oligos, which is more laborious and less time 
efficient. The generation of 26 targeting vectors required for this project was a big 
challenge, however, with the strategy described in chapter 3 and 4, I achieved a cloning 
efficiency of 100 percent, making every colony picked correctly cloned. Using our 
strategy, within a very short space of time and effort, the required tools were generated. 
Like in the saturation editing assay, I used a heterozygous β-catenin KO E14 cell line with 
CRISPR/Cas9 technology. Having guides specific to the selection cassette ensured 
keeping the WT β-catenin allele intact, resulted in generation of heterozygous mutant cell 
lines with an HDR efficiency of over 80 percent. I also used a multiplex approach for each 
residue, which meant that in only six targetings, I generated a total of 78 cell line for 26 
mutants. The presence of clonal heterogeneity in mESCs required the analysis of multiple 
clones, and hence I chose to analyse triplicate clones for the majority of the mutants. 
Initially, the endogenous mutant cell lines were analysed for differences in β-catenin 
activity by the widely used TOP/FOP luciferase assay. Although in an ideal scenario this 
analysis should have been performed all together in a single experiment, it was not a 
practical option for this case due to the large number of samples. Therefore the 
experiment was done in 6 batches, however, I included the same WT E14 control cell line 
in every experiment. The values from all samples were normalized to the control cell line, 
which made it possible to compare the results across all the mutant clones. All of the 
168 
 
mutants, except T41S, showed an increase β-catenin activity in comparison to the 
control. The Gsk3 being an S/T kinase explains the lower activity level conferred by the 
T41S variant. Similar to the saturation analysis, the activity from each residue was clearly 
different, with S37 being the highest activating mutation, the difference between S37 
variants and S45 variants were very significant, confirming the phenotypical differences 
in these phosphorylation sites. In addition, T41 residue showed big variation among the 
amino acid variants we tested. 
In addition, comparable results obtained from two different reporter systems TOP flash 
luciferase and TCF/Lef:H2B-GFP based on the same principle, performed in two 
separate mESC cell lines E14 and TCF, validates the differential Wnt activity conferred 
by the various mutants. These observed differences in degree of TCF dependent 
activation by the different β-catenin mutant alleles, strengths our hypothesis of genotype-
phenotype correlation among β-catenin mutations. Next, the treatment with DKK1 
inhibitor resulted in an unexpected increased activity level in certain clones, indicating a 
possible compensatory mechanism in D32, S37 and clones of T41. These mutant clones 
being heterozygous, we would expect the DKK1 to have an effect at least on the WT β-
catenin, causing it to degrade in the absence of Wnt signal and thus resulting in reduced 
β-catenin activity. However, the mutant allele may be constitutively expressed and 
unresponsive to Wnt dependent activation. It can be speculated that the WT β-catenin in 
every clone might still be subjected to degradation in response to DKK1 treatment, 
resulting in reduced activity, similar to that seen in the WT EI4 controls. However, the 
decrease in β-catenin activity in the mutant clones might be compensated by the activity 
of the expressed mutant protein. This compensatory effect, may occur at varying rates 
and clones such as D32, S37 and T41 I and A with overall higher activity thus may have 
slightly higher compensatory effect resulting in the increased β-catenin activity observed 
in these clones in response to DKK1 treatment. However, the exact mechanism as to 
how these clones act differently to DKK1 treatment remains to be investigated. 
Analysis of the target genes and the differentiation markers in these mutant cells would 
be a way to understand the effect of the individual mutations. Ideally this requires a much 
more detailed analysis, such as single cell RNA seq, however, the limitations in time and 
resources did not allow to do this. So I decided to perform a small pilot experiment using 
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Taqman assay, to investigate how the stem cell markers and the well-known targets of 
this pathway were affected,  
Although β-catenin activity is required for stem cell renewal in mouse ES cells, it has also 
been shown that it promotes mesendodermal differentiation (Bakre et al., 2007). Adding 
recombinant Wnt protein or GSK3β inhibitor to these cells, to increase β-catenin activity, 
resulted in differentiation towards mesenchymal lineage, even though the cells were kept 
in culture media which was shown to keep them in pluripotent undifferentiated state, and 
high β-catenin activity from these mutant allele could already be sufficient to result in 
some degree of  differentiation. In addition to mesendodermal differentiation, increasing 
the β-catenin activity by overexpression of full length or the N terminal truncated forms of 
β-catenin, has been shown to induce neural differentiation in mES cells (Otero et al. 
2004). Given the importance of β-catenin in facilitating lineage commitment, I therefore 
added some differentiation markers in my study. 
The Taqman analysis of the differentiation markers that are also known to be the 
downstream targets of β-catenin showed variable transcript levels, not particularly 
correlating with the β-catenin activity levels. Furthermore, the marker genes showed a 
heterogeneous expression profile with fluctuations existing even among triplicates clones 
harboring the same mutations. However, comparison of the overall expression profile 
between the variants points towards a probably variability and existence of a differential 
expression that is either directly or indirectly regulated by the mutant β-catenin allele. The 
N terminal regulatory domain has been attributed to contributing to the stability of β-
catenin and no known signaling or transcriptional regulatory activity is attributed to this 
domain. If not based on the stability dependent activation (with downstream target gene 
expression not particularly correlating with the activity levels), it remains to be explored 
how each of these β-catenin mutant alleles contribute to the observed variation in gene 
expression. In addition to the differentiation markers, the analysis of Pouf51, Nanog and 
Klf2 revealed a considerable but heterogeneous expression of these pluripotency 
markers among all the mutant clones in comparison to the WT E14.  
The Taqman analysis although provided clues on the existing differential gene expression 
among mutant clones, however to draw definitive conclusion on the role of each of the 
mutant alleles requires the analysis of the complete transcriptional profile, preferably at 
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single cell resolution. Also, each of the mutant alleles may have different or specific 
additional roles compared to that of the wild type (probably contributed by the changing 
binding specificities) and hence it is difficult and also inappropriate to directly extrapolate 
the phenotypic observations of the WT alleles onto their mutant counterparts, without 
performing a detailed analysis. The functional assays performed here only provide a 
preliminary perspective of the existing genotype-phenotype differences among the 


























Mutations in β-catenin gene have long been reported in multiple cancer types. These 
activating mutations result in the aberrant expression of Wnt target genes, many of which 
are known to contribute to various aspects of the tumourigenic process. Although being 
one of the most extensively studied pathways, there is however very little effort made 
towards understanding the molecular consequences of β-catenin mutations observed in 
these tumours. Nevertheless, there is compelling evidence in literature, suggesting that 
the current model for the regulation of β-catenin may not be sufficient to explain this 
complex pathway, and that there may be phenotypical differences among these β-catenin 
mutations. To be able to gain a better perspective of the phenotypic consequences of the 
observed mutational variants, in this thesis, I generated an in vitro system modelling 
these mutations, tested their potential in activating the pathway, and studied the 
genotype-phenotype correlation in β-catenin in cancer. 
Before the in vitro analysis of the genotype phenotype consequences of β-catenin 
mutations, a comprehensive analysis of the spectrum of oncogenic CTNNB1 mutations 
across the various cancer types was necessary. With this in mind, I initially analysed the 
various β-catenin mutations occurring across the different types of cancers using data 
compiled from the COSMIC database. As expected, the exon3 region of β- was observed 
to be the focal point of mutations (specifically between residues L31-G50), with the 
highest frequency of mutations at the phosphorylatable serine and threonine residues 
and the adjacent residues D32, G34.  When I analysed the frequency of each of the 
mutated residue in every cancer type, I saw that there was a preferential selection for 
mutations at different residues in different cancers. I also observed that the bias was not 
restricted to the residues, but also present among the different amino acid substitutions 
across multiple different cancer types. This specific selection of mutations among 
different types of cancers present in statistically significant proportions already pointed 
towards the existence of a fundamental difference between these mutations, that was 
worthy of further investigation. To explore the observed genotype-phenotype correlation 
in β-catenin mutations two complementary approaches, saturation editing and multiplex 
targeting, were adapted. 
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Although overexpression studies have been widely used, and have contributed 
significantly in uncovering the functional importance of multiple oncogenes under various 
conditions in different in vitro systems, they still fail to recapitulate the native context of 
expression. For both our complementary approaches, we therefore decided to study the 
mutants in their endogenous context. The ease and simplistic adaptability of the 
CRISPR/Cas9 system, together with the added advantage to study the effect of the 
mutations in an endogenous context, made it the technique of choice for this 
investigation. However, at the start of this project not many details were available 
regarding the optimal conditions required for efficient targeting in different systems using 
the CRISPR Cas9 technology. Hence, I started with the optimization of the technique. 
We and others, quickly realized that the generation of random insertions and deletions 
were much easier than the precise genome editing due to the active NHEJ pathway. The 
low efficiency of HDR was a set-back, especially for large scale genome editing projects 
such as ours, which required generation of multiple mutants. Although mESCs are known 
to have a higher HDR efficiency than other somatic cells, our initial targeting experiments 
yielded a low rate of HDR editing. By trying different transfection methods, and use of 
HDR enhancing drugs, I found the most optimal condition to edit mES cells. 
One of the other advantages of using CRISPR/Cas9 technology, is the ability to use short 
single stranded oligos as HDR template. This eliminates the need to generate targeting 
vectors (TVs), which is usually the most time consuming part, especially in large scale 
projects. Therefore, this was also my first choice of DNA template in our targetings. 
However, as I started to test various guide RNAs for HDR efficiency, I noticed that, it was 
essential to have the guides cutting site as close as possible to the desired edit. The 
efficiency of HDR was decreasing to almost zero percent only after about 8bp far from 
the cutting site. As I was aiming to edit every amino acid in 20 amino acid region, using 
ssDNA as the DNA template did not seem to be a plausible option. I therefore tested 
using vector as HDR template, and achieved a good efficiency of HDR in the distant 
residues as well.  
Due to the bialleleic nature of CRISPR cutting and an active NHEJ repair mechanism, 
generating clean heterozygous mutations proved to be a challenging task as well. I 
wanted to perform saturation editing in heterozygous condition, not only because this 
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would be more physiologically relevant, but also would ensure that the activity difference 
is due to one specific mutation and not due to additional indel mutations in the other allele. 
This problem was finally resolved by generating a heterozygous β-catenin KO cell line in 
which one of the β-catenin allele was replaced by puDeltatk selection cassette. Using this 
counter selection strategy along with TVs as HDR template proved to be a successful 
combination, and helped us achieve a high rate of HDR throughout the region in both 
approaches.  
The CRISPR nuclease system although provides a highly efficient on target activity, they 
are also known to have off-target effects. Due to time constraints I was unable to check 
the off-target effects of the guides used in this project, which will need to be done in the 
future. Since the introduction of the nuclease mediated genome editing, various methods 
have been adopted to identify the off-targets. The guide designing software have included 
off-target prediction score or rank and based on these scores the loci with predicted off-
targets can be selected, PCR amplified and sequenced using Sanger sequencing to 
check for off-target activities of the guides. However, the computational prediction 
methods are not absolutely fool proof in precise detection of every possible off-target, 
and better options include whole genome sequence techniques for detection of off-
targets. Various methods have been developed including GUIDE-seq, Digenome 
sequencing and BLESS (Zischewski, Fischer and Bortesi, 2017). Since the same guides 
were used for both saturation and multiplex strategies, testing of either the pooled DNA 
from saturation assay or the DNA from few of the independent clonal cell lines generated 
by multiplex targeting will provide evidence of the specificity of the guides used in our 
experimental system. 
The first approach of saturation editing of the β-catenin hot spot, was performed to 
analyse the β-catenin activity levels of all the amino acid variants across L31-G50, 
allowing us to compare the activity levels of both cancerous and non-cancerous 
mutations. The analysis of the proportion of variants for each residue across the different 
sorted population for the first time provided evidence of the of allele-specific activity levels 
conferred by the different endogenous β-catenin variants. The differential activity 
response were mostly confined to the phosphorylatable serine and threonine residues 
and the residues D32 and G34 that are known to be a part of the degron motif. These six 
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residues also being the most frequently observed residues in our analysis of COSMIC 
database, strongly highlights the β-catenin activity levels to be a major criterion for 
selection of these mutations in the tumourigenic process. 
As expected, the synonymous substitutions of residues (D32D, S33S, G34G etc) gave 
no increase in the activity levels. The phosphorylatable S and T when interchanged to T 
or S were seen to produce no increase in β-catenin activity levels. This is in accordance 
with the priming and sequential model of phosphorylation. However, according to the 
priming model the substitution of S45 to other amino acid that prevents its 
phosphorylation should block the GSK3 dependent prevent phosphorylation of the other 
three residues in this sequential cascade, and in turn prevent the ubiquitin ligase 
degradation, leading to increased β-catenin activity. Although the S45 variants are 
capable of increasing the activity levels, the overall strength of activity is much lower 
when compared to the activity levels conferred by T41, S33 and S37 residues, indicating 
the presence of additional mechanism of regulating β-catenin activity even in the absence 
of priming. The phosphorylation of both S37 and S33 have been shown to form a docking 
site for the E3 ligase, however the activity difference of mutations at these two residues 
suggests the possibility of the two residues being differently regulated. In addition to the 
phosphorylatable residues, the D32 and G34 variants were able to increase the activity 
levels, which confirms the importance of these two residues in β-catenin regulation.  
Furthermore, variability in activity levels was evident among the amino acid variants each 
of the six residues. For example although the overall activity of residue T41 was lower 
than that of S37, individual amino acid variants such as T41I and T41A were capable of 
increasing the activity levels in the highest intensity spectrum. Using the regression 
analysis to assign a score of overall activity for each of the amino acid variants, we were 
able to confirm the observed differences in the activity levels for the individual 
substituents for each of the residues from L31-G48. This allele-specific variability 
indicates a differential binding strength of the amino acid variants with their interacting 
protein partners. Overall, these results draw focus on the molecular and biochemical 
properties governing the regulation of TCF/Lef dependent β-catenin activity that still 
remain unexplained.  
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Next, the analysis of the mutational effect vs the frequency of mutations (compiled from 
COSMIC database) of the individual tumour types showed a distinct pattern indicating a 
tissue-specific selection of mutations based on the mutational effect. Majority of the 
tumour types selected for mutations that include a variable range of mutational effect. 
The difference in activity based on tumour subtype, presence of additional mechanism 
that could increase the β-catenin effect and association of specific β-catenin mutations 
with particular genetic alterations might be some of the possible factors contributing to 
the selection of distinct pattern of mutations with low, medium and high mutational effect 
observed in the individual tumour types. Although in this study we did not categorize the 
cancers according to the sub type, doing so would determine if the β-catenin activity is 
indeed subtype specific. In addition, analysis of the whole genome sequencing data for 
each of the tumour samples would help us understand if particular β-catenin mutations 
are associated with specific genetic alteration.  
The analysis of the background mutational rate for the endometrial and liver tumours 
showed that likelihood of amino acid substitution does play an important role in 
determining the presence of a mutation. However, the tissue specific selectivity of 
mutations in these tumour types does not entirely correlate with the likelihood of amino 
acid substitution, suggesting that the Darwinian selection based on functional 
significance has a much larger influence in contributing to the observed tumour type 
specific mutational bias. This analysis of the background mutational rate was restricted 
to liver and endometrial tumour due low number of sample size for other tumour types in 
the TCGA database. In the future, as more and more whole genome or whole exome 
sequences of tumour samples are available, it will be possible to analyse the background 
mutational profile of the various other tumour types, which will give a better perspective 
of the contribution of the mutational processes in the observed tissue specific mutational 
bias. 
These mutations being specific to human cancers, the saturation mutagenesis screen 
could be extended to human cell lines. Similar to mESCs the role of Wnt signaling in self 
renewal and differentiation have been extensively studied in hESCs, making it a suitable 
in vitro model for studying these β-catenin mutations. Wnt Reporter hESCs such as those 
generated by Nusse lab with a similar TCF-GFP system that allows FACS based sorting 
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could be used to perform a similar saturation mutagenesis assay (Blauwkamp et al 2012). 
In addition, tissue specific cell lines can be used to generate the mutations observed in 
that particular tissue type, which will not only provide a more physiologically relevant 
analysis of phenotypic differences in terms of β-catenin activity levels, but will also help 
in understanding the differences in tumourigeneic potential of mutational variants. These 
mutational variants when modelled in specific tissue type could be used for performing 
various conventional in vitro transformation assays including soft agar assay (for analysis 
of anchorage independent growth), focus formation assay (for analysis of loss of contact 
inhibition), scratch assay/transwell migration assay (for analysis of migration and invasion 
potential) and BrdU assay for cell proliferation. Understanding the tumourigenic potential 
of these β-catenin variants through such experiments will provide better insights into the 
disease pathogenesis. 
In addition to in vitro analysis, it would be essential to perform in vivo analysis by 
generating conditional mouse models. Few interesting mutations could initially be 
selected to generate mouse models. For example, based on our screen, the two I35 
variants selected for by salivary gland and liver were seen to have variable mutational 
effect. The I35T variant observed in the salivary gland conferred a low mutational effect 
compared to I35S variant selected for liver cancers that yielded a higher mutational effect. 
Conditional expression of I35T and I35S in salivary gland and liver using tissue specific 
CRE would provide better insights into the phenotypic advantage leading to the observed 
tissue specific selectivity. Traditionally, mouse models with N terminally truncated β-
catenin forms (involving exon 3 deletion) have been used to replicate the constitutively 
active form of β- catenin (Brault et al., 2001; Huelsken et al., 2001) . However, the allele 
specific activity levels of the various β-catenin variants observed in our study questions 
the credibility of using these deletion mutants as a general model for studying the various 
disease phenotypes, and emphasizes on the necessity of modelling the specific mutation 
(also taking into account the amino acid substitution) to draw more physiologically 
relevant conclusions.     
In the second complementary approach the endogenous β-catenin heterozygous clonal 
cell lines were generated to perform functional analysis. Even before the functional 
analysis of the mutant clones, there were several observable differences in morphology. 
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Although due to time constraints the detailed analysis was not possible, the initial 
microscopic observation of the multiplex clones revealed a difference in morphology, 
specifically evident among the T41 and S45 variants. Majority of the mutants from D32, 
S33, G34 and S37 resembled cells being cultured in 2i with a more compact and 
homogeneous morphology, however T41N/P and S45C/Y mostly resembled the wild type 
E14 phenotype with a more scattered and heterogenous appearance. The T41S variants 
started to differentiate and increased cell death was observed after few passages of being 
cultured in normal ES media and had to be shifted to 2i supplemented media for 
continued survival and growth. In addition, the more compact clones seem to grow at a 
slower rate when compared to the clones with a heterogeneous morphology. β-catenin 
is known to be important for both maintenance of stemness and self-renewal of ESCs 
and further experiments to include a detailed analysis of these clones by performing 
alkaline phosphatase staining for analysis of the differentiation state and also analysis of 
the proliferative index and rate of apoptosis of these clones will be needed for better 
characterization of these observed differences.   
The Luciferase assay on multiplex clones once again showed an allele specific β-catenin 
activity level with a pattern similar to those observed by saturation assay. The S37 
variants were among those that conferred the highest activity, and the activity levels 
exhibited by the variants of the priming S45 residue were much lower in comparison. In 
addition, the β-catenin activity between the various amino acid variants for a given 
residue also varied and a significant difference in the activity levels was specifically 
observed among the T41 variants. The T41S variant was the only mutant among the 
multiplex clones not yielding an increase in activity level, and its activity was similar to 
that observed in the WT E14 cell line. Given that GSK3 is a serine/threonine kinase, this 
was expected. Although having activity levels comparable to WT, the inability of these 
T41S mutants to survive in culture without being supplemented by 2i, is unexpected and 
cannot be explained based on the current knowledge of regulation.  
The Taqman analysis of multiplex clones resulted in a heterogeneous expression among 
the triplicate clones for majority of the genes analysed, however there was still evidence 
of differential expression among the β-catenin mutants. For example, the gene 
expression profile of differentiation markers T/Brachyury was specifically enriched in the 
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S37 variants. Differentiation assays towards mesodermal lineage would show whether or 
not these S37 mutants have a preference to differentiate into mesodermal lineage. In 
addition, the β-catenin mutants could be differentiated into neuronal or cardiomyocyte to 
understand if the different mutations confers selective advantage to differentiate towards 
specific lineages.  
Furthermore, it is necessary to analyse the expression of additional β-catenin target 
genes either by performing Taqman assay or by using other conventional techniques 
such as microarray, both of which allow analysis of gene expression profile of known 
genes. However, analysis of the complete transcriptome profile using assays based on 
the second and third generation sequencing platforms including RNA-seq and CAGE-
seq, preferably at single cell level will provide higher sensitivity quantification of 
expression. The analysis of the complete expression profile, will not only help to 
quantitate the expression of known genes, but will also help uncover novel genes 
regulated by these β-catenin variants.  
Both the saturation screen and multiplex assay was performed in heterozygous condition, 
however the saturation vectors and the puDeltatk system have been designed so as to 
allow generation of hemizygous mutant clones. Using g9B CRISPR and targeting the WT 
β-catenin allele and keeping the puDeltatk selection cassette intact in the heterozygous 
β-catenin KO clones, would provide a second option of generating hemizygous clones. 
Although the DKK1 on multiplex clones showed that the activity of the mutant allele to be 
dominant over the WT allele, analyzing the variants in hemizygous condition would further 
help in analyzing the strength of activity confined to the mutant allele. Also, the presence 
of the WT allele in the heterozygous clone might be a complication for downstream 
experimental approaches, and hence, would require the generation of either hemizygous 
or homozygous mutants.  
In the intial round of multiplex targeting using ssODN, I have successfully generated 
homozygous S45 F, C, Y and P mutants, and these can be used as a starting point. 
These S45 homozygous mutants could be used to test the phosphorylation state of 
mutant protein. Wang et al have shown that the T41, S37 and S33 residues can still be 
phosphorylated in S45 mutant cells (Wang, Vogelstein and Kinzler, 2003). This can be 
tested by performing western blot using phospho-specific antibodies. In addition, it has 
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been observed that the S45 variants differ in their localization (Austinat et al., 2008a). For 
the purpose of analyzing the sub-cellular localization, during the course of my PhD I had 
optimized the subcellular fractionation protocol and was successful in separating the 
nuclear cytoplasmic and membrane fragments, but due to time constraints was unable to 
complete the analysis. These clones can also be used for confocal analysis by performing 
β-catenin antibody staining to visualize the localization. These analysis can then be 
extended for other residues, and now that we have all the tools ready it would be very 
easy to generate both homozygous or hemizygous mutants for the rest of the residues. 
The results from both the saturation and multiplex clones have shown allele-specific 
activity levels that cannot be explained by the current signaling model based on the 
sequential cascade, and hence, would require further analysis of the mechanism of 
regulation. In addition to assays to understand the localization and transcriptome profile, 
it is necessary to perform proteomic analysis. The analysis of the protein-protein 
interaction in the β-catenin variants can be done by performing mass spectrometry 
analysis on the hemi/homozygous mutants which will help in identifying the differential 
binding partners. These experiments together will provide insights into mechanism of 
regulation of the differential activity response by the mutational variants, which will help 
in understanding their role in the tumourigenic process.  
Concluding Remarks 
In conclusion, using two complementary approaches, I provide evidence confirming the 
genotype-phenotype correlation among the various β-catenin mutational variants. These 
results not only emphasize the importance of understanding the allele specific variation 
in β-catenin activity, in contributing to the tumourigenic response, but also highlights the 
drawbacks in the current model of β-catenin signaling, and thus underscores the need to 











                                                                                                                                                                                             














7.1 General buffers and solutions 
The general buffers and solutions including phosphate buffered saline (PBS), 3M NaAc, 
50X TAE, TE, 5M NaCl and Tris Hcl were prepared and autoclaved by the Central 
Support Unit (CSU) of the Roslin institute. 
7.2 Molecular Biology 
7.2.1 DNA isolation techniques 
7.2.1.1 Genomic DNA isolation  
DNA isolation was done using mainly two different methods based on the quality of DNA 
required for downstream applications. For genotyping purpose, DNA was isolated using 
QuickExtract (QE) DNA extraction solution (Epicentre). The cells were washed with PBS 
followed by the addition of appropriate amount of QE to cover the cell surface, typically 
for cells cultured in 96 well plates 50µl of QE was added and incubated for 1-2min. The 
cell lysates were then transferred to 96 well PCR plates and incubated at 68°C for 15 min 
followed by 98°C for 8 min in a thermocycler. The crude lysates were then directly used 
for PCR purpose. For saturation assay, where better quality of DNA was required, 
DNeasy blood and tissue kit (Qiagen) was used and DNA was isolated according to the 
manufacturer's protocol. 
7.2.1.2 Plasmid DNA isolation 
Plasmid DNA was isolated using either QIAprep spin miniprep kit or maxiprep kit (Qiagen) 
depending on the quantity of DNA required. For restriction digestion experiments and 
sequencing purpose where smaller quantity of DNA is sufficient, miniprep kit was used, 
and for transfection experiments that require larger quantity of DNA, the plasmid DNA 
was isolated using maxiprep kit, following the manufacturer's protocol. 
7.2.2 Quantification – Nanodrop 
DNA was quantified using Nanodrop 2000 UV VIS spectrophotometer (ThermoScientific). 
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7.2.3 DNA clean up and ethanol precipitation for transfection 
Before the use of maxiprep plasmid DNA for transfection, the DNA was precipitated and 
made ethanol free. For this, 50µg of plasmid DNA was brought to a total volume of 200µl 
in TE buffer. First, 1/20 3M Sodium acetate was added and mixed well by vortexing. This 
was followed by the addition of three volumes of 100 percent ethanol, and the tubes were 
placed overnight at -20°C or at -80°C for 15min. The tubes were centrifuged at 13k rpm 
for 15min to pellet the DNA and then transferred to T/C hood. The supernatant was 
aspirated and the pellet was allowed to air dry for 15min. The DNA was then reconstituted 
in 50µl PBS to obtain a final concentration of 1µg/µl and mixed well to completely 
resuspend the DNA in the solution. The ethanol free DNA was stored at 4°C and used 
for transfection purpose. 
7.2.4 PCR components 
7.2.4.1 Primers 
All primers were designed using either Primer3Plus (www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) or Geneious software (https://www.geneious.com/), and 
ordered from Sigma, in desalted and dried form. The primers were reconstituted to 100µM 
concentration with dH2O. Aliquots of 12.5µM concentration of working solution were 
made and used for PCR at a final concentration of 0.25 µM. 
7.2.4.2 PCR Master-mix components 
Different PCRs were optimized using different polymerases, and were used along with 
the available compatible buffers/master mixes. High fidelity DNA polymerases including 
Q5 high fidelity DNA polymerases and Q5 hot start high fidelity DNA polymerases (NEB), 
Phusion high fidelity DNA polymerases (Thermo scientific) were available with their own 
ready to use compatible master mixes with all components added. The master mix for 
standard taq polymerase/platinum taq (Thermo scientific) used for general genotyping 
purpose was supplemented with dNTPs and Mgcl2are given below. The components for 




100mM dNTPs (Invitrogen) each of dATP, dTTP, dCTP, dGTP were mixed in equal ratios 
and diluted with appropriate amount of dH2O to obtain a working concentration of 2mM, 
and was used for PCR at a final concentration of 200µM. 
7.2.4.2.2 MgCl2  
50mM Mgcl2 was used for PCR at a final concentration of 2.5mM. 
Reaction components Volume  
10X master mix 2.5µl 
dNTP (2mM) 2.5µl 
MgCl2 (50mM) 1.25µl 
Forward primer (12.5µM) 0.5µl 
Reverse primer (12.5µM) 0.5µl 
Taq polymerase- Thermo scientific (5u/µl) 0.2µl 
DNA (10-100ng) 1.0µl 
dH2O Made upto 25.0µl 
Table 7-1: Components for PCR using taq polymerase. 
7.2.5 Agarose gel electrophoresis 
Separation of DNA fragments based on their size was done using agarose gel 
electrophoresis. The concentration of agarose was determined based on the size of the 
DNA being separated. Appropriate amount of agarose was weighed and dissolved in 1X 
TAE buffer by heating the mixture in a microwave oven. Next, gel red dye (Cambridge 
Biosciences) (an alternative to EtBr that acts as intercalating agents and allows 
visualization of DNA under UV) was added to the agarose mixture, mixed well and poured 
onto a gel casting tray containing a comb and allowed to set. 
The DNA was mixed with loading dye and loaded into the wells along with a DNA ladder. 
Hyper ladder 1kb or 100bp (Bioline) were used to determine the size of the DNA. The 
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electrophoresis tank was filled with 1X TAE and the gel was run at 100-120V for 1hr. The 
gel was visualized under a UV transilluminator. 
7.2.5.1 Elution of DNA from agarose gel 
Elution of DNA from agarose gel was performed using GeneJet gel extraction kit (Thermo 
Scientific) according to the manufacturer's protocol. 
7.2.6 CRISPR design and assembly 
The online CRISPR design tool provided by Feng Zhang's lab (http://crispr.mit.edu/) was 
mostly used to identify suitable target site for recognition of sgRNA and to design the 20nt 
guide oligo. In addition, the recently available Sanger Institute design tool – WGE 
(http://www.sanger.ac.uk/htgt/wge/) and Benchling (https://benchling.com/) were also 
used to design guide oligos.  
7.2.6.1 Ordering of guide oligo 
Processing by U6 promoter is significantly enhanced by the presence of G nucleotide at 
the beginning of the guide (Ran et al. 2013). Hence an additional G nucleotide was added 
at the start of the oligo (if G is not the first base of the oligo). In addition bases 
complementary to the 5' and 3' overhangs formed following restriction digestion of the 
backbone pX458 nuclease vector, were added on either ends of the oligo. Using these 
guidelines the complementary top and bottom strand of guide oligos were ordered 
separately from Sigma. The sequence of the top and bottom oligos for each of the 
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Table 7-2: Sequence of the designed guides. 
*CACC/AAAC – complementary sequences (sticky ends) required for ligation with BbsI 
digested pX458 vector. 
G/complemtary C– additional G nucleotide required for U6 promoter when the guide 
sequence does not begin with a G and complementary C added to the bottom oligo for 
base pairing with G nucleotide in the top oligo. 
7.2.6.2 Backbone vector for cloning sgRNA 
The mammalian codon optimized Cas9 nuclease from S. pyogenes along with T2A EGFP 
has been cloned in a mammalian vector system by Feng Zhang's lab ( Ran et al., 2013). 
In addition, it consist of insertion site for sgRNA of interest and allows single step cloning 
of the guide based on Golden gate cloning strategy detailed in section 7.2.9.2.3, thus 
allowing expression of both Cas9 and sgRNA required for targeted induction of DSB. The 
EGFP further provides a selection strategy for fluorescence based separation of 
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successfully transfected cells. pSpCas9(BB)-2A-GFP (pX458) was a gift from Feng 
Zhang (Addgene plasmid # 48138). 
In addition to GFP pX458, a mCherry version of pX458 nuclease vector was cloned as 
follows: 
A PCR was performed (using platinum taq) to amplify the mCherry sequence from an 
existing mCherry vector with primers mCherry F and R (Table 7-3) having regions 
overlaping with the pSpCas9 (BB)-2A-(pX458) backbone vector. The PCR was 
performed using the reaction mix given in table 7-4 and thermocycler parameters given 
in table 7-5. Following amplification, DpnI digestion was performed to get rid of the 
template plasmid using the reaction mix given in table 7-6. Next, backbone vector was 
generated by restriction digestion. The GFP pX458 CRISPR vector (used as backbone 
vector) has an EcoRI site on either side of the GFP tag and could be cleaved out with 
restriction digestion with EcoRI, and then mCherry sequence was inserted into the pX458 
CRISPR vector in a single step Gibson assembly by incubating the reaction mix 
consisting of mCherry amplicon, the backbone vector and home-made GA master mix 
for 1 hour at 50°C, as described in section 7.2.9.2.1. The assembled vector was then 
transformed into competent Stbl3 cells and cultured on LB plates containing ampicillin 
selection. A colony PCR was performed to shortlist clones with the mCherry insert and 
















Reaction components Volume  Incubation parameter 
DNA (GFP pX458) (1 µg/ µl) 2.0µl  
37°C for 2hrs Buffer H 2.0µl 
EcorI enzyme (Promega) 1.0µl 
dH20 Made up to 20.0 µl 
Table 7-4: Reaction mix and incubation parameter for EcoRI Restriction digestion of GFP 
pX458 vector. 
Step Temperature  Time 
1 94°C 2min 
2 94°C 30s 
3 59°C 30s 
4 72°C 60s 
5 72°C 10min 
6 16°C ∞ 
Table 7-5: PCR parameters for amplification of mCherry insert for cloning and mCherry 
colony PCR. 
Reaction components Volume  Incubation parameter 
DNA (mCherry PCR product) 3.0µl  
 
37°C for 2hrs 
Acetylated 1/10 BSA 2.0µl 
Buffer B 2.0µl 
DpnI enzyme (Promega) 1.0µl 
dH2O Made up to 20.0 µl 
Table 7-6: Reaction mix and incubation parameter for DpnI digestion of GFP pX458 vector.  
7.2.6.3  Annealing and Phosphorylation of guide oligos 
Initially, the top and bottom strands of the guide oligos were annealed and 
phosphorylated in a single reaction. The components of the reaction mix and 
thermocycler parameters are shown in table 7-7 and table 7-8. 
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Reaction components Volume  
sgRNA TOP (100µM) 1.0µl 
sgRNA Botom (100µM) 1.0µl 
T4 ligase buffer with 10mM 
ATP – NEB (10X)  
1.0µl 
T4 Polynucleiotide Kinase - 
NEB 
1.0µl 
dH2O Made up to 10.0µl 
Table 7-7: Reaction mix for sgRNA annealing and phosphorylation. 
Step Temperature Time 
1 37°C 5min 
2 94°C 5min 
3 25°C 5min 
4 Ramp down to 25C at 0.1°C/s  
Table 7-8: Thermocycler parameters for sgRNA annealing and phosphorylation 
7.2.6.4 Insertion of guide oligo into pX458 
Next, the annealed and phosphorylated oligo was cloned into the pX458 nuclease vector. 
The cloning of the inserts into the pX458 nuclease vector is based on Golden Gate 
cloning strategy making use of the typeIIS restriction enzyme BbsI that cuts outside the 
recognition site, hence allowing the restriction digestion of the pX458 nuclease vector 
using BbsI and ligation of ds oligo by base pairing with the complementary overhangs to 
be carried out in a single reaction, as described in section 7.2.9.2.3. The reaction mix and 






Reaction components Volume  
pX458 nuclease (100ng) 1.0µl 
1:20 diluted oligo  2.0µl 
T4 ligase buffer with 10mM 
ATP (NEB) 
2.0µl 
ATP (1mM) 1.0µl 
Fast digest BbsI (Thermo 
scientific) 
1.0µl 
Quick ligase (NEB) 0.5µl 
dH20 Made up to 20.0 
µl 
Table 7-9: Reaction mix for insertion of guide oligos into pX458. 
Step Temperature/Cycle condition Time 
1 37°C 5min 
2 21°C 5min 
3 Cycle to step 1, 5 times  
Table 7-10: Thermocycler parameters for insertion of guide oligos into pX458. 
7.2.6.5 PlasmidSafe nuclease treatment 
To remove any residual linearized DNA that may result in false positive, the ligation 
reaction was treated with plasmidSafe nuclease using the reaction mix and incubation 








Reaction Components Volume  
Ligation reaction 11.0µl 
ATP (1mM) 1.5µl 
Plasmid safe buffer – 10X 1.5µl 
Plasmid safe ATP dependent DNase - Epicentre 1.0µl 
dH20 1.0µl 
Table 7-11: Reaction mix for PlasmidSafe nuclease treatment. 
Step Temperature Time 
1 37°C 30min 
2 70°C 30min 
Table 7-12: Reaction mix for PlasmidSafe nuclease treatment 
Following plasmid safe treatment 2µl of the vector was transformed into Stbl3 (20µl) 
competent cells using the manufacturers instruction and plated on ampicillin LB plates 
and incubated at 37°C overnight. 
All the designed guides given in table 7-2 were cloned into either GFP pX458 or mCherry 
pX458. Next day, following transfection and plating, 3 clones were picked for each guide 
and inoculated for miniprep plasmid isolation. The isolated plasmids were sequenced 
using U6 F primer given in table 7-13, and one vector with correct guide sequence was 
chosen for further targeting. For the purpose of transfection, plasmid DNA was isolated 
by maxiprep isolation and cleaned by ethanol precipitation and reconstituted to 1µg/µl in 
sterile PBS as described in section 7.2.3. 
Sequencing target Forward primer 
U6 GAGGGCCTATTTCCCATGATTCC 
Table 7-13: Primer for sequencing the CRISPR guides. 
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7.2.7 Sanger sequencing 
Sanger sequencing was done at the sequencing unit at MRC, HGU and the ABI files were 
analysed using geneious software. 
7.2.8 T7 Endonuclease I assay 
The efficiency of CRISPRs to induce strand breaks and the resulting indels (for guides 
targeting the exon 3 region) was analysed by performing T7 assay. The CRISPR 
plasmids with the specific guides inserted were transfected into mouse embryonic cells 
E14 with lipofectamine 2000 using transfection protocol given in section 7.4.1.5, and the 
transfected cells were FACS sorted and collected 24 hours post transfection. The sorted 
cells were put back in culture for 2 days, genomic DNA was isolated, and PCR 
amplification using Phusion high fidelity DNA polymerase (Thermo Scientific) was done 
with primers flanking the exon 3 region given in table 7-14 (β-catenin exon 3 forward and 
reverse primers). The PCR reaction mix and thermocycler parameters are shown in table 
7-15 and table 7-16. Following amplification, 25µl of the PCR product was purified using 
QIAquick PCR purification kit (Qiagen) according to the manufacturer's protocol, and 
eluted in 50µl of elution buffer. 
The purified PCR product was then denatured and reannealed to form heteroduplexes. 
For this, 2µl of NEB buffer 2 (10X) was mixed with 18 µl of the purified PCR product and 
the reaction mix was incubated using the thermocycler parameters given in table 7-17. 
The denatured and reannealed product was finally digested with T7 endonuclease I 
(T7EI) enzyme and run on an agarose gel. The reaction mix and incubation parameters 
for T7E1 digestion are given in table 7-18 .The indels formed by NHEJ following induction 
of strand break are visible as extra bands on the agarose gel. The bands were then 
quantified based on the intensity using the software ImageJ. The percentage of indels 
was calculated using the formula 100 x (1 – (1 – (b + c)/(a + b + c))1/2), where a is the 
integrated intensity of the undigested PCR product and b and c are the integrated 
intensities of the products cleaved by T7E1 ( Ran et al., 2013). 
 Target Forward primer Reverse primer 
 β-catenin exon 3 TCTCCTTGGCTGCCTTTCTA  GTCACACAGCCCTGTC 
Table 7-14: Primers used for amplifying β-catenin exon 3 region. 
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Reaction components Volume  
HF Buffer (5X) 10.0µl 
10mM dNTP 5.0µl 
Exon 3 F primer 1.3µl 
Exon 3 R primer 1.3µl 
Phusion HF DNA polymerase – Thermo scientific  0.5µl 
DNA 4.0µl 
dH2O Made upto 50µl 
Table 7-15: Thermocycler parameters for amplifying exon 3 region for T7E1 assay. 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 58°C 15s 
4 72°C 30s 
Cycle to step 2 for 30 more times 
5 72°C 5min 
6 16°C  ∞ 
Table 7-16: PCR reaction mix for amplifying exon 3 region for T7E1 assay.  
Step Temperature Time 
1 95°C 7 min 
2 85°C 
Ramp to 85°C at 2.0°C / second 
30s 
3 85°C 





Ramp to 80°C at 0.3°C/second 
Decrease by 5.0°C every cycle 
30s 
4 Cycle to step 3 for 11 more times  
5 4°C  ∞ 
Table 7-17: Thermocycler parameters for denaturation and reannealing for T7E1 assay.  
Reaction components Volume  Incubation parameter 
Buffer2 – NEB (10x) 0.5µl  
37°C for 15 min T7 E1 - NEB 0.5µl 
Denatured and reannealed product 20.0µl 
dH2O 4.0µl 
Table 7-18: Reaction mix and incubator parameters for T7E1 Restriction Digestion. 
7.2.9 HDR templates 
7.2.9.1 Design of short single strand oligodinucleotide  
Short (70-130bp) single stranded oligonucleotide with the desired mutation were ordered 
from IDT as ultramers and used as templates for CRISPR mediated HDR. Sequence of 
4mut PAM oligo, S33Y oligo, ∆S45 oligo, S45 and T41 multiplex oligos used for targeting 






































Table 7-19: ssODNs used as repair templates.  
7.2.9.2 Design and cloning of targeting vectors 
Targeting vectors to be used as HDR templates were generated mainly using three 
efficient cloning approaches: Gibson assembly, TOPO TA cloning and Golden Gate 
cloning. 
7.2.9.2.1 Gibson assembly  
Gibson assembly is a simple and efficient method of cloning multiple fragments in a single 
step. It makes use of the 5’ exonuclease activity and requires overlap sequences between 
the inserts and the backbone vector. The digestion of the 5' end by exonuclease is 
followed by the addition of nucleotides by the polymerase and nick joining by ligases at 
the region of annealed overlap (Gibson et al., 2009). The online Tool NEBuilder 
(https://nebuilder.neb.com/) was used for Gibson assembly design. By providing the 
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backbone and insert sequences, the tool generates primers with overlap sequences to 
amplify insert fragments, and backbone can be generated either by PCR or restriction 
digestion based approaches. The tool also allows addition of spacers at the 5' end of the 
primers that allows various modifications to be made. On generating the inserts and 
backbone, the fragments can be easily assembled in a single step reaction. The reaction 
mix consisting of homemade Gibson assembly master mix and appropriate proportions 
of insert and backbone vector fragments were incubated for 1 hour at 50°C as shown in 
table 7-20.  
Reaction components Volume Incubation parameters 
Insert Vector : Insert was used at 
ratio of either 1:2 or 1:3  
 
50°C for 1hr Vector Backbone 
Gibson assembly master mix 10µl 
dH2O Made upto 20µl 
Table 7-20: Reaction mix for Gibson assembly reaction 
7.2.9.2.1.1 Home-made Gibson assembly master mix 
Gibson assembly master mix was made according to the modified Gibson assembly 
protocol provided by Brand Lab and 10 µl aliquots Gibson assembly master mix were 
stored at -20°C. The reaction mix is given in table 7-21. 
Reaction components  Volume  Final 
concentration 
1M Tris Hcl pH 7.5 40.0µl 100mM 
1M MgCl2 4.0µl 10mM 
Q5 high fidelity DNA polymerse (NEB) 5.0µl 0.5U/reaction 
100Mm dNTPs- dATPs, dTTPs, dGTPs, 
dCTPs (Promega) 
1.6µl (0.4 µl each from 
100mM) 
0.2mM each 
5' T5 exonuclease (Epicentre) 0.32µl 0.16U/reaction 
dH2O 149.08µl  
Table 7-21: Reaction components for home-made Gibson assembly master mix. 
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7.2.9.2.2  TOPO cloning 
TOPO cloning is another efficient approach for cloning of PCR generated products. 
TOPO cloning is based on the property of terminal transferase activity of the taq 
polymerase which incorporates an additional A at the end of the non-template strand of 
every PCR product. The amplified product anneals to the T overhangs of the TOPO 
vector followed by the formation of phosphodiester bond by the action of topoisomerase 
I, which is covalently attached to the TOPO vector. 
To avoid mismatches that are generated while amplifying large fragments using taq 
polymerase, PCR was performed using Q5 high fidelity DNA polymerase. The PCR 
product was purified to remove the residual polymerase and then incubated with taq 
polymerase. The removal of Q5 is crucial as its proofreading 3'-5' activity prevents 
addition of A overhangs (A tailing) by taq polymerase. Following addition of A overhangs 
using the reaction components given in table 7-22, the PCR product was then cloned into 
TOPO 4 vector. TOPO cloning was performed using TOPO TA cloning kit (Invitrogen) 
according to the manufacturer's protocol. 
Reaction components Volume Incubation parameter 
Cleaned PCR product 5.0µl  
 
72°C for 20min 
 
10X Buffer 2.5µl 
 1mM ATP 5.0µl 
MgCl2 1.25µl 
Taq polymerase 0.2µl 
dH20 Made upto 25.0µ 
Table 7-22: Reaction mix and incubation parameters for A tailing. 
7.2.9.2.3 Golden gate cloning  
The Golden Gate cloning, described as precision cloning method by Engler et al, is yet 
another simple and efficient cloning strategy that is based on the properties of typeIIS 
restriction enzymes (Engler, Kandzia and Marillonnet, 2008). This method harnesses the 
property of typeIIS restriction enzymes to cut outside their recognition site, and in 
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combination with T4 DNA ligase, provides a seamless cloning approach with the 
convenience of performing both restriction digestion and ligation reaction in a single step. 
7.2.9.2.4 Cloning of targeting vector with 1Kb homology arm 
For cloning of the 1Kb homology arm vector, a previously targeted E14 clone with 
homozygous S45 deletion in exon 3 and V5 tag inserted immediately after the start codon 
in the exon 2 region in the endogenous Ctnnb1 gene was used. The genomic DNA 
isolated from these S45 mutant cells were used as template to amplify the region covering 
1kb homology arm on the 5’ side and 3’ end of the region of interest, using primers given 
in table 7-23. A Touch down PCR was performed with Q5 high fidelity master mix using 
the reaction components and thermocycler parameters given in table 7-24 and 7-25. The 
PCR product was purified and TOPO cloned. Following TOPO cloning, the vector was 
transformed into competent cells and plasmid DNA was sequence verified. 
Target Forward primer Reverse primer 
β-catenin region 






Table 7-23: Primer sequence of 1Kb homology arm vector. 
Step Temparature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 1.30min 
Cycle to step2 9 more times 
6 98°C 10s 
7 66.5°C 15s 
8 72°C 1.30min 
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Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-24: Thermocycler parameters for amplifying β-catenin homology arm insert. 
7.2.9.2.5 Cloning of 5.5Kb WT β-catenin TOPO vector 
Initially, a 5.5kb region of β-catenin was amplified using WT genomic DNA from E14 cells 
as template with primers given in table 7-25. A touch down PCR was performed using 
Q5 2X high fidelity master mix using the thermocycler parameters given in table 7-26. 
Following PCR clean up, A- tailing was done using taq polymerase and then the PCR 
product was cloned into TOPO 4 vector using TOPO cloning strategy. The vector was 
then transformed into competent cells and plasmid DNA was sequence verified. 
Target Forward Primer  Reverse Primer 
5.5Kb region of β-
catenin 
GGTTGATACTACCTTGAGTACTC GATTCACAGGGCTGCTAGTG 
Table 7-25: Primers for amplifying 5.5kb region of β-catenin. 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 3min 
Cycle to step2 9 more times 
6 98°C 10s 
7 67°C 15s 
8 72°C 3min 
Cycle to step 6 for 20 more times 
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9 72°C 5min 
10 16°C ∞ 
Table 7-26: PCR Reaction mix for amplifying 5.5kb region of β-catenin. 
7.2.9.2.6 Cloning of PuDeltatk TV  
A Gibson assembly was designed for cloning of puDeltatk vector. Primers were designed 
to amplify the puDeltatk selection cassette and having overlap with β-catenin region in 
5.5Kb WT β-catenin TOPO vector. The selection cassette was amplified using a 
puDeltatk vector (kindly provided by Ailbhe Brazel) as template. The β-catenin region that 
would constitute the 3' and 5' arms were amplified along with the vector backbone from 
the 5.5kb WT β-catenin TOPO vector. The primers for amplifying the insert and the vector 
backbone are given in table 7-27. A touchdown PCR was performed using Q5 2X high 
fidelity master mix to amplify both the fragments. The thermocycler parameters are given 
in table 7-28 and 7-29. The two amplicons were gel eluted and the fragments were cloned 
using Gibson assembly as described in section 7.2.9.2.1. The vector was then 
transformed into competent cells and plasmid DNA was isolated using miniprep kit. Next, 
double digestion of the plasmid DNA was performed using XhoI and XbaI enzymes 
(Roche) using the reaction mix given in table 7-30, and plasmids with fragments of correct 
size were sequence verified. 






















Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 1.30min 
Cycle to step2 9 more times 
6 98°C 10s 
7 69°C 15s 
8 72°C 1.30min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-28: Thermocycler parameters for amplifying puDeltak selection cassette. 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 65°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 3min 
Cycle to step2 9 more times 
6 98°C 10s 
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7 59°C 15s 
8 72°C 3min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-29: Thermocycler parameters for amplifying β-catenin backbone vector for 
PuDeltatk cloning. 
Reaction components  Volume µl Incubation parameter 
XhoI 1.0µl  
 
37°C for 2 hours 
XbaI 1.0µl  
Sure cut buffer H 2.0µl 
Miniprep plasmid DNA 1.0µl  
Nuclease free dH20 15.0µl  
Table 7-30: Reaction mix and incubation parameters for identification of correctly cloned 
puDeltatk vector.  
7.2.9.2.7  Cloning of β-catenin Golden gate vector 
For the purpose of cloning, all the TVs for multiplex targeting and saturation editing using 
Golden Gate cloning, initially a β-catenin designation vector was cloned by Gibson 
assembly by incorporating two typeIIS restriction enzyme BbsI recognition sites flanking 
the region of interest. The β-catenin region constituting the 5' and 3' arm and the 
backbone vector was amplified using the 5.5Kb WT β-catenin TOPO vector as template. 
However, this template already had a BbsI site in the 5' end of β-catenin region, and 
hence primers were designed such that the F primer included a synonymous mutation in 
BbsI recognition site (as a spacer) and the R primer deleted the region of our interest and 
inserted two BbsI sites in the opposite orientation with two extra bases between the two 
recognition sites. The primer sequences are given in table 7-31. 
Both the insert and backbone vector PCRs were performed using Q5 2X master mix 
(NEB) using the reaction mix and thermocycler parameters given in table 7-32. The two 
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amplicons were gel eluted and the fragments were cloned using Gibson assembly as 
described in section 7.2.9.2.1. Next, the vector was transformed into competent cells and 
plasmid DNA was isolated using miniprep kit. Then, double digestion of the plasmid DNA 
was performed using Fast digest BbsI and NotI enzymes (Thermo Scientific) using the 
reaction mix given in table 7-33 and plasmids with fragments of correct size were 
sequence verified. 















Table 7-31: Primers used for generation of β-catenin golden gate vector. 
Step Temperature Time 
1 98°C 30s 
2 98°C 10s 
3 64°C 30s 
4 72°C 3min 
5 72°C 5min 
6 16°C ∞ 
Table 7-32: Thermocycler parameters for amplifying β-catenin backbone and insert for β-








Reaction components  Volume  Incubation parameter 
Fast digest BbsI 1.0µl  
 
37°C for 40 min 
Fast digest NotI 1.0µl 
Fast digest buffer 2.0µl 
Miniprep plasmid DNA 1.0µl 
Nuclease free dH20 15.0µl 
Table 7-33: Reaction mix and incubation parameters for identification of correctly cloned 
β-catenin golden gate vector.  
7.2.9.2.8 Golden gate cloning of vectors for multiplex targeting 
For the purpose of cloning the TVs for multiplex targeting, ds oligos were ordered from 
Geneart Strings DNA Libraries (Thermo Fisher Scientific). The ds oligos were ordered in 
6 sets, one set (consisting of all chosen amino acid variants) for each of the top six chosen 
residues from COSMIC database. Each library consisting of the required degenerate 
nucleotides (depending on the required amino acid variants) was synthesized by random 
distribution of variants based on IUPAC nomenclature, and hence contained additional 
variants. The sequence of the ds oligos is given in table 7-34. 
The libraries were delivered in dried form, and were reconstituted to a concentration of 
0.1µM in dH2O according to the manufacturer's protocol. Next, ds library was cloned into 
the β-catenin backbone vector using Gibson assembly protocol using 1µl of the 
reconstituted product in the ligation step of Ran et al protocol described in section 7.2.6, 
followed by plasmidSafe treatment and transformation in Stbl3. The six sets of 
transformants were plated on LB plates with kanamycin selection and incubated 
















































Table 7-34: Sequence of the six ds libraries synthesized by Geneart Strings DNA library for 
cloning of multiplex TVs 
GAAGACCC/CCGTCTTC BbsI restriction site, IUPAC nomenclature of nucleic acids Y-C/T, N-
A/C/G/T, R-A/G, D-A/G/T, K-G/T, H-A/C/T   
Next day, colonies were picked from each plate to perform colony PCR (in 96 well PCR 
format) and simultaneously inoculated in 96 well plates containing LB broth with 
kanamycin selection that was used to make glycerol stock which were then stored at -
80°C. A small amount of the amplicons from colony PCR was checked for insertion by 
running on agarose gel, and the remaining products were sent for Sanger sequencing. 
As the synthesized library contained extra variants 3X96 well plates (288 clones) were 
sequenced and the required variants were selected. Further, maxiprep was performed 
separately for each of the 26 TVs and were cleaned and reconstituted in PBS as detailed 
in section 7.2.3. 
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7.3 Bacterial work 
All microbiology work was carried out using aseptic techniques. Nutrient media, both 
liquid and solid- LB broth and LB agar were prepared and autoclaved by the Central 
Support Unit of Roslin Institute.  For culturing of LB broth containing bacterial inoculum 
(usually bacteria transformed with plasmids with resistance gene), the media was 
supplemented with appropriate antibiotics – mostly either ampicillin (100mg/ml) or 
kanamycin (50mg/ml) just before inoculation and cultured overnight at 37°C in a shaker 
incubator. Usual volumes of either 500ml or 5ml LB broth was inoculated for maxiprep 
and miniprep plasmid isolation, respectively.  
For culturing of bacteria on LB agar, the solidified media was heated and defrosted in a 
microwave and allowed to cooldown to 50°C and then supplemented with the appropriate 
antibiotic and poured on to petri dishes and allowed to solidify. Bacteria was cultured on 
petri dishes using spread plate technique to obtain a good spread of single cell colonies. 
The petri plates were incubated (placed inverted) overnight in an incubator at 37°C.  
7.3.1  Bacterial transformation 
Various chemically competent E.coli strains (Stbl3, DH5α, C2987H, TOP 10) were used 
for transformation of plasmid DNA using heat shock method. Briefly, the plasmid DNA 
was incubated with competent cells on ice (the incubation times vary for different 
competent cells) after which the tubes are transferred to 42°C water bath (for 30-45s 
again depending on the strain being used) allowing to create pores for uptake of the DNA, 
and then the tubes were placed on ice for 2 min for the pores to close. The transformed 
bacteria was immediately plated if containing ampicillin resistance, but kanamycin 




ES cell targeting and screening  
7.3.2 Cell culture  
7.3.2.1 Sterility  
A high standard of aseptic conditions was maintained in ES lab to reduce the risk of 
contamination, as ES cells are culture without antibiotics. Clean lab coats and nitrile 
gloves were worn at all times. Before start of work, the TC hood was sprayed thoroughly 
with 70 percent ethanol and wiped clean. All reagent bottles, falcons, pipettes etc were 
sprayed with 70 percent ethanol and wiped clean before placing in the T/C hood. The T/C 
hoods were kept uncluttered to increase space, and to avoid risk of infection. In addition, 
the T/C hoods were UV irradiated at the end of each day. 
7.3.2.2 Cell lines and culture media 
The mouse embryonic feeder free stem cell line E14IVtg2a (E14) and the TCF cell line 
were used in this project. The TCF cell line was derived from blastocyst from established 
TCF/Lef:H2B-GFP reporter mouse strain in the lab of Kat Hadjkonaikis (Ferrer-Vaquer et 
al., 2010) . 
Both E14 and TCF cell lines were grown on gelatinized flask in the presence LIF 
supplemented media. Both normal ES media (for culturing E14) and R2i media (for 
culturing R2i) consisted of the following components: 
Homemade LIF was prepared by transfecting LIF expressing constructs into Cos7 cells 
and the expressed LIF is released by the cells. The LIF containing supernatant was tested 
by titrating different concentrations, and the optimal concentration was selected based 
on the morphology of E14 cells.  
Fetal Bovine Serum (FBS) was batch tested for quality suitable for ES cell culture at MRC, 
and used at either 10 or 15 percent. However due to batch to batch variability, the Knock 
out serum replacement (KOSR - Thermo Scientific) was substituted for FBS and used at 
15 percent at later stages of the project. 
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The media was supplemented with sodium pyruvate, non-essential amino acids, 2-
mercaptoethanol. In addition, R2i media consisted of GSK3β inhibitor CHIR99021 and 
MEK inhibitor PD0325901 and both these components are known to maintain cells 
ground state pluripotency of ES cells. The exact composition of normal ES media and 
R2i media are given in table 7-35 and table 7-36. 
Normal ES media components Volume Final 
Concentration 
Glasgow MEM (BHK 21) Life 
Technologies 
500ml  
FBS 50-75ml 10-15% 
MEM Non-essential amino acids (Life 
Technologies) 
5.0ml 0.1Mm 
Sodium pyruvate (Life Technologies) 5.0ml 1Mm 
2-mercaptoethanol (Life Technologies) 1.0ml 0.1Mm 
L-Glutamine (Life Technologies) 5.0ml 2Mm 
Homemade LIF (Life Technologies) 1.0-2.0ml depending on titre 
amount  
 
Table 7-35: Normal ES cell media composition. 
R2i media components Volume Final 
Concentration 
Knockout DMEM Life Technologies 500ml  
FBS 50-75ml 10-15% 
MEM Non-essential amino acids (Life 
Technologies) 
5.0ml 0.1Mm 
2-mercaptoethanol (Life Technologies) 1.0ml 0.1Mm 
L-Glutamine (Life Technologies) 5.0ml 2Mm 
Homemade LIF (Life Technologies) 1.0-2.0ml depending on titre 
amount  
 
CHIR99021 (10 mM stock made up in 
DMSO)   
0.150ml 3µM 
PD0325901 (10 mM stock made up in 
DMSO)   
0.050ml 1µM 
Table 7-36: R2i media composition 
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7.3.2.3 Passaging of cells 
Both E14 and TCF cells were generally grown in gelatinized T75 flask and were passaged 
on alternate days at 1/5- 1/8 ratio depending on the confluency. Prior to splitting culture 
flasks were gelatinized by adding 0.1 percent gelatin, enough to cover the entire flask, 
and placed in the incubator for a minimum of 15 minutes. For splitting a T75 flask, the 
media was aspirated and the cells were washed with 5ml of PBS to remove any residual 
serum. After aspiration of PBS, the flask was coated thoroughly with 1ml trypsin and 
placed in the incubator for few minutes, until the cells detach and become rounded. Next, 
9ml of media was added to stop the activity of trypsin and the cells were mixed few times. 
The cell suspension was transferred to a 15ml falcon tube and centrifuged at 1000rpm 
for 5 min. Meanwhile, the gelatin was aspirated from flask and immediately replaced with 
9ml of culture media. Next, the supernatant was aspirated and the cell pellet was 
resuspended in media by gentle pipetting to obtain a single cell suspension. The cell 
suspension was plated at appropriate density (1:4-1:8) in a gelatinized flask, in a total 
volume of around 10ml of media, and the flask was shaken well to get an equal 
distribution of cells throughout the flask. 
7.3.2.4 Cryopreservation and thawing 
For cryopreservation, cells were washed with PBS, trypsinized and centrifuged as 
described above. The cell pellet was resuspended with freezing media constituting 
10percent DMSO in FBS, and then transferred to cryovials. The cryovials were 
immediately placed in Styrofoam box, to ensure steady decrease in temperature and 
placed in -80°C overnight. The cryovials were then transferred to liquid nitrogen for long 
term storage. 
Prior to thawing of cells, 9ml of media was added to a 15 ml falcon and a Pasteur pipette 
was kept ready in the T/C hood. The cryovial immediately after removal from liquid 
nitrogen storage, was held in 37°C water bath for 1min until the frozen media just begins 
to melt. The cells along with freezing media was transferred to the falcon containing 
media using the Pasteur pipette. The tubes were centrifuged at 1000rpm for 5min. The 




The cells were transfected with either nucleofection or lipofection method.  
Prior to transfection using nucleofection method, cells were cultured and split the day 
before transfection. Electroporation using nucleofection was carried out according to the 
manufacturer's protocol (Lonza). For nucleofection a total of 2µg of DNA (1µg each of 
CRISPR vector and template DNA) was used to transfect 2X106 cells.  
Transfection using lipofection method was carried out using suspension cells. For 
lipofection 8X105 cells were counted and plated in 2ml media in 6 well plate, 9µL of 
Lipofectamine 2000 (Thermo) was diluted in 191µl of OPTIMEM media (reduced serum 
media) and DNA (2µg each of CRISPR vector and template DNA) was diluted in 
OPTIMEM media to a total volume of 200µl. Both DNA and lipofectamine were briefly 
vortexed and incubated for 5min at RT after which 200µl of lipofectamine was mixed with 
200µl DNA vortexed briefly and incubated at RT for (a minimum of) 20min. Meanwhile 
8X105 cells were counted and plated in 2ml media (without penstrep) in 6 well plate and 
400µl of DNA:lipofectamine suspension was added, mixed well and incubated. 4-6 hours 
after transfection the media was replaced and cultured overnight. 
Small molecule enhancers: Two drugs were tested for their ability to enhance HDR 
efficiency. The drugs SCR7 and L755507 were added to the media at a final 
concentration of 1µM and 5 µM, respectively. In each case, the cells prior to plating for 
transfection were resuspended in media containing the drug. 
The combination of transfection by lipofection and addition of L755507 was used for all 
the targeting performed post optimization. 
7.3.2.5.1 Selection of transfected clones 
The fluorescence markers either GFP/mCherry in the pX458 nuclease vectors allowed 
selection of clones successfully transfected with the CRISPR Cas9 vector that would 
enrich for clones edited by DSB induction. The cells transfected by either nucleofection 
or lipofectamine were sorted into single cells 24 hours post transfection by FACS, and 
collected into a 15ml falcon. The pooled cells were diluted and approximately 500 cells 
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were plated in each of the 10cm dishes. This method was used for all targeting 
experiments performed for the purpose of optimization. 
The generation of heterozygous β-catenin mutant cell lines for both multiplex targeting 
and saturation editing was based on positive negative selection strategy. Hence, instead 
of FACS sorting, the transfected cells were selected based on the antibiotic resistance 
conferred by the introduced puDeltatk selection cassette.  
7.3.2.5.2 Picking, archiving and sequencing for selection of correctly targeted mutant clones 
The cells were incubated at 37°C for about 10 days or until visible colonies appear. In 
preparation for picking clones, 96 well flat bottom plates were gelatinized, and also 30µl 
of trypLE was added to U bottom 96 well plates. The media was aspirated from petri 
dishes, washed with 5ml of PBS, and replaced with 5ml fresh PBS. The single cell clones 
were picked (along with small amount of PBS) into individual wells of the U bottom 96 
well plate containing trypLE using sterile passettes. The plates were then incubated to 
break up the cells in the colony, and 100µl of media was added and mixed by pipetting 
to get single cell suspension. Meanwhile, the gelatin from flat bottom 96 well plates was 
aspirated and replaced with 100 µl of media, and the entire cell suspension from U bottom 
96 well plate was transferred to this flat bottom 96 well plate. Next day, the media was 
replaced, and the cells were cultured until they reach confluency. On reaching 80 percent 
confluency, the clones were split into two replicates. One plate was cultured further to 
freeze down, and the other plate was used to extract genomic DNA to test for correct 
editing. The crude DNA lysates were prepared using QE DNA extraction solution as 
described in section 7.2.1. The DNA from the clones was PCR amplified using β-catenin 
exon 3 F/R primers given in section 7.2.8 and the PCR product was sequenced using 
Sanger sequencing.  
7.3.2.5.3 Freezing of 96 well plates and restarting of mutant clones 
For freezing, the media was aspirated from 96 well plates, and washed with 200µl of PBS. 
After removing the PBS, 50µl of trypsin was added and placed in the incubator. Once the 
cells detach and become rounded, 70µl of FBS (fetal bovine serum) was added and 
pipetted thoroughly to make a single cell suspension. This was followed by the addition 
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of 70µl of 2X Freezing media constituting 20 percent DMSO in FBS and mixed quickly. 
The plate was then placed in styrofoam box and stored at -80°C. 
Following sequence confirmation of mutant clones, the correctly targeted clones were 
started up from the frozen stocks. The 96 well plate was quickly removed from -80°C, 
and warm media was added to the appropriate wells containing the mutant clones, and 
allowed to thaw. The thawed cells were transferred to 24 well plate and cultured. 
7.3.3 Generation of heterozygous β-catenin KO cell line 
Both TCF and E14 cell lines were used to generate heterozygous β-catenin KO mutants. 
The TCF and E14 cells were transfected with 2µg of CRISPR vectors (targeting the intron 
1 and intron 6 region of β-catenin) and 2µg of the puDeltatk TV using suspension cell 
protocol as described in section 7.4.1.5. The transfections were performed in R2i media 
for TCF cells and in normal ES media for E14s. Next day post transfection, the cells were 
trypsinized and plated in 10cm dishes at a low density in their respective media. Eight 
hours after plating, the media was supplemented with puromycin (positive selection 
antibiotic) at a final concentration of 1µg/ml. Ten days later colonies were picked into 96 
well plates and processed as described in section 7.4.1.5.2. 
7.3.3.1 PCR based selection of rightly targeted clones 
The DNA from the targeted clones was used to perform four PCRs to identify the 5' and 
3' region of puDeltatk and WT alleles. The PCRs were performed using Q5 2X master 
mix (NEB). The PCR parameters and primer sequences for each of the four PCRs is 
given in table 7-37 to 7-41. The PCR products were then sent for sequencing. 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 2.30min 
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Cycle to step2 9 more times 
6 98°C 10s 
7 69°C 15s 
8 72°C 2.30min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-37: PCR parameters for puDeltatk allele 5' arm PCR 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 1.30min 
Cycle to step2 9 more times 
6 98°C 10s 
7 70°C 15s 
8 72°C 1.30min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-38: PCR parameters for puDeltatk allele 5' arm PCR 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
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3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 2min 
Cycle to step2 9 more times 
6 98°C 10s 
7 66°C 15s 
8 72°C 2min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-39: PCR parameters for β-catenin WT allele 5' arm PCR 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 2min 
Cycle to step2 9 more times 
6 98°C 10s 
7 66°C 15s 
8 72°C 2min 
Cycle to step 6 for 20 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-40: PCR parameters for β-catenin WT allele 3' arm PCR 
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allele 5' arm 
GTGGACATCAGAGGACAACTTG AGAAGGGAAGAGAACAAAGGCA 
β-catenin WT 
allele 3' arm 
AGTTGTTTGTACAGAGTGTGGAGT GCACCGTCCTCTACATGATG 
Table 7-41: Primers used for amplification of puDeltatk and WT β-catenin alleles of 
heterozygous β-catenin KO cell lines 
7.3.4 Generation of fluorescence tagged S33Y ∆S45 and WT 
heterozygous and hemizygous pool of cells. 
The BFP and RFP tagged S33Y, ∆S45 and WT β-catenin vectors were available in the 
lab. The fluroscence tag in these vectors was present next to the start codon, the 
S33Y/∆S45/WT in the exon 3 region, and each of these vectors had 1Kb homology arm. 
The scg3 and g9B guides were cloned into pX459 plasmid. Since the TCF cells had a 
GFP reporter and I was using BFP and RFP tagged TVs, the fluorescence based CRISPR 
plasmids could not be used. Hence, I cloned the two CRISPR guides in pX459 nuclease 
plasmid based on puromycin selection. For generating the S33Y/∆S45 heterozygous 
pool, the TCF cells were transfected with BFP tagged WT β-catenin vector and RFP 
tagged S33Y/∆S45 vector along with the two guides using suspension cell protocol 
described in section 7.4.1.5. In addition, another transfection was performed where in the 
BFP and RFP tagged WT β-catenin vectors were transfected along with the CRISPR 
guides. For generation of hemizygous pool, the β-catenin heterozygous KO TCF cell line 
was transfected with S33Y BFP/∆S45 BFP/WT BFP along with two CRISPR guides scg3 
and g9B, keeping the puDeltaK allele intact.  
Second day post transfection, pools of BFP RFP red double positive cells were sorted 
from heterozygous condition and BFP positive cells were sorted for hemizygous 
condition, and the sorted cells were plated back in culture. Since the TCF cells were being 
cultured in the presence of 2i with one of the components being CHIRON, a GSK3β 
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inhibitor that would affect β-catenin activity. To avoid the effect of GSK3 β inhibitor, next 
day post sorting R2i media was replaced with normal ES media and the cells were further 
cultured for 2 days in normal ES media and GFP activity was analyzed using Flow 
cytometry. 
7.3.5 Multiplex targeting 
The heterozygous β-catenin KO E14 cell line was transfected with 2µg of CRISPR vectors 
targeting the selection cassette and 2µg of the multiplex TV variants of a particular 
residue using suspension cell protocol previously described in section 7.4.1.5. Since the 
heterozygous β-catenin KO E14 cell line was being cultured in R2i media, the cells were 
transfected in the same media. Next day post transfection, the cells were trypsinized and 
plated in 10cm dishes at a low density in normal ES media. Following 8hrs of plating, the 
media was supplemented with FIAU negative selection analogue at a final concentration 
of 0.2µM. Ten days later colonies were picked into 96 well plates and processed as 
described in section 7.4.1.5.2.  The DNA from multiplex clones was used to perform exon 
3 PCR which was then used for sequencing for identification of correctly targeted clones. 
Six sets of multiplex targeting was performed separately for each of the top six residues 
(D32, S33, G34, S37, T41 and S45) including all the selected corresponding amino acid 
substitutions. 
7.4  RNA isolation 
Total RNA was isolated from cells using Qiagen mini RNA kit according to the 
manufacturer's protocol. RNA being very sensitive to degradation by ubiquitously present 
ribonucleases, appropriate care was taken at every step of isolation and also while further 
handling and storage, including cleaning of bench top and gloves using RNA ZAP while 
handling RNA, using RNase free filter tips while pipetting and use of RNase free dH20 
for isolation and reconstitution. Following isolation, RNA was immediately placed on ice, 
quantified, aliquoted and stored at -80°C until future use.  
7.5 cDNA synthesis 
Synthesis of cDNA from total RNA was carried out using AMV reverse transcriptase kit 
(Promega). A reaction mix comprising of AMV Reverse transcriptase buffer, dNTP's, oligo 
(dT) primer, AMV Reverse trasnscriptase enzyme (Promega) was added to each tube 
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(+RT) containing 2µg of RNA in a total volume of 20µl as given in table 7-42. Control –
RT reactions consisting of the same reaction mix but without RTase were also set up to 
detect genomic DNA amplification giving false positive results. +RT reactions were set 
up for all E14 multiplex clones and two controls E14 and E14 β-catenin KO clone and –
RT reactions were set up for S37, T41, S45 E14 multiplex clones and the two controls. 
The + and – RT tubes were then incubated at 50°C for 1hour. The cDNA synthesized 
was diluted to obtain a final concentration of 10ng/µl. 
Reaction components Volume 
RNA 2µg 
dNTPs  1.25µl 
RNase inhibitor (Roche) 0.25µl 
Oligo d(T) primer 1.0µl 
AMV Reverse transcriptase 5X master mix (Promega) 4.0µl 
AMV Reverse transcriptase (Promega) 1.0µl 
dH2O Made up to 20µl 
Table 7-42: Reaction mix for cDNA synthesis 
7.6 Taqman assay 
Primers and probes for Taqman analysis were designed using Universal Probe library 
system assay design tool (Roche life sciences) 
(https://lifescience.roche.com/en_in/brands/universal-probe-library.html#assay-design-
center). Where possible, primers were designed spanning exon-exon boundary. A 
reaction mix consisting of Light cycler 480 master mix, target specific primer and probe, 
reference primer and probe ( Universal ProbeLibrary Mouse ACTB Gene Assay) along 
with cDNA equivalent to 20ng of RNA in a total volume of 10µl was set up in 384 well 
(barcoded LC480 plates) plates. The reaction components used for Taqman assay is 
given in table 7-43.PCR reactions were carried out in LightCycler 480 instrument (Roche 
Life sciences) using the inbuilt dual colour hydrolysis probe program (that allows 
detection of fluorescence signal from both target and reference probe). The Reference 
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gene β-actin expression was used for normalization of Taqman data. The primers and 
probes used for Taqman assay is given in table 7-44. 
Reaction components Volume 
Light cycler 480 master mix (Roche) 5µl 
Target specific primer F 0.2µl 
Target specific primer R 0.2µl 
Target probe 0.2µl 
Reference primers  0.1µl 
Reference probe 0.1µl 
cDNA (10ng/µl) 2.0µl 
dH2O Made up to 10µl 
Table 7-43: Reaction mix for Taqman assay 
Target 
gene 
Forward primer Reverse primer Probe# 
































































Klf2   
 
AGGCCTGTGGGTTCGCTATAA
A    
GGCAAATTATGGCTCAAAGTAGC




Table 7-44: Primers used for Taqman assay of multiplex clones. 
7.7 Protein isolation  
For protein isolation, the cells were trypsinized and the pelleted down. The pellet was 
then washed twice with ice cold PBS. Following PBS washes, the cells were lysed by 
addition of appropriate amount of Nonidet P40 (NP-40) cell lysis buffer (Thermo Fisher 
Scientific) and the lysate was processed according to the manufacturer's protocol. To 
avoid degradation by protease, NP-40 was supplemented with Protease inhibitor cocktail 
and PMSF (Thermo Fisher Scientific). The isolated total protein was aliquoted and stored 
at -80°C. 
7.7.1 Protein Quantitation 
The protein was quantitated using BCA protein assay kit (Thermo Fisher Scientific) 
according to the manufacturer's protocol. The concentration of the protein was measured 
at 562nm using a plate reader. The assay was performed in duplicates and along with 
the protein of interest, Bovine Serum Albumin (BSA) protein standards ranging from 0.2-
2mg/ml were included in every experiment. Following measurement of optical density at 
562nm, the total protein concentration was determined by comparing it to the standard 
protein.  
7.7.2 SDS PAGE and western blot 
20µg of total protein was mixed with SDS loading dye (6X) and incubated at 90°C for 5 
min and centrifuged briefly and the samples were placed on ice. The samples were 
resolved by running on 10 percent Tris-glycine SDS Polyacrylamide gel in 1X Tris glycine 
Buffer (Running buffer) for 2 hours at 100V. Following separation by electrophoresis, the 
protein was transferred onto PVDF membrane (GE Amersham Hybond –P) using transfer 
buffer in a Biorad transfer apparatus at 100V for 1 hour. The membrane was then blocked 
in 10 percent skimmed milk powder in TBST for 1 hour at room temperature on a shaker. 
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Next, the membrane was probed with 1:1000 primary antibody diluted in 5percent 
skimmed milk powder in TBST and incubated overnight at 4°C on a shaker. Next day, 
the membrane was washed twice for 20 min each with TBST and incubated in 1:10,000 
HRP conjugated secondary antibody in 5 percent skimmed milk powder in TBST for 1 
hour at room temperature on a shaker. The membrane was again washed twice for 20 
min each with TBST, and incubated in Super signal west dura extended duration 
substrate (Thermo Scientific) according to the manufacturers protocol and then exposed 
on an X-ray film (Amersham hyperfilm ECL – GE Healthcare),developed and fixed. The 
composition of the buffers and antibody concentrations used are given in table 7-45 to 7-
48. 







Table 7-45: Composition of running buffer. 







Table 7-46: Composition of transfer buffer. 
Components Volume 
Tris (pH 7.5) 25ml 
NaCl (5M) 15ml 
Tween 0.5ml 
dH2O 400ml 




Primary antibody Secondary antibody 
Purified mouse anti β-catenin – BD transduction 
Lab (1:1000) 
HRP conjugate anti mouse (GE 
Healthcare) 1:10000 
PCNA – mouse monoclonal Santa Cruz Biotech 
(1:1000) 
HRP conjugate anti mouse (GE 
Healthcare) 1:10000 
Table 7-48: Antibody concentrations used for western blot. 
7.8 FACS sorting and flow cytometry 
BD FACS Aria III (BD Biosciences) was used for sorting cells based on their fluorescence 
spectrum. Prior to FACS sorting cells were trypsinized, resuspended in PBS substituted 
with 10 percent FBS and centrifuged. The supernatant was discarded and pellet was 
resuspended in approximately 300-500µl of PBS substituted with 10 percent FBS, mixed 
thoroughly by pipetting and  transferred to FACS tubes (BD falcon tubes with cell strainer 
caps) by passing through the cell strainer cap to avoid clumps and make a single cell 
suspension. The tubes were placed on ice until sorting. 
Filters used for FACS were: 530/30 GFP (FITC), 450/40 TagBFP, 585/42 RFP/mCherry 
(PE). 
7.9 Compilation of CTNNB1 mutation data from 
COSMIC database and statistical analysis  
The CTNNB1 mutation data was compiled from COSMIC database. Tissues types 
harbouring more than 10 samples with missense mutation in CTNNB1 were selected for 
further analysis. A basic tabulation of the frequency distribution of mutation in various 
residues and also of the amino acid variants for each residue across different cancer 
types was performed. Statistical analysis of the compiled data was performed by Helen 
Brown (senior statistician at the Roslin Institute). 
To test if there were significant differences in the proportion of mutation (of a specific 
residue/amino acid substitution) across all the tumour types: here a simulation approach 
was used to test whether the chi-squared test statistic obtained for the observed data is 
significantly greater than expected given a null hypothesis of no difference in residue 
proportions between the sites. One thousand frequency tables were randomly simulated 
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under the assumption that the residue proportions were the same at all sites. The size of 
chi-squared test statistics generated from the simulated tables was compared to the chi-
squared statistic observed, and a p-value was obtained from the rank of the observed 
chi-squared statistic. 
To test which sites have an overall significant difference in mutation (of a specific residue 
/ amino acid substitution) between tumour types: here, it was necessary to test for each 
site whether the observed frequency of an individual mutation (of a particular residue/ 
amino acid substitution) is different than expected, given its expected frequency across 
all sites. This was addressed by comparing the observed proportion of mutation at a site 
to its expected proportion, assuming null hypothesis that the proportion of the observed 
mutation is no different to that expected. 
7.10 Luciferase assay 
The TOP/FOP and Renilla vectors were purchased from Addgene. The transfections 
were performed in triplicates using suspension cells in 96 well plates. Following plating 
of approximately 25,000 cells/well onto gelatinized 96 well plates, the cells in each well 
were transfected with 122.7ng of either TOP/FOP and 25ng of Renilla vector control. 
Following 4-6hrs of transfection the media was replaced by fresh media with penstrep. 
Next day the media was again replenished. After 36hrs post transfection the cells were 
processed using Dual luciferase reporter assay system (Promega) according to the 
manufacturers protocol, and the luciferase signal was measured by MicroLumatPlus 
LB96V microplate luminometer (EG and G Berthold). 
For DKK1 treatment, 6 hrs post transfection the media was replaced by fresh media 
supplemented with 300ng/ml of Recombinant human DKK1 (Merk Millipore). Next day, 
the media was replenished with fresh DKK1 supplemented media and the signal was 
measured as described above. 
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7.11 Saturation assay detailed protocol 
7.11.1 Cloning of Targeting vectors 
7.11.1.1 Template for Twist library synthesis  
Ds oligo library for golden gate cloning of 400 targeting vectors was ordered from Twist 
Biosciences. 200bp ds oligo consisting our region of interest which included BbsI sites at 
either ends, synonymous mutation in PAM region and 19th bp of g9b CRISPR guide and 
3 additional synonymous mutations that act as handle for identification of specifically the 
HDR targeted clones was ordered as gblock from IDT (given in table 7-49) and cloned 









Table 7-49: gblock used for cloning of template for Twist library synthesis. 
 *GAAGACCC/CCGTCTTC BbsI restriction site; T/C/A synonymous handle mutation; A 
synonymous PAM mutation of g9B CRISPR; T synonymous mutation in 19thbp of g9B CRISPR. 
7.11.1.2 Twist Library synthesis of ds oligos 
The TOPO vector was used as template and ds oligos with all amino acid substitutions 
at each of the 20 residues between L31 and G50 were synthesized by Twist Biosciences. 
We received the ds oligo as 20 pools with each pool consisting of all the 20amino acid 
substitutions for a specific residue. 
7.11.1.3 Cloning of Targeting vectors for saturation assay 
The ds oligo pools for each residue were cloned into the β-catenin backbone Golden 
Gate vector with BbsI sites. The ds oligos were reconstituted to a concentration of 5ng/µl 
in dH2O and cloning and transformation was done as described in section 7.2.9.2.8. 
However, instead of plating on LB petri plates, the transformed bacteria was inoculated 
in LB broth supplemented with kanamycin and incubated overnight in a shaker at 37°C. 
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Next day, equal volumes of inoculum were combined from each of the 20 pools and used 
as starter culture for maxiprep plasmid isolation. A single maxiprep of the pooled vectors 
was performed followed by ethanol purification and reconstituted in PBS at 1µg/µl 
concentration as described in section 7.2.3. 
7.11.2 Transfection for saturation assay 
200X106 heterozygous β-catenin KO TCF clone cultured in R2i media were used for 
transfection. 312µg of each of the four CRISPR/ Cas9 and 312 µg of pooled Twist HDR 
vector template was used. Transfection was done using lipofection and with the addition 
of L755507 as described in section 7.4.1.5 and the cells were plated in 26 six well culture 
plates in R2i media (day1). Next day post transfection (day2) the cells from all 26 six well 
plates were trypsinized and plated back in T75 plates in R2i media. On day 3 the media 
was replaced with normal ES media along with FIAU negative selection. Further on day 
4, the media was replaced with fresh normal ES media supplemented with FIAU. Finally, 
on day 5, the cells from all 26 flask were trypsinized and prepared for FACS sorting batch 
wise as described in section 7.9. 
7.11.3 FACS sorting 
The cells were FACS sorted based on GFP activity into six segments and collected in 
separate tubes. The number of cells collected from each segment is given in table 7-50. 
In addition a small sample of cells (pooled) was collected prior to sorting. 
Segment Replicate1 cell numbers Replicate2 cell numbers 
P2 200,000 200,000 
P3 200,000 200,000 
P4 200,000 200,000 
P5 80,000 1,130,000 
P6 445,427 942,000 
P7 8,309 11,641 
Table 7-50: Number of cells sorted from different segments of Replicate1 and Replicate2. 
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7.11.3.1 DNA isolation 
The entire cell pellet from each segment was used to isolate DNA. DNA isolation was 
done on the same day of FACS sort using Qiagen DNeasy blood and tissue kit. Next, 
DNA was quantitated using nanodrop 2000. 
7.11.3.2 Long range PCR 
All PCRs for saturation assay was performed in TC hoods. Initially a long range PCR for 
P2-P6 and pooled samples from both replicates was done with F primer (B cat 5' WT/F) 
outside the homology arm of the targeting vector (to prevent amplification of random 
integration) and Handle specific reverse primer (Handle test R). The primer sequences 
are given in table 7-51. 
Primers  Sequence 
B cat 5' WT/F GTGGACATCAGAGGACAACTTG 
Handle test R  TGTCAACATCTTCTTCTTCGGGA 
Table 7-51: Primers used for long range PCR. 
Both PCRs were done using Q5 Hot Start High-Fidelity 2X Master Mix (NEB) with same 
reaction mix and PCR parameters with touchdown protocol. The reaction mix and PCR 
parameters are shown in table 7-52 and table 7-53. The entire DNA obtained was used 
to perform PCR, except for pool samples and P5 segment of replicate 2 due to excess 
DNA available. 
Reaction components Volume 
Q5 Hot Start High-Fidelity 2X 
Master Mix 
12.5µl 
F Primer 1.0µl 
R Primer  1.0µl 
DNA Different amounts of DNA (0.5-3.0µl) used for each segment 
depending on the concentration  
PCR grade Water (sigma) Made upto 25.0µl 
Table 7-52: PCR Reaction mix for long range PCR. 
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Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 72°C 15s 
4 Decrease by 1°C every cycle 
5 72°C 2.30min 
Cycle to step2 9 more times 
6 98°C 10s 
7 67°C 15s 
8 72°C 2.30min 
Cycle to step 6 for 21 more times 
9 72°C 5min 
10 16°C ∞ 
Table 7-53: Thermocycler parameters for long range PCR. 
7.11.3.3 DpnI digestion 
Following the first round of PCR, all samples were digested with Fast digest DpnI (Thermo 
Scientific) to remove any residual vector. The components of the reaction mix are given 
in table 7-54. 
Reaction Components Volume  Incubation parameter 
3Kb PCR product 25.0µl  
37°C for 1hr FastDigest DpnI 2.0 µl 
10X Fast digest buffer 3.0 µl 
Table 7-54: Reaction mix and incubation parameters for DpnI digestion. 
7.11.3.4 Gel elution 
Following DpnI digestion, the products from the first round of PCR was run on 0.8 percent 
gel at 120V for 3 hours 30min to get maximum resolution of bands. The bands were then 
cut using a UV trans illuminator and gel extraction was performed using GeneJet gel 
extraction and DNA micro cleanup kit (Thermo Scientific) according to the manufacturer's 
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protocol, and finally the DNA was eluted in 10µl of dH20. Several PCR bands from each 
segment were gel extracted individually and later pooled into a single sample. 
PCR products from each segment were run individually in a single tank to avoid mixing 
up of PCR products from the different segments. In addition, after each run the gel tank, 
gel tray and combs were thoroughly washed and soaked overnight in 0.5M NaOH. NaoH 
is a good denaturing agent used to remove residual DNA, RNA and protein 
contamination. Next day, the tanks, trays and combs were rinsed with water and each 
time the gels were made and run in fresh 1X TAE.  
7.11.3.5 Second short PCR 
To allow sequencing using Illumina Miseq, a second round PCR was done using the gel 
eluted first round 3.2kb amplicon as the template to amplify a short fragment consisting 
of only the sequence of interest. The primers for the second round of PCR in addition to 
the target specific sequence, had the Illumina specific barcode, primer pad, linker and 
adaptors necessary for Illumina sequencing platform. The Illumina specifc primers were 
designed based on the earth microbiome project 
(http://press.igsb.anl.gov/earthmicrobiome/protocols-and-standards/16s/). The primers 
were ordered as ultramers of 4nM from IDT. Each segment (P2-P7 and pooled 3Kb 
handle PCR) was amplified using a Forward primer with specific barcode and handle 
specific reverse primer. 
The short PCR was also done on the targeting vectors used for transfection using the 
barcoded Forward primer and handle specific reverse primer. The primer sequences are 
given in table 7-55. Three PCR reactions were performed for each of the 16 segments 
(P2-P7, pooled, plasmid from both replicate 1 and 2) using Q5 Hot Start High-Fidelity 2X 
Master Mix (NEB) with touch down protocol. The reaction mix and PCR parameters are 



























































used for 16 
samples  
Table 7-55: Primers used for second short PCR. 
Reaction components Volume 
Q5 Hot Start High-Fidelity 2X Master Mix (NEB) 12.5µl 
Forward primer 0.7µl 
Reverse primer 0.7µl 
DNA 1.0µl 
dH2O 10.1µl 
Table 7-56: PCR Reaction mix for second short PCR 
Step Temperature Time 
1 98°C 2min 
2 98°C 10s 
3 67°C 15s 
4 72°C 25s 
5 Cycle to step 2 for 13 more times 
6 72°C 1min 
7 16°C ∞ 
Table 7-57: Thermocycler parameters for second short PCR 
7.11.3.6 Purification of PCR products 
The second short PCR products from each segment was cleaned separately using 
magnetic beads (Agencourt AMPure XP, Beckman Coulter Life Sciences) using the 
manufacturers protocol.  
7.11.3.7 Quantitation and final pooling of samples for deep sequencing 
For sequencing purpose required accurate pooling of the 16 segments. Hence the 
purified second short PCR products were quantitated using Qubit 3.0 fluorometer. The 
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samples were processed using Qubit dsDNA HS Assay kit (Life Technologies) according 
to the manufacturer's protocol. 
Finally, equimolar ratios of the PCR products from all the 16 segments were pooled to 
obtain a final concentration of 5nM. Following pooling of the samples, the integrity of DNA 
was assessed using a bioanalyzer. A high sensitivity DNA assay was performed, and the 
quality of the amplified product was analysed. The Bioanalyzer assay was done at the 
MRC sequencing facility. 
7.11.4 Deep sequencing 
Sequencing was done by Edinburgh genomics. A paired end sequencing (200bp read1 
and 100 read2) was performed using the Illumina MiSeq system. The sequencing primers 
are given in table 7-58. The primers were ordered as ultramers of 4nM from IDT and 
reconstituted in TE buffer and submitted at concentration of 100µM. 
QC-Before passing the samples for the MiSeq run another QC check was performed by 
Edinburgh genomics which included a qPCR and another round of Bioanalyser- high 
sensitivity DNA assay. 
Primer Sequence 
Read 1 seq TATGGTAATTGTATGGCCATGGAGCCGGA 
Read 2 seq AGTCAGCCAGCCTGTCAACATCTTCTTCTTCGGGA 
Index seq AATGATACGGCGACCACCGAGATCTACACGCT 
Table 7-58: Sequencing primers used for MiSeq. 
7.11.5 Processing and analysis of Deep sequencing data 
The processing of raw sequencing data and analysis was done by Martijn Kelder PhD 
student in Andrew Wood's lab (MRC Human Genetics Unit, IGMM, The University of 
Edinburgh). Quality control of reads in raw fastq files was done using fastqc (see sheet 
‘FastQC’ in BCat_fastqc_summary.xlsx). As forward and reverse reads were 




Reads were then trimmed for adapter sequences (<1 percent of reads) using Trimgalore 
and aligned to the reference sequence using BowTie2. Forward and reverse reads were 
merged into a single 100nt contig using Python. Only contigs without indels and with 
consensus between forward and reverse read for each position were passed on for 
further analysis. These files were then used for further analysis described below. 
Amino acid substitutions were counted for each saturated codon using Python and the 
reads were then normalized to the pool sample. 
7.11.6 Regression analysis 
The statistical regression analysis of the samples normalized to pool was performed by 
Helen Brown (senior statistician at The Roslin Institute) and the slope (m), SE and p 
values were calculated. The heatmap was plotted using heatmapper 
(http://www.heatmapper.ca/). 
7.11.7 Analysis of background mutation rate 
The analysis of the background mutational rate of β-catenin was performed by Ailith 
Ewing in Colin Semple's group in IGMM. The background mutational profiles for liver and 
endometrial cancers were calculated as follows: 
7.11.7.1 Mutational data 
The somatic mutation calls taken from the whole exome sequence for each cancer were 
calculated by the TCGA project as follows: the tumour sequence was aligned to the 
reference exome (GRCh38) and the normal sequence was aligned to the reference 
exome. Then, any mutations that occur in the tumour but not the normal were called as 
single nucleotide variants (SNVs). TCGA use four SNV callers: muse, mutect2, varscan 
and somaticsniper. These calls can be downloaded as .maf files. Next, an ensemble 
approach of these calls were taken and only mutations that had been called by at least 2 
of these callers were considered. Then, the samples were filtered to only include those 
with a mutation in the β-catenin region in question. Then, for the purposes of calculating 
relative frequencies and probabilities non-synonymous mutations (missense and 
nonsense) were excluded in an effort to make these mutations mostly selectively neutral. 
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After these steps there were 4996 mutations across the liver HCCs and 33,223 mutations 
across the endometrial cancers. 
7.11.7.2 Relative trinucleotide contexts 
Then, each nucleotide change was annotated with its trinucleotide context using the 
reference exome (GRCh38). With this the relative frequencies of each of the 96 possible 
mutations accounting for trinucleotide context were calculated. For each of the 96 types 
the relative frequency is: (number of that type)/ (total number of mutations). Therefore, 
the relative frequencies sum to 1.  
7.11.7.3 Calculation of the likelihood of particular amino acid substitution 
For a given amino acid substitution, the likelihood of that amino acid substitution in a 
given cancer type was calculated combining the three possible scenarios (only requires 
one SNV, requires several SNVs, can be achieved by 2+ paths) along with the SNV rates 














Appendix 1A Statistical analysis result of test performed to determine if there are significant differences between the 
proportions of mutation at each of the top 18 residues across the cancer types 
residue pvalue test_stat Significant? 
T41 0.001 1705.41965                Yes 
S45 0.001 1084.57036 Yes 
I35 0.001 790.162202 Yes 
S37 0.001 722.367373 Yes 
D32 0.001 600.984042 Yes 
S33 0.001 589.631303 Yes 
K49 0.001 516.482237 Yes 
T42 0.001 516.482237 Yes 
E53 0.001 452.509655 Yes 
G34 0.001 313.366331 Yes 
T40 0.001 311.100107 Yes 
A43 0.001 189.779571 Yes 
P44 0.001 157.942864 Yes 
G48 0.002 146.221487 Yes 
G24 0.002 144.049664 Yes 
H36 0.001 105.544157 Yes 
K33 0.054 52.1975665 No 





Appendix 1B Statistical analysis result of test performed to determine if there are significant differences between the 
proportions of the observed amino acid variants for each of the top 6 residues across the cancer types 
residue pvalue mutation test_stat Significant?  
D32 0.008 D32E 123.051823 Yes  
D32 0.001 D32Y 113.326286 Yes  
D32 0.001 D32H 80.8909966 Yes  
D32 0.001 D32N 52.9578491 Yes  
D32 0.001 D32G 52.852131 Yes  
D32 0.039 D32V 33.0106119 Yes  
D32 0.597 D32A 13.1892563 No  
D32 0.318 D32d 7.30693307 No  
G34 0.001 G34R 105.753345 Yes  
G34 0.001 G34V 71.3603046 Yes  
G34 0.001 G34E 65.6808879 Yes  
G34 0.092 G34I 25.5804416 No  
S33 0.001 S33C 168.653133 Yes  
S33 0.002 S33L 146.013947 Yes  
S33 0.001 S33Y 110.981388 Yes  
S33 0.001 S33F 98.0592472 Yes  
S33 0.058 S33T 67.5005577 No  
S33 0.079 S33N 58.6667995 No  
S33 0.004 S33P 47.2505151 Yes  
S33 0.492 S33A 19.8924563 No  
S37 0.001 S37A 227.067767 Yes  
S37 0.001 S37F 217.260869 Yes  
S37 0.001 S37C 161.974547 Yes  
S37 0.048 S37Y 37.305067 Yes  
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S37 0.277 S37P 25.078841 No  
S45 0.001 S45F 785.344011 Yes  
S45 0.001 S45d 250.491087 Yes  
S45 0.006 S45C 79.5602774 Yes  
S45 0.001 S45P 77.7361193 Yes  
S45 0.006 S45Y 74.9261189 Yes  
S45 0.065 S45A 49.1220549 No  
S45 0.202 S45T 12.4740222 No  
S45 0.198 S45E 5.76061455 No  
T41 0.001 T41A 1867.6365 Yes  
T41 0.001 T41I 476.556462 Yes  
T41 0.001 T41P 273.371509 Yes  
T41 0.001 T41S 183.188424 Yes  
T41 0.001 T41N 85.3267468 Yes  
 
Appendix 1C Statistical analysis result of test performed to determine whether the observed frequency of an individual 
residue (top 18 and other) is different than expected, given its expected frequency across all tumour types 
residue site total observed obs_propn expected_propn ratio_propns p 
A43 
Haematopoietic and 
lymphoid 49 5 0.102040816 0.003070175 33.2361516 4.65E-07 
A43 Pituitary 110 3 0.027272727 0.003070175 8.883116883 0.00489 
A43 Large intestine 371 3 0.008086253 0.003070175 2.63380824 0.107293 
A43 Thyroid 62 1 0.016129032 0.003070175 5.253456221 0.173573 
A43 Endometrium 326 1 0.003067485 0.003070175 0.999123576 0.633009 
A43 Soft tissue 1325 1 0.000754717 0.003070175 0.245822102 0.982995 
D32 CNS 295 85 0.288135593 0.100219298 2.875050996 0 
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D32 Pancreas 143 48 0.335664336 0.100219298 3.349298404 1.87E-14 
D32 Liver 892 134 0.150224215 0.100219298 1.498954971 1.81E-06 
D32 Stomach 182 37 0.203296703 0.100219298 2.028518527 2.48E-05 
D32 Pituitary 110 25 0.227272727 0.100219298 2.267754128 7.52E-05 
D32 Endometrium 326 55 0.168711656 0.100219298 1.683424843 9.4E-05 
D32 Prostate 25 7 0.28 0.100219298 2.793873085 0.009588 
D32 Testis 10 4 0.4 0.100219298 3.991247265 0.012893 
D32 Ovary 115 17 0.147826087 0.100219298 1.475026163 0.066872 
D32 Skin 143 20 0.13986014 0.100219298 1.395541002 0.079659 
D32 Urinary tract 19 3 0.157894737 0.100219298 1.575492341 0.295737 
D32 Oesophagus 11 1 0.090909091 0.100219298 0.907101651 0.687029 
D32 Small intestine 12 1 0.083333333 0.100219298 0.831509847 0.718395 
D32 Bone 25 2 0.08 0.100219298 0.798249453 0.729958 
D32 Biliary tract 45 2 0.044444444 0.100219298 0.443471918 0.948098 
D32 
Haematopoietic and 
lymphoid 49 1 0.020408163 0.100219298 0.203635065 0.994342 
D32 Lung 71 2 0.028169014 0.100219298 0.281073751 0.995063 
D32 Large intestine 371 6 0.016172507 0.100219298 0.161371183 1 
D32 Soft tissue 1325 7 0.005283019 0.100219298 0.052714587 1 
E53 
Haematopoietic and 
lymphoid 49 8 0.163265306 0.002850877 57.26844584 1.77E-12 
E53 Large intestine 371 4 0.010781671 0.002850877 3.781878499 0.02254 
E53 Soft tissue 1325 1 0.000754717 0.002850877 0.264731495 0.977241 
G245 Large intestine 371 13 0.035040431 0.002850877 12.29110512 1.04E-10 
G34 Liver 892 122 0.1367713 0.069517544 1.967435742 1.24E-12 
G34 CNS 295 45 0.152542373 0.069517544 2.19430038 6.61E-07 
G34 Endometrium 326 47 0.144171779 0.069517544 2.073890577 1.93E-06 
G34 Pancreas 143 22 0.153846154 0.069517544 2.213055084 0.000376 
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G34 Ovary 115 14 0.12173913 0.069517544 1.75120011 0.028866 
G34 Stomach 182 20 0.10989011 0.069517544 1.580753631 0.028886 
G34 Testis 10 2 0.2 0.069517544 2.876971609 0.150031 
G34 Skin 143 12 0.083916084 0.069517544 1.207120955 0.292095 
G34 Bone 25 2 0.08 0.069517544 1.150788644 0.526575 
G34 Prostate 25 2 0.08 0.069517544 1.150788644 0.526575 
G34 Lung 71 5 0.070422535 0.069517544 1.013018172 0.554171 
G34 Breast 15 1 0.066666667 0.069517544 0.958990536 0.66067 
G34 Biliary tract 45 2 0.044444444 0.069517544 0.639327024 0.829566 
G34 Pituitary 110 5 0.045454546 0.069517544 0.653857184 0.887066 
G34 Large intestine 371 12 0.032345014 0.069517544 0.465278427 0.999359 
G34 Soft tissue 1325 4 0.003018868 0.069517544 0.043425987 1 
G48 
Haematopoietic and 
lymphoid 49 4 0.081632653 0.002850877 28.63422292 1.26E-05 
G48 Stomach 182 4 0.021978022 0.002850877 7.709213863 0.001953 
G48 Large intestine 371 3 0.008086253 0.002850877 2.836408874 0.090949 
G48 Thyroid 62 1 0.016129032 0.002850877 5.657568238 0.162226 
G48 Skin 143 1 0.006993007 0.002850877 2.452931684 0.335192 
H36 Liver 892 31 0.034753363 0.010087719 3.445116007 6.04E-09 
H36 Kidney 197 9 0.045685279 0.010087719 4.528801589 0.000203 
H36 Thyroid 62 1 0.016129032 0.010087719 1.59887798 0.46667 
H36 Stomach 182 2 0.010989011 0.010087719 1.089345437 0.549019 
H36 Skin 143 1 0.006993007 0.010087719 0.693219824 0.765399 
H36 Large intestine 371 1 0.002695418 0.010087719 0.267197937 0.976752 
H36 Soft tissue 1325 1 0.000754717 0.010087719 0.074815423 0.999999 
I35 Salivary gland 14 12 0.857142857 0.014254386 60.13186813 0 
I35 Liver 892 39 0.043721973 0.014254386 3.067264574 1.71E-09 
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I35 Adrenal gland 65 2 0.030769231 0.014254386 2.158579882 0.237039 
I35 Lung 71 1 0.014084507 0.014254386 0.98808234 0.639168 
I35 Pituitary 110 1 0.009090909 0.014254386 0.637762238 0.793873 
I35 Ovary 115 1 0.008695652 0.014254386 0.610033445 0.808152 
I35 CNS 295 2 0.006779661 0.014254386 0.475619296 0.923774 
I35 Kidney 197 1 0.005076142 0.014254386 0.356110894 0.940888 
I35 Endometrium 326 2 0.006134969 0.014254386 0.430391694 0.946998 
I35 Large intestine 371 2 0.005390836 0.014254386 0.37818785 0.969058 
I35 Soft tissue 1325 2 0.001509434 0.014254386 0.105892598 1 
K335 Liver 892 14 0.015695067 0.003289474 4.771300448 2.48E-06 
K335 Kidney 197 1 0.005076142 0.003289474 1.543147208 0.477481 
K49 Thyroid 62 10 0.161290323 0.003070175 52.53456221 6.88E-15 
K49 Large intestine 371 4 0.010781671 0.003070175 3.51174432 0.028496 
Other Large intestine 371 102 0.274932615 0.067982456 4.044170072 0 
Other Thyroid 62 25 0.403225807 0.067982456 5.93132154 7.84E-14 
Other 
Haematopoietic and 
lymphoid 49 20 0.408163265 0.067982456 6.003949967 1.81E-11 
Other Lung 71 24 0.338028169 0.067982456 4.972285325 2.13E-11 
Other Stomach 182 33 0.181318681 0.067982456 2.667139312 2.39E-07 
Other Bone 25 7 0.28 0.067982456 4.118709677 0.001081 
Other Breast 15 5 0.333333333 0.067982456 4.903225807 0.002445 
Other Oesophagus 11 4 0.363636364 0.067982456 5.348973607 0.004779 
Other Ovary 115 10 0.086956522 0.067982456 1.279102384 0.255894 
Other Prostate 25 2 0.08 0.067982456 1.176774194 0.51427 
Other Salivary gland 14 1 0.071428571 0.067982456 1.050691244 0.626804 
Other Urinary tract 19 1 0.052631579 0.067982456 0.774193548 0.737543 
Other Skin 143 7 0.048951049 0.067982456 0.720054139 0.860398 
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Other Endometrium 326 17 0.052147239 0.067982456 0.767069068 0.897528 
Other Biliary tract 45 1 0.022222222 0.067982456 0.32688172 0.957919 
Other Kidney 197 7 0.035532995 0.067982456 0.522678893 0.982472 
Other Pancreas 143 1 0.006993007 0.067982456 0.102864877 0.999958 
Other Liver 892 30 0.033632287 0.067982456 0.494720093 0.999997 
Other Adrenal gland 310 3 0.009677419 0.067982456 0.142351717 1 
Other CNS 295 2 0.006779661 0.067982456 0.099726627 1 
Other Soft tissue 1325 8 0.006037736 0.067982456 0.088813147 1 
P44 Thyroid 62 5 0.080645161 0.004385965 18.38709677 8.53E-06 
P44 Kidney 197 5 0.025380711 0.004385965 5.786802031 0.001902 
P44 Adrenal gland 20 2 0.1 0.004385965 22.8 0.003468 
P44 
Haematopoietic and 
lymphoid 49 1 0.020408163 0.004385965 4.653061225 0.193769 
P44 Large intestine 371 3 0.008086253 0.004385965 1.843665768 0.223478 
P44 Skin 143 1 0.006993007 0.004385965 1.594405594 0.466647 
P44 Stomach 182 1 0.005494506 0.004385965 1.252747253 0.550672 
P44 Liver 892 2 0.002242153 0.004385965 0.511210762 0.90228 
S33 CNS 295 111 0.376271186 0.107894737 3.487391484 0 
S33 Pituitary 110 28 0.254545455 0.107894737 2.359201774 1.19E-05 
S33 Endometrium 326 58 0.17791411 0.107894737 1.648960048 0.000103 
S33 Ovary 115 23 0.2 0.107894737 1.853658537 0.002589 
S33 Liver 892 123 0.137892377 0.107894737 1.278026906 0.00302 
S33 Pancreas 143 25 0.174825175 0.107894737 1.620330889 0.010522 
S33 Skin 143 24 0.167832168 0.107894737 1.555517653 0.019203 
S33 Stomach 182 29 0.159340659 0.107894737 1.476815867 0.021255 
S33 Biliary tract 45 9 0.2 0.107894737 1.853658537 0.048523 
S33 Breast 15 4 0.266666667 0.107894737 2.471544715 0.070031 
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S33 Bone 25 5 0.2 0.107894737 1.853658537 0.125247 
S33 Prostate 25 4 0.16 0.107894737 1.482926829 0.281141 
S33 Parathyroid 11 2 0.181818182 0.107894737 1.685144124 0.33625 
S33 Urinary tract 19 2 0.105263158 0.107894737 0.975609756 0.623168 
S33 Lung 71 7 0.098591549 0.107894737 0.913775335 0.656058 
S33 Testis 10 1 0.1 0.107894737 0.926829268 0.680728 
S33 Oesophagus 11 1 0.090909091 0.107894737 0.842572062 0.715176 
S33 
Haematopoietic and 
lymphoid 49 2 0.040816327 0.107894737 0.378297661 0.974243 
S33 Large intestine 371 24 0.064690027 0.107894737 0.599566104 0.998403 
S33 Thyroid 62 1 0.016129032 0.107894737 0.149488592 0.999157 
S33 Kidney 197 3 0.015228426 0.107894737 0.141141513 1 
S33 Soft tissue 1325 6 0.004528302 0.107894737 0.041969627 1 
S37 Endometrium 326 83 0.254601227 0.112938597 2.254333194 9.20E-13 
S37 Stomach 182 50 0.274725275 0.112938597 2.432518937 1.71E-09 
S37 Ovary 115 36 0.313043478 0.112938597 2.771802448 7.42E-09 
S37 Lung 71 25 0.352112676 0.112938597 3.11773554 1.08E-07 
S37 Biliary tract 45 19 0.422222222 0.112938597 3.738511327 1.30E-07 
S37 Parathyroid 11 9 0.818181818 0.112938597 7.244483672 1.33E-07 
S37 Small intestine 12 9 0.75 0.112938597 6.640776699 4.77E-07 
S37 Skin 143 36 0.251748252 0.112938597 2.229071899 2.85E-06 
S37 Pancreas 143 34 0.237762238 0.112938597 2.105234571 1.96E-05 
S37 Urinary tract 19 9 0.473684211 0.112938597 4.194174757 9.51E-05 
S37 Pituitary 110 23 0.209090909 0.112938597 1.851368049 0.002555 
S37 Oesophagus 11 5 0.454545455 0.112938597 4.024713151 0.004714 
S37 CNS 295 45 0.152542373 0.112938597 1.350666447 0.023219 
S37 Testis 10 3 0.3 0.112938597 2.65631068 0.094191 
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S37 Liver 892 96 0.107623318 0.112938597 0.952936567 0.707091 
S37 Breast 15 1 0.066666667 0.112938597 0.590291262 0.834307 
S37 Thyroid 62 4 0.064516129 0.112938597 0.571249609 0.930252 
S37 Bone 25 1 0.04 0.112938597 0.354174757 0.950015 
S37 Prostate 25 1 0.04 0.112938597 0.354174757 0.950015 
S37 Large intestine 371 17 0.045822102 0.112938597 0.4057258 0.999998 
S37 Adrenal gland 515 3 0.005825243 0.112938597 0.051578848 1 
S37 Soft tissue 1325 6 0.004528302 0.112938597 0.040095256 1 
S45 Kidney 197 151 0.766497462 0.239473684 3.200758632 0 
S45 Soft tissue 1325 510 0.38490566 0.239473684 1.607298362 0 
S45 Large intestine 371 107 0.288409704 0.239473684 1.204348212 0.017278 
S45 Urinary tract 19 3 0.157894737 0.239473684 0.659340659 0.868101 
S45 Bone 25 3 0.12 0.239473684 0.501098901 0.958825 
S45 Prostate 25 3 0.12 0.239473684 0.501098901 0.958825 
S45 Skin 143 24 0.167832168 0.239473684 0.700837624 0.985236 
S45 Biliary tract 45 2 0.044444444 0.239473684 0.185592186 0.999932 
S45 Lung 71 5 0.070422535 0.239473684 0.294072125 0.999958 
S45 Liver 892 164 0.183856502 0.239473684 0.767752427 0.999974 
S45 
Haematopoietic and 
lymphoid 49 1 0.020408163 0.239473684 0.085220902 0.999999 
S45 Thyroid 62 2 0.032258065 0.239473684 0.134704006 0.999999 
S45 Ovary 115 5 0.043478261 0.239473684 0.181557573 1 
S45 Pituitary 110 4 0.036363636 0.239473684 0.151848152 1 
S45 Pancreas 143 5 0.034965035 0.239473684 0.146007838 1 
S45 Endometrium 326 26 0.079754601 0.239473684 0.333041192 1 
S45 Adrenal gland 1092 73 0.066849817 0.239473684 0.279153081 1 
S45 CNS 295 2 0.006779661 0.239473684 0.028310672 1 
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S45 Stomach 182 2 0.010989011 0.239473684 0.045888178 1 
S47 Large intestine 371 5 0.013477089 0.002850877 4.727348124 0.004547 
S47 Thyroid 62 2 0.032258065 0.002850877 11.31513648 0.013722 
S47 Pancreas 143 1 0.006993007 0.002850877 2.452931684 0.335192 
S47 Skin 143 1 0.006993007 0.002850877 2.452931684 0.335192 
S47 Stomach 182 1 0.005494506 0.002850877 1.927303466 0.405242 
S47 Liver 892 3 0.003363229 0.002850877 1.179717144 0.467361 
T40 Thyroid 62 8 0.129032258 0.003508772 36.77419355 6.56E-11 
T40 
Haematopoietic and 
lymphoid 49 2 0.040816327 0.003508772 11.63265306 0.012979 
T40 Bone 25 1 0.04 0.003508772 11.4 0.084123 
T40 CNS 295 1 0.003389831 0.003508772 0.966101695 0.645451 
T40 Endometrium 326 1 0.003067485 0.003508772 0.874233129 0.682053 
T40 Large intestine 371 1 0.002695418 0.003508772 0.76819407 0.728568 
T40 Soft tissue 1325 2 0.001509434 0.003508772 0.430188679 0.946223 
T41 Soft tissue 1325 777 0.586415094 0.248903509 2.355993683 0 
T41 Breast 15 4 0.266666667 0.248903509 1.071365639 0.534757 
T41 Prostate 25 6 0.24 0.248903509 0.964229075 0.616896 
T41 Biliary tract 45 10 0.222222222 0.248903509 0.892804699 0.714338 
T41 Small intestine 12 2 0.166666667 0.248903509 0.669603524 0.83957 
T41 Bone 25 4 0.16 0.248903509 0.642819383 0.901706 
T41 Pituitary 110 21 0.190909091 0.248903509 0.767000401 0.938892 
T41 Salivary gland 14 1 0.071428571 0.248903509 0.286972939 0.981814 
T41 Urinary tract 19 1 0.052631579 0.248903509 0.211453745 0.995653 
T41 
Haematopoietic and 
lymphoid 49 5 0.102040816 0.248903509 0.409961341 0.997265 
T41 Large intestine 371 64 0.172506739 0.248903509 0.693066721 0.999839 
T41 Skin 143 16 0.111888112 0.248903509 0.449524044 0.999988 
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T41 Ovary 115 9 0.07826087 0.248903509 0.314422524 0.999999 
T41 Thyroid 62 2 0.032258065 0.248903509 0.129600682 1 
T41 Kidney 197 20 0.101522843 0.248903509 0.407880319 1 
T41 Lung 71 2 0.028169014 0.248903509 0.113172427 1 
T41 Endometrium 326 36 0.110429448 0.248903509 0.443663685 1 
T41 Pancreas 143 7 0.048951049 0.248903509 0.196666769 1 
T41 Liver 892 134 0.150224215 0.248903509 0.603543984 1 
T41 Adrenal gland 1135 9 0.007929515 0.248903509 0.031857789 1 
T41 CNS 295 2 0.006779661 0.248903509 0.02723811 1 
T41 Stomach 182 3 0.016483517 0.248903509 0.066224524 1 
*Statistically significant scores (p<0.05) are highlighted 
 
Appendix 1D Statistical analysis result of test performed to determine whether the observed frequency of an individual 
amino acid variant (of the top 6 residues) is different than expected, given its expected frequency across all tumour 
types 
residue mutation site total observed obs_propn expected_propn ratio_propns p 
D32 D32A Liver 134 11 0.082089552 0.041575492 1.974469757 0.02456 
D32 D32A Pancreas 48 3 0.0625 0.041575492 1.503289474 0.322073 
D32 D32A Ovary 17 1 0.058823529 0.041575492 1.414860681 0.51417 
D32 D32A Endometrium 55 2 0.036363636 0.041575492 0.874641148 0.672394 
D32 D32A CNS 85 2 0.023529412 0.041575492 0.565944272 0.873136 
D32 D32E Small intestine 1 1 1 0.008752735 114.25 0.008753 
D32 D32E Skin 20 1 0.05 0.008752735 5.7125 0.161236 
D32 D32E Stomach 37 1 0.027027027 0.008752735 3.087837838 0.277673 
D32 D32E Pancreas 48 1 0.020833333 0.008752735 2.380208333 0.344253 
D32 D32G Large intestine 6 4 0.666666667 0.164113786 4.062222222 0.008219 
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D32 D32G Liver 134 33 0.246268657 0.164113786 1.500597015 0.009513 
D32 D32G Lung 2 1 0.5 0.164113786 3.046666667 0.301294 
D32 D32G Pancreas 48 9 0.1875 0.164113786 1.1425 0.388371 
D32 D32G Stomach 37 7 0.189189189 0.164113786 1.152792793 0.405956 
D32 D32G Urinary tract 3 1 0.333333333 0.164113786 2.031111111 0.415961 
D32 D32G Skin 20 4 0.2 0.164113786 1.218666667 0.421048 
D32 D32G Ovary 17 3 0.176470588 0.164113786 1.075294118 0.545144 
D32 D32G Prostate 7 1 0.142857143 0.164113786 0.870476191 0.714878 
D32 D32G Soft tissue 7 1 0.142857143 0.164113786 0.870476191 0.714878 
D32 D32G Pituitary 25 1 0.04 0.164113786 0.243733333 0.988684 
D32 D32G CNS 85 7 0.082352941 0.164113786 0.501803922 0.990703 
D32 D32G Endometrium 55 3 0.054545455 0.164113786 0.332363636 0.996393 
D32 D32H Pituitary 25 12 0.48 0.120350109 3.988363636 1.05E-05 
D32 D32H Stomach 37 11 0.297297297 0.120350109 2.47027027 0.003268 
D32 D32H Testis 4 2 0.5 0.120350109 4.154545455 0.073589 
D32 D32H 
Haematopoietic  
and lymphoid 1 1 1 0.120350109 8.309090909 0.12035 
D32 D32H Urinary tract 3 1 0.333333333 0.120350109 2.76969697 0.319341 
D32 D32H Prostate 7 1 0.142857143 0.120350109 1.187012987 0.592461 
D32 D32H Ovary 17 2 0.117647059 0.120350109 0.977540107 0.624013 
D32 D32H Endometrium 55 6 0.109090909 0.120350109 0.906446281 0.662823 
D32 D32H Pancreas 48 4 0.083333333 0.120350109 0.692424242 0.845098 
D32 D32H Skin 20 1 0.05 0.120350109 0.415454546 0.923052 
D32 D32H Liver 134 10 0.074626866 0.120350109 0.620081411 0.967856 
D32 D32H CNS 85 4 0.047058824 0.120350109 0.391016043 0.993862 
D32 D32N CNS 85 29 0.341176471 0.221006565 1.54373908 0.007435 
D32 D32N Oesophagus 1 1 1 0.221006565 4.524752475 0.221007 
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D32 D32N Pancreas 48 13 0.270833333 0.221006565 1.225453795 0.249477 
D32 D32N Pituitary 25 7 0.28 0.221006565 1.266930693 0.307088 
D32 D32N Bone 2 1 0.5 0.221006565 2.262376238 0.393169 
D32 D32N Endometrium 55 13 0.236363636 0.221006565 1.069486949 0.443571 
D32 D32N Testis 4 1 0.25 0.221006565 1.131188119 0.631756 
D32 D32N Stomach 37 7 0.189189189 0.221006565 0.856034252 0.739672 
D32 D32N Large intestine 6 1 0.166666667 0.221006565 0.754125413 0.776538 
D32 D32N Prostate 7 1 0.142857143 0.221006565 0.646393211 0.825925 
D32 D32N Liver 134 24 0.179104478 0.221006565 0.810403428 0.900996 
D32 D32N Skin 20 1 0.05 0.221006565 0.226237624 0.993229 
D32 D32N Biliary tract 101 2 0.01980198 0.221006565 0.089599059 1 
D32 D32V Liver 134 23 0.171641791 0.10940919 1.56880597 0.019539 
D32 D32V Prostate 7 2 0.285714286 0.10940919 2.611428571 0.173488 
D32 D32V Soft tissue 7 2 0.285714286 0.10940919 2.611428571 0.173488 
D32 D32V Testis 4 1 0.25 0.10940919 2.285 0.37091 
D32 D32V Skin 20 3 0.15 0.10940919 1.371 0.376852 
D32 D32V Pancreas 48 6 0.125 0.10940919 1.1425 0.430534 
D32 D32V CNS 85 10 0.117647059 0.10940919 1.075294118 0.454226 
D32 D32V Pituitary 25 2 0.08 0.10940919 0.7312 0.775258 
D32 D32V Endometrium 55 1 0.018181818 0.10940919 0.166181818 0.998293 
D32 D32Y Endometrium 55 29 0.527272727 0.332603939 1.585287081 0.002252 
D32 D32Y Ovary 17 11 0.647058824 0.332603939 1.945433437 0.007862 
D32 D32Y Skin 20 10 0.5 0.332603939 1.503289474 0.090714 
D32 D32Y CNS 85 33 0.388235294 0.332603939 1.167260062 0.164938 
D32 D32Y Soft tissue 7 4 0.571428571 0.332603939 1.718045113 0.172178 
D32 D32Y Bone 2 1 0.5 0.332603939 1.503289474 0.554582 
D32 D32Y Lung 2 1 0.5 0.332603939 1.503289474 0.554582 
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D32 D32Y Urinary tract 3 1 0.333333333 0.332603939 1.002192983 0.70273 
D32 D32Y Stomach 37 11 0.297297297 0.332603939 0.893847795 0.731491 
D32 D32Y Prostate 7 2 0.285714286 0.332603939 0.859022556 0.735279 
D32 D32Y Large intestine 6 1 0.166666667 0.332603939 0.501096491 0.911631 
D32 D32Y Pancreas 48 12 0.25 0.332603939 0.751644737 0.917233 
D32 D32Y Liver 134 33 0.246268657 0.332603939 0.740426159 0.98815 
D32 D32Y Pituitary 25 3 0.12 0.332603939 0.360789474 0.99642 
D32 D32del Endometrium 55 1 0.018181818 0.002188184 8.309090909 0.113507 
G34 G34E Stomach 20 10 0.5 0.302839117 1.651041667 0.050944 
G34 G34E Skin 12 6 0.5 0.302839117 1.651041667 0.1224 
G34 G34E CNS 45 16 0.355555556 0.302839117 1.174074074 0.267518 
G34 G34E Endometrium 47 16 0.340425532 0.302839117 1.124113475 0.337582 
G34 G34E Prostate 2 1 0.5 0.302839117 1.651041667 0.513967 
G34 G34E Testis 2 1 0.5 0.302839117 1.651041667 0.513967 
G34 G34E Large intestine 12 4 0.333333333 0.302839117 1.100694444 0.516216 
G34 G34E Liver 122 37 0.303278689 0.302839117 1.001451503 0.529881 
G34 G34E Ovary 14 4 0.285714286 0.302839117 0.943452381 0.653449 
G34 G34E Lung 5 1 0.2 0.302839117 0.660416667 0.835311 
G34 G34I Skin 12 1 0.083333333 0.003154574 26.41666667 0.037205 
G34 G34R Pancreas 22 15 0.681818182 0.38170347 1.786250939 0.004201 
G34 G34R Soft tissue 4 4 1 0.38170347 2.619834711 0.021228 
G34 G34R CNS 45 24 0.533333333 0.38170347 1.397245179 0.027567 
G34 G34R Pituitary 5 4 0.8 0.38170347 2.095867769 0.073728 
G34 G34R Ovary 14 7 0.5 0.38170347 1.309917355 0.258808 
G34 G34R Bone 2 1 0.5 0.38170347 1.309917355 0.617709 
G34 G34R Testis 2 1 0.5 0.38170347 1.309917355 0.617709 
G34 G34R Lung 5 2 0.4 0.38170347 1.047933884 0.630716 
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G34 G34R Skin 12 3 0.25 0.38170347 0.654958678 0.895237 
G34 G34R Liver 122 40 0.327868853 0.38170347 0.8589622 0.907168 
G34 G34R Stomach 20 5 0.25 0.38170347 0.654958678 0.929481 
G34 G34R Endometrium 47 13 0.276595745 0.38170347 0.724635133 0.951554 
G34 G34R Large intestine 12 2 0.166666667 0.38170347 0.436639119 0.973754 
G34 G34V Biliary tract 2 2 1 0.312302839 3.202020202 0.097533 
G34 G34V Liver 122 45 0.368852459 0.312302839 1.181073025 0.106714 
G34 G34V Large intestine 12 6 0.5 0.312302839 1.601010101 0.138317 
G34 G34V Endometrium 47 18 0.382978723 0.312302839 1.226305609 0.186091 
G34 G34V Breast 1 1 1 0.312302839 3.202020202 0.312303 
G34 G34V Lung 5 2 0.4 0.312302839 1.280808081 0.496941 
G34 G34V Bone 2 1 0.5 0.312302839 1.601010101 0.527073 
G34 G34V Prostate 2 1 0.5 0.312302839 1.601010101 0.527073 
G34 G34V Pancreas 22 7 0.318181818 0.312302839 1.01882461 0.55609 
G34 G34V Stomach 20 5 0.25 0.312302839 0.800505051 0.797337 
G34 G34V Pituitary 5 1 0.2 0.312302839 0.64040404 0.846189 
G34 G34V Ovary 14 3 0.214285714 0.312302839 0.686147186 0.861765 
G34 G34V Skin 12 2 0.166666667 0.312302839 0.533670034 0.92784 
G34 G34V CNS 45 5 0.111111111 0.312302839 0.355780022 0.99962 
S33 S33A Pituitary 28 4 0.142857143 0.040650407 3.514285714 0.025635 
S33 S33A Endometrium 58 5 0.086206897 0.040650407 2.120689655 0.086457 
S33 S33A Soft tissue 6 1 0.166666667 0.040650407 4.1 0.220419 
S33 S33A Liver 123 5 0.040650407 0.040650407 1 0.563155 
S33 S33A Pancreas 25 1 0.04 0.040650407 0.984 0.645658 
S33 S33A Stomach 29 1 0.034482759 0.040650407 0.848275862 0.699856 
S33 S33A CNS 111 3 0.027027027 0.040650407 0.664864865 0.83357 
S33 S33C Ovary 23 16 0.695652174 0.414634146 1.677749361 0.00606 
249 
 
S33 S33C Lung 7 5 0.714285714 0.414634146 1.722689076 0.111115 
S33 S33C Parathyroid 2 2 1 0.414634146 2.411764706 0.171921 
S33 S33C Breast 4 3 0.75 0.414634146 1.808823529 0.196467 
S33 S33C Soft tissue 6 4 0.666666667 0.414634146 1.607843137 0.200042 
S33 S33C Stomach 29 14 0.482758621 0.414634146 1.164300203 0.286861 
S33 S33C Biliary tract 9 5 0.555555556 0.414634146 1.339869281 0.297874 
S33 S33C Pancreas 25 12 0.48 0.414634146 1.157647059 0.319745 
S33 S33C Oesophagus 1 1 1 0.414634146 2.411764706 0.414634 
S33 S33C Testis 1 1 1 0.414634146 2.411764706 0.414634 
S33 S33C Liver 123 52 0.422764228 0.414634146 1.019607843 0.46151 
S33 S33C Pituitary 28 12 0.428571429 0.414634146 1.033613445 0.512322 
S33 S33C Endometrium 58 23 0.396551724 0.414634146 0.956389452 0.657596 
S33 S33C CNS 111 44 0.396396396 0.414634146 0.956014838 0.685044 
S33 S33C Bone 5 2 0.4 0.414634146 0.964705882 0.687858 
S33 S33C Kidney 3 1 0.333333333 0.414634146 0.803921569 0.799423 
S33 S33C Prostate 4 1 0.25 0.414634146 0.602941177 0.882589 
S33 S33C Large intestine 24 3 0.125 0.414634146 0.301470588 0.99959 
S33 S33C Skin 24 3 0.125 0.414634146 0.301470588 0.99959 
S33 S33F Skin 24 14 0.583333333 0.237804878 2.452991453 0.0003 
S33 S33F CNS 111 39 0.351351351 0.237804878 1.477477478 0.004653 
S33 S33F Urinary tract 2 2 1 0.237804878 4.205128205 0.056551 
S33 S33F Thyroid 1 1 1 0.237804878 4.205128205 0.237805 
S33 S33F Prostate 4 2 0.5 0.237804878 2.102564103 0.241316 
S33 S33F 
Haematopoietic  
and lymphoid 2 1 0.5 0.237804878 2.102564103 0.419059 
S33 S33F Stomach 29 7 0.24137931 0.237804878 1.015030946 0.553411 
S33 S33F Kidney 3 1 0.333333333 0.237804878 1.401709402 0.557209 
250 
 
S33 S33F Endometrium 58 13 0.224137931 0.237804878 0.942528736 0.646172 
S33 S33F Ovary 23 5 0.217391304 0.237804878 0.914158306 0.669442 
S33 S33F Pituitary 28 6 0.214285714 0.237804878 0.901098901 0.685506 
S33 S33F Bone 5 1 0.2 0.237804878 0.841025641 0.742765 
S33 S33F Pancreas 25 5 0.2 0.237804878 0.841025641 0.743511 
S33 S33F Lung 7 1 0.142857143 0.237804878 0.600732601 0.850561 
S33 S33F Liver 123 18 0.146341463 0.237804878 0.615384615 0.995498 
S33 S33F Large intestine 24 1 0.041666667 0.237804878 0.175213675 0.998522 
S33 S33L Biliary tract 9 4 0.444444444 0.012195122 36.44444444 2.65E-06 
S33 S33L Liver 123 2 0.016260163 0.012195122 1.333333333 0.443201 
S33 S33N Kidney 3 1 0.333333333 0.008130081 41 0.024192 
S33 S33N Lung 7 1 0.142857143 0.008130081 17.57142857 0.055541 
S33 S33N Endometrium 58 1 0.017241379 0.008130081 2.120689655 0.377164 
S33 S33N Liver 123 1 0.008130081 0.008130081 1 0.633621 
S33 S33P Liver 123 29 0.235772358 0.128048781 1.841269841 0.000755 
S33 S33P Pancreas 25 7 0.28 0.128048781 2.186666667 0.033371 
S33 S33P Pituitary 28 5 0.178571429 0.128048781 1.394557823 0.284819 
S33 S33P Endometrium 58 8 0.137931035 0.128048781 1.077175698 0.468849 
S33 S33P Bone 5 1 0.2 0.128048781 1.561904762 0.495965 
S33 S33P Stomach 29 3 0.103448276 0.128048781 0.807881773 0.736458 
S33 S33P Large intestine 24 2 0.083333333 0.128048781 0.650793651 0.831197 
S33 S33P Skin 24 2 0.083333333 0.128048781 0.650793651 0.831197 
S33 S33P Ovary 23 1 0.043478261 0.128048781 0.339544514 0.957212 
S33 S33P CNS 111 5 0.045045045 0.128048781 0.351780352 0.999098 
S33 S33T Breast 4 1 0.25 0.006097561 41 0.024168 
S33 S33T Soft tissue 6 1 0.166666667 0.006097561 27.33333333 0.036032 
S33 S33T Liver 123 1 0.008130081 0.006097561 1.333333333 0.528717 
251 
 
S33 S33Y Large intestine 24 18 0.75 0.152439024 4.92 1.04E-10 
S33 S33Y CNS 111 20 0.18018018 0.152439024 1.181981982 0.242744 
S33 S33Y 
Haematopoietic  
and lymphoid 2 1 0.5 0.152439024 3.28 0.28164 
S33 S33Y Skin 24 5 0.208333333 0.152439024 1.366666667 0.298644 
S33 S33Y Prostate 4 1 0.25 0.152439024 1.64 0.483959 
S33 S33Y Bone 5 1 0.2 0.152439024 1.312 0.562624 
S33 S33Y Stomach 29 4 0.137931035 0.152439024 0.904827586 0.664593 
S33 S33Y Endometrium 58 8 0.137931035 0.152439024 0.904827586 0.675862 
S33 S33Y Liver 123 15 0.12195122 0.152439024 0.8 0.85811 
S33 S33Y Ovary 23 1 0.043478261 0.152439024 0.285217391 0.977719 
S33 S33Y Pituitary 28 1 0.035714286 0.152439024 0.234285714 0.990255 
S37 S37A Parathyroid 9 9 1 0.130097087 7.686567164 1.07E-08 
S37 S37A Large intestine 17 12 0.705882353 0.130097087 5.425812116 7.68E-08 
S37 S37A Small intestine 9 8 0.888888889 0.130097087 6.832504146 6.53E-07 
S37 S37A Stomach 50 12 0.24 0.130097087 1.844776119 0.024316 
S37 S37A Prostate 1 1 1 0.130097087 7.686567164 0.130097 
S37 S37A Soft tissue 6 1 0.166666667 0.130097087 1.281094527 0.566664 
S37 S37A Endometrium 83 10 0.120481928 0.130097087 0.926092429 0.651429 
S37 S37A Liver 96 9 0.09375 0.130097087 0.720615672 0.891273 
S37 S37A CNS 45 3 0.066666667 0.130097087 0.512437811 0.943577 
S37 S37A Ovary 36 2 0.055555556 0.130097087 0.427031509 0.95773 
S37 S37C Ovary 36 22 0.611111111 0.32038835 1.907407407 0.000313 
S37 S37C Pituitary 23 15 0.652173913 0.32038835 2.035573123 0.001107 
S37 S37C Biliary tract 19 11 0.578947368 0.32038835 1.807017544 0.017746 
S37 S37C Endometrium 83 33 0.397590361 0.32038835 1.240963855 0.083993 
S37 S37C Liver 96 37 0.385416667 0.32038835 1.202967172 0.105709 
252 
 
S37 S37C Lung 25 11 0.44 0.32038835 1.373333333 0.143345 
S37 S37C Urinary tract 9 4 0.444444444 0.32038835 1.387205387 0.318213 
S37 S37C Bone 1 1 1 0.32038835 3.121212121 0.320388 
S37 S37C Breast 1 1 1 0.32038835 3.121212121 0.320388 
S37 S37C Pancreas 34 7 0.205882353 0.32038835 0.642602496 0.95186 
S37 S37C CNS 45 9 0.2 0.32038835 0.624242424 0.974882 
S37 S37C Large intestine 17 2 0.117647059 0.32038835 0.367201426 0.987313 
S37 S37C Skin 36 4 0.111111111 0.32038835 0.346801347 0.999171 
S37 S37C Stomach 50 5 0.1 0.32038835 0.312121212 0.999944 
S37 S37C Adrenal gland 165 3 0.018181818 0.32038835 0.056749311 1 
S37 S37F Skin 36 27 0.75 0.411650485 1.821933962 3.97E-05 
S37 S37F Oesophagus 5 5 1 0.411650485 2.429245283 0.011821 
S37 S37F Pancreas 34 21 0.617647059 0.411650485 1.500416204 0.012308 
S37 S37F Thyroid 4 4 1 0.411650485 2.429245283 0.028715 
S37 S37F Testis 3 3 1 0.411650485 2.429245283 0.069757 
S37 S37F Stomach 50 25 0.5 0.411650485 1.214622642 0.130484 
S37 S37F Lung 25 13 0.52 0.411650485 1.263207547 0.184198 
S37 S37F Soft tissue 6 4 0.666666667 0.411650485 1.619496855 0.195694 
S37 S37F Urinary tract 9 5 0.555555556 0.411650485 1.349580713 0.291378 
S37 S37F Endometrium 83 35 0.421686747 0.411650485 1.024380541 0.467815 
S37 S37F Biliary tract 19 8 0.421052632 0.411650485 1.022840119 0.553826 
S37 S37F CNS 45 17 0.377777778 0.411650485 0.917714885 0.727992 
S37 S37F Pituitary 23 7 0.304347826 0.411650485 0.739335521 0.897606 
S37 S37F Ovary 36 11 0.305555556 0.411650485 0.742269392 0.93044 
S37 S37F Liver 96 26 0.270833333 0.411650485 0.657920598 0.998545 
S37 S37F Large intestine 17 1 0.058823529 0.411650485 0.142896781 0.999879 
S37 S37P Liver 96 12 0.125 0.062135922 2.01171875 0.01594 
253 
 
S37 S37P CNS 45 6 0.133333333 0.062135922 2.145833333 0.058625 
S37 S37P Large intestine 17 2 0.117647059 0.062135922 1.893382353 0.285501 
S37 S37P Pancreas 34 3 0.088235294 0.062135922 1.420036765 0.354678 
S37 S37P Small intestine 9 1 0.111111111 0.062135922 1.788194444 0.438617 
S37 S37P Stomach 50 3 0.06 0.062135922 0.965625 0.607985 
S37 S37P Pituitary 23 1 0.043478261 0.062135922 0.699728261 0.771325 
S37 S37P Endometrium 83 3 0.036144578 0.062135922 0.581701807 0.895586 
S37 S37P Skin 36 1 0.027777778 0.062135922 0.447048611 0.90068 
S37 S37Y CNS 45 10 0.222222222 0.075728155 2.934472935 0.00168 
S37 S37Y Liver 96 12 0.125 0.075728155 1.650641026 0.058897 
S37 S37Y Skin 36 4 0.111111111 0.075728155 1.467236467 0.289138 
S37 S37Y Stomach 50 5 0.1 0.075728155 1.320512821 0.327743 
S37 S37Y Soft tissue 6 1 0.166666667 0.075728155 2.200854701 0.376555 
S37 S37Y Pancreas 34 3 0.088235294 0.075728155 1.165158371 0.480919 
S37 S37Y Lung 25 1 0.04 0.075728155 0.528205128 0.860365 
S37 S37Y Ovary 36 1 0.027777778 0.075728155 0.366809117 0.941279 
S37 S37Y Endometrium 83 2 0.024096386 0.075728155 0.31819586 0.988689 
S45 S45A Liver 164 12 0.073170732 0.014652015 4.993902439 6.56E-06 
S45 S45A Adrenal gland 16 1 0.0625 0.014652015 4.265625 0.210351 
S45 S45A Endometrium 26 1 0.038461539 0.014652015 2.625 0.318712 
S45 S45A Large intestine 107 1 0.009345794 0.014652015 0.637850467 0.793894 
S45 S45A Kidney 151 1 0.006622517 0.014652015 0.451986755 0.892345 
S45 S45C Kidney 151 19 0.125827815 0.029304029 4.293874172 1.16E-07 
S45 S45C Stomach 2 1 0.5 0.029304029 17.0625 0.057749 
S45 S45C Endometrium 26 2 0.076923077 0.029304029 2.625 0.176281 
S45 S45C Liver 164 6 0.036585366 0.029304029 1.24847561 0.349496 
S45 S45C Skin 24 1 0.041666667 0.029304029 1.421875 0.510224 
254 
 
S45 S45C Large intestine 107 1 0.009345794 0.029304029 0.318925234 0.958514 
S45 S45C Soft tissue 510 2 0.003921569 0.029304029 0.133823529 0.999996 
S45 S45E Kidney 151 1 0.006622517 0.000915751 7.23178808 0.129199 
S45 S45F Soft tissue 510 408 0.8 0.576923077 1.386666667 0 
S45 S45F Large intestine 107 73 0.682242991 0.576923077 1.182554517 0.016534 
S45 S45F Biliary tract 2 2 1 0.576923077 1.733333333 0.33284 
S45 S45F CNS 2 2 1 0.576923077 1.733333333 0.33284 
S45 S45F 
Haematopoietic  
and lymphoid 1 1 1 0.576923077 1.733333333 0.576923 
S45 S45F Ovary 5 3 0.6 0.576923077 1.04 0.641971 
S45 S45F Stomach 2 1 0.5 0.576923077 0.866666667 0.821006 
S45 S45F Endometrium 26 13 0.5 0.576923077 0.866666667 0.839541 
S45 S45F Skin 24 11 0.458333333 0.576923077 0.794444444 0.915791 
S45 S45F Urinary tract 3 1 0.333333333 0.576923077 0.577777778 0.924272 
S45 S45F Lung 5 1 0.2 0.576923077 0.346666667 0.986445 
S45 S45F Pancreas 5 1 0.2 0.576923077 0.346666667 0.986445 
S45 S45F Liver 164 59 0.359756098 0.576923077 0.623577236 1 
S45 S45F Adrenal gland 630 18 0.028571429 0.576923077 0.04952381 1 
S45 S45F Kidney 151 36 0.238410596 0.576923077 0.413245033 1 
S45 S45P Liver 164 68 0.414634146 0.26007326 1.594297492 1.2E-05 
S45 S45P Pituitary 4 3 0.75 0.26007326 2.883802817 0.056639 
S45 S45P Thyroid 2 2 1 0.26007326 3.845070423 0.067638 
S45 S45P Bone 3 2 0.666666667 0.26007326 2.563380282 0.167733 
S45 S45P Prostate 3 2 0.666666667 0.26007326 2.563380282 0.167733 
S45 S45P Urinary tract 3 2 0.666666667 0.26007326 2.563380282 0.167733 
S45 S45P Lung 5 2 0.4 0.26007326 1.538028169 0.388428 
S45 S45P Pancreas 5 2 0.4 0.26007326 1.538028169 0.388428 
255 
 
S45 S45P Endometrium 26 7 0.269230769 0.26007326 1.035211268 0.532066 
S45 S45P Ovary 5 1 0.2 0.26007326 0.769014085 0.778209 
S45 S45P Skin 24 4 0.166666667 0.26007326 0.64084507 0.904677 
S45 S45P Kidney 151 28 0.185430464 0.26007326 0.712993191 0.987816 
S45 S45P Large intestine 107 14 0.130841122 0.26007326 0.503093326 0.999637 
S45 S45P Soft tissue 510 99 0.194117647 0.26007326 0.746396023 0.999806 
S45 S45P Adrenal gland 284 48 0.169014085 0.26007326 0.649871057 0.999902 
S45 S45T Liver 164 3 0.018292683 0.003663004 4.993902439 0.022934 
S45 S45T Large intestine 107 1 0.009345794 0.003663004 2.551401869 0.324742 
S45 S45Y Liver 164 15 0.091463415 0.034798535 2.628369705 0.000664 
S45 S45Y Skin 24 5 0.208333333 0.034798535 5.986842105 0.001246 
S45 S45Y Kidney 151 12 0.079470199 0.034798535 2.283722551 0.006819 
S45 S45Y Pituitary 4 1 0.25 0.034798535 7.184210526 0.132096 
S45 S45Y Ovary 5 1 0.2 0.034798535 5.747368421 0.162297 
S45 S45Y Adrenal gland 38 2 0.052631579 0.034798535 1.512465374 0.383072 
S45 S45Y Endometrium 26 1 0.038461539 0.034798535 1.105263158 0.601831 
S45 S45Y Soft tissue 510 1 0.001960784 0.034798535 0.056346749 1 
S45 S45del Kidney 151 54 0.357615894 0.07967033 4.488696049 0 
S45 S45del Large intestine 107 17 0.158878505 0.07967033 1.994199162 0.004741 
S45 S45del Lung 5 2 0.4 0.07967033 5.020689655 0.053951 
S45 S45del Pancreas 5 2 0.4 0.07967033 5.020689655 0.053951 
S45 S45del Bone 3 1 0.333333333 0.07967033 4.183908046 0.220475 
S45 S45del Prostate 3 1 0.333333333 0.07967033 4.183908046 0.220475 
S45 S45del Skin 24 3 0.125 0.07967033 1.568965517 0.298375 
S45 S45del Endometrium 26 2 0.076923077 0.07967033 0.965517241 0.624585 
S45 S45del Adrenal gland 87 4 0.045977012 0.07967033 0.577090765 0.923154 
S45 S45del Liver 164 1 0.006097561 0.07967033 0.076534903 0.999999 
256 
 
T41 T41A Soft tissue 777 770 0.990990991 0.8969163 1.104886812 0 
T41 T41A Breast 4 4 1 0.8969163 1.114931238 0.647154 
T41 T41A CNS 2 2 1 0.8969163 1.114931238 0.804459 
T41 T41A Lung 2 2 1 0.8969163 1.114931238 0.804459 
T41 T41A Small intestine 2 2 1 0.8969163 1.114931238 0.804459 
T41 T41A Urinary tract 1 1 1 0.8969163 1.114931238 0.896916 
T41 T41A Biliary tract 10 8 0.8 0.8969163 0.89194499 0.9244 
T41 T41A Large intestine 64 54 0.84375 0.8969163 0.940723232 0.938346 
T41 T41A Kidney 20 16 0.8 0.8969163 0.89194499 0.951726 
T41 T41A Stomach 3 2 0.666666667 0.8969163 0.743287492 0.970312 
T41 T41A Prostate 6 4 0.666666667 0.8969163 0.743287492 0.982766 
T41 T41A Ovary 9 6 0.666666667 0.8969163 0.743287492 0.990716 
T41 T41A Liver 134 111 0.828358209 0.8969163 0.923562443 0.994824 
T41 T41A Bone 4 2 0.5 0.8969163 0.557465619 0.995957 
T41 T41A 
Haematopoietic  
and lymphoid 5 2 0.4 0.8969163 0.445972495 0.999482 
T41 T41A Pancreas 7 2 0.285714286 0.8969163 0.318551782 0.999992 
T41 T41A Skin 16 5 0.3125 0.8969163 0.348416012 1 
T41 T41A Endometrium 36 15 0.416666667 0.8969163 0.464554682 1 
T41 T41A Adrenal gland 1018 9 0.008840864 0.8969163 0.009856956 1 
T41 T41A Pituitary 21 1 0.047619048 0.8969163 0.053091964 1 
T41 T41I Pituitary 21 19 0.904761905 0.086343612 10.47862002 0 
T41 T41I Endometrium 36 18 0.5 0.086343612 5.790816327 1.39E-10 
T41 T41I Skin 16 9 0.5625 0.086343612 6.514668367 1.73E-06 
T41 T41I Pancreas 7 5 0.714285714 0.086343612 8.272594752 8.68E-05 
T41 T41I Liver 134 19 0.141791045 0.086343612 1.642171794 0.021962 
T41 T41I Ovary 9 3 0.333333333 0.086343612 3.860544218 0.036361 
257 
 
T41 T41I Bone 4 2 0.5 0.086343612 5.790816327 0.039748 
T41 T41I Prostate 6 2 0.333333333 0.086343612 3.860544218 0.088468 
T41 T41I Large intestine 64 9 0.140625 0.086343612 1.628667092 0.098186 
T41 T41I Thyroid 2 1 0.5 0.086343612 5.790816327 0.165232 
T41 T41I Biliary tract 10 2 0.2 0.086343612 2.316326531 0.211583 
T41 T41I Stomach 3 1 0.333333333 0.086343612 3.860544218 0.237309 
T41 T41I 
Haematopoietic  
and lymphoid 5 1 0.2 0.086343612 2.316326531 0.36333 
T41 T41I Soft tissue 777 7 0.009009009 0.086343612 0.104339033 1 
T41 T41N Skin 16 2 0.125 0.006167401 20.26785714 0.004309 
T41 T41N Haematopoietic and lymphoid 5 1 0.2 0.006167401 32.42857143 0.030459 
T41 T41N Liver 134 3 0.02238806 0.006167401 3.630063966 0.050755 
T41 T41N Kidney 20 1 0.05 0.006167401 8.107142857 0.116382 
T41 T41P Kidney 20 3 0.15 0.005286344 28.375 0.000157 
T41 T41P Salivary gland 1 1 1 0.005286344 189.1666667 0.005286 
T41 T41P Large intestine 64 1 0.015625 0.005286344 2.955729167 0.287677 
T41 T41P Liver 134 1 0.007462687 0.005286344 1.411691542 0.508478 
T41 T41S Endometrium 36 3 0.083333333 0.005286344 15.76388889 0.000926 
T41 T41S Thyroid 2 1 0.5 0.005286344 94.58333333 0.010545 
T41 T41S 
Haematopoietic  
and lymphoid 5 1 0.2 0.005286344 37.83333333 0.026154 
T41 T41S Pituitary 21 1 0.047619048 0.005286344 9.007936508 0.105337 






Appendix 2A Multiple comparison (Tukey's test) of one way ANOVA for luciferase assay on multiplex clones 
Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
  D32H vs. D32V -159.9 -349.6 to 29.82 No ns 0.2179 
  D32H vs. D32Y -154.1 -343.8 to 35.61 No ns 0.2764 
  D32H vs. D32N -25.78 -215.5 to 163.9 No ns >0.9999 
  D32H vs. D32G -135.4 -325.1 to 54.36 No ns 0.5219 
  D32H vs. S33Y 94.25 -95.47 to 284 No ns 0.9658 
  D32H vs. S33P 90.34 -99.38 to 280.1 No ns 0.9785 
  D32H vs. S33C 112.2 -77.53 to 301.9 No ns 0.8367 
  D32H vs. S33F 107.6 -82.08 to 297.4 No ns 0.8815 
  D32H vs. S33L 165.3 -24.46 to 355 No ns 0.1722 
  D32H vs. G34V 5.638 -184.1 to 195.4 No ns >0.9999 
  D32H vs. G34E 43.45 -146.3 to 233.2 No ns >0.9999 
  D32H vs. G34R -10.71 -200.4 to 179 No ns >0.9999 
  D32H vs. S37C -319.8 -531.9 to -107.7 Yes **** <0.0001 
  D32H vs. S37F -242.2 -431.9 to -52.44 Yes ** 0.0019 
  D32H vs. S37A -241.7 -453.8 to -29.55 Yes * 0.0104 
  D32H vs. S37Y -461.1 -673.2 to -249 Yes **** <0.0001 
  D32H vs. S45Y 207.4 17.69 to 397.1 Yes * 0.0179 
  D32H vs. S45P 183.5 -6.176 to 373.3 No ns 0.0699 
  D32H vs. S45F 145 -44.74 to 334.7 No ns 0.3868 
  D32H vs. S45C 233.5 21.4 to 445.6 Yes * 0.0163 
  D32H vs. T41I -446.1 -635.8 to -256.3 Yes **** <0.0001 
  D32H vs. T41A -309 -498.7 to -119.3 Yes **** <0.0001 
  D32H vs. T41S 254.4 64.69 to 444.1 Yes *** 0.0008 
  D32H vs. T41N 156.1 -33.66 to 345.8 No ns 0.2556 
  D32H vs. T41P 80.21 -109.5 to 269.9 No ns 0.9951 
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  D32H vs. E14 254.9 90.63 to 419.2 Yes **** <0.0001 
  D32V vs. D32Y 5.795 -183.9 to 195.5 No ns >0.9999 
  D32V vs. D32N 134.1 -55.59 to 323.8 No ns 0.54 
  D32V vs. D32G 24.55 -165.2 to 214.3 No ns >0.9999 
  D32V vs. S33Y 254.2 64.43 to 443.9 Yes *** 0.0008 
  D32V vs. S33P 250.2 60.53 to 440 Yes ** 0.0011 
  D32V vs. S33C 272.1 82.37 to 461.8 Yes *** 0.0002 
  D32V vs. S33F 267.5 77.83 to 457.3 Yes *** 0.0003 
  D32V vs. S33L 325.2 135.4 to 514.9 Yes **** <0.0001 
  D32V vs. G34V 165.5 -24.18 to 355.3 No ns 0.1701 
  D32V vs. G34E 203.4 13.64 to 393.1 Yes * 0.0228 
  D32V vs. G34R 149.2 -40.53 to 338.9 No ns 0.3332 
  D32V vs. S37C -159.9 -372 to 52.22 No ns 0.4132 
  D32V vs. S37F -82.26 -272 to 107.5 No ns 0.9931 
  D32V vs. S37A -81.76 -293.9 to 130.4 No ns 0.9987 
  D32V vs. S37Y -301.2 -513.3 to -89.06 Yes *** 0.0003 
  D32V vs. S45Y 367.3 177.6 to 557 Yes **** <0.0001 
  D32V vs. S45P 343.4 153.7 to 533.2 Yes **** <0.0001 
  D32V vs. S45F 304.9 115.2 to 494.6 Yes **** <0.0001 
  D32V vs. S45C 393.4 181.3 to 605.5 Yes **** <0.0001 
  D32V vs. T41I -286.2 -475.9 to -96.44 Yes **** <0.0001 
  D32V vs. T41A -149.1 -338.8 to 40.65 No ns 0.3347 
  D32V vs. T41S 414.3 224.6 to 604 Yes **** <0.0001 
  D32V vs. T41N 316 126.2 to 505.7 Yes **** <0.0001 
  D32V vs. T41P 240.1 50.4 to 429.8 Yes ** 0.0022 
  D32V vs. E14 414.8 250.5 to 579.1 Yes **** <0.0001 
  D32Y vs. D32N 128.3 -61.39 to 318.1 No ns 0.6253 
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  D32Y vs. D32G 18.75 -171 to 208.5 No ns >0.9999 
  D32Y vs. S33Y 248.4 58.64 to 438.1 Yes ** 0.0012 
  D32Y vs. S33P 244.5 54.73 to 434.2 Yes ** 0.0016 
  D32Y vs. S33C 266.3 76.58 to 456 Yes *** 0.0003 
  D32Y vs. S33F 261.8 72.03 to 451.5 Yes *** 0.0005 
  D32Y vs. S33L 319.4 129.7 to 509.1 Yes **** <0.0001 
  D32Y vs. G34V 159.7 -29.97 to 349.5 No ns 0.2194 
  D32Y vs. G34E 197.6 7.843 to 387.3 Yes * 0.0321 
  D32Y vs. G34R 143.4 -46.32 to 333.1 No ns 0.408 
  D32Y vs. S37C -165.7 -377.8 to 46.43 No ns 0.3456 
  D32Y vs. S37F -88.06 -277.8 to 101.7 No ns 0.984 
  D32Y vs. S37A -87.55 -299.7 to 124.6 No ns 0.9964 
  D32Y vs. S37Y -307 -519.1 to -94.86 Yes *** 0.0002 
  D32Y vs. S45Y 361.5 171.8 to 551.2 Yes **** <0.0001 
  D32Y vs. S45P 337.7 147.9 to 527.4 Yes **** <0.0001 
  D32Y vs. S45F 299.1 109.4 to 488.8 Yes **** <0.0001 
  D32Y vs. S45C 387.6 175.5 to 599.7 Yes **** <0.0001 
  D32Y vs. T41I -292 -481.7 to -102.2 Yes **** <0.0001 
  D32Y vs. T41A -154.9 -344.6 to 34.85 No ns 0.2682 
  D32Y vs. T41S 408.5 218.8 to 598.2 Yes **** <0.0001 
  D32Y vs. T41N 310.2 120.5 to 499.9 Yes **** <0.0001 
  D32Y vs. T41P 234.3 44.6 to 424 Yes ** 0.0032 
  D32Y vs. E14 409 244.7 to 573.3 Yes **** <0.0001 
  D32N vs. D32G -109.6 -299.3 to 80.14 No ns 0.8634 
  D32N vs. S33Y 120 -69.69 to 309.7 No ns 0.7421 
  D32N vs. S33P 116.1 -73.6 to 305.8 No ns 0.7917 
  D32N vs. S33C 138 -51.75 to 327.7 No ns 0.484 
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  D32N vs. S33F 133.4 -56.3 to 323.1 No ns 0.5504 
  D32N vs. S33L 191 1.321 to 380.8 Yes * 0.0465 
  D32N vs. G34V 31.42 -158.3 to 221.1 No ns >0.9999 
  D32N vs. G34E 69.23 -120.5 to 259 No ns 0.9994 
  D32N vs. G34R 15.06 -174.7 to 204.8 No ns >0.9999 
  D32N vs. S37C -294 -506.1 to -81.9 Yes *** 0.0004 
  D32N vs. S37F -216.4 -406.1 to -26.67 Yes * 0.0102 
  D32N vs. S37A -215.9 -428 to -3.77 Yes * 0.0414 
  D32N vs. S37Y -435.3 -647.4 to -223.2 Yes **** <0.0001 
  D32N vs. S45Y 233.2 43.47 to 422.9 Yes ** 0.0034 
  D32N vs. S45P 209.3 19.6 to 399 Yes * 0.0159 
  D32N vs. S45F 170.8 -18.96 to 360.5 No ns 0.1334 
  D32N vs. S45C 259.3 47.18 to 471.4 Yes ** 0.0037 
  D32N vs. T41I -420.3 -610 to -230.6 Yes **** <0.0001 
  D32N vs. T41A -283.2 -472.9 to -93.48 Yes *** 0.0001 
  D32N vs. T41S 280.2 90.47 to 469.9 Yes *** 0.0001 
  D32N vs. T41N 181.8 -7.879 to 371.6 No ns 0.0765 
  D32N vs. T41P 106 -83.73 to 295.7 No ns 0.8957 
  D32N vs. E14 280.7 116.4 to 445 Yes **** <0.0001 
  D32G vs. S33Y 229.6 39.89 to 419.3 Yes ** 0.0044 
  D32G vs. S33P 225.7 35.98 to 415.4 Yes ** 0.0056 
  D32G vs. S33C 247.5 57.83 to 437.3 Yes ** 0.0013 
  D32G vs. S33F 243 53.28 to 432.7 Yes ** 0.0018 
  D32G vs. S33L 300.6 110.9 to 490.3 Yes **** <0.0001 
  D32G vs. G34V 141 -48.72 to 330.7 No ns 0.441 
  D32G vs. G34E 178.8 -10.91 to 368.5 No ns 0.0895 
  D32G vs. G34R 124.6 -65.07 to 314.4 No ns 0.6786 
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  D32G vs. S37C -184.4 -396.5 to 27.68 No ns 0.1746 
  D32G vs. S37F -106.8 -296.5 to 82.91 No ns 0.8888 
  D32G vs. S37A -106.3 -318.4 to 105.8 No ns 0.9625 
  D32G vs. S37Y -325.7 -537.8 to -113.6 Yes **** <0.0001 
  D32G vs. S45Y 342.8 153 to 532.5 Yes **** <0.0001 
  D32G vs. S45P 318.9 129.2 to 508.6 Yes **** <0.0001 
  D32G vs. S45F 280.3 90.62 to 470.1 Yes *** 0.0001 
  D32G vs. S45C 368.9 156.8 to 581 Yes **** <0.0001 
  D32G vs. T41I -310.7 -500.4 to -121 Yes **** <0.0001 
  D32G vs. T41A -173.6 -363.3 to 16.1 No ns 0.1161 
  D32G vs. T41S 389.8 200.1 to 579.5 Yes **** <0.0001 
  D32G vs. T41N 291.4 101.7 to 481.1 Yes **** <0.0001 
  D32G vs. T41P 215.6 25.85 to 405.3 Yes * 0.0108 
  D32G vs. E14 390.3 226 to 554.6 Yes **** <0.0001 
  S33Y vs. S33P -3.906 -193.6 to 185.8 No ns >0.9999 
  S33Y vs. S33C 17.94 -171.8 to 207.7 No ns >0.9999 
  S33Y vs. S33F 13.39 -176.3 to 203.1 No ns >0.9999 
  S33Y vs. S33L 71.01 -118.7 to 260.7 No ns 0.9991 
  S33Y vs. G34V -88.61 -278.3 to 101.1 No ns 0.9828 
  S33Y vs. G34E -50.8 -240.5 to 138.9 No ns >0.9999 
  S33Y vs. G34R -105 -294.7 to 84.76 No ns 0.904 
  S33Y vs. S37C -414 -626.2 to -201.9 Yes **** <0.0001 
  S33Y vs. S37F -336.4 -526.1 to -146.7 Yes **** <0.0001 
  S33Y vs. S37A -335.9 -548 to -123.8 Yes **** <0.0001 
  S33Y vs. S37Y -555.3 -767.4 to -343.2 Yes **** <0.0001 
  S33Y vs. S45Y 113.2 -76.56 to 302.9 No ns 0.8261 
  S33Y vs. S45P 89.29 -100.4 to 279 No ns 0.9812 
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  S33Y vs. S45F 50.73 -139 to 240.5 No ns >0.9999 
  S33Y vs. S45C 139.3 -72.85 to 351.4 No ns 0.6797 
  S33Y vs. T41I -540.3 -730 to -350.6 Yes **** <0.0001 
  S33Y vs. T41A -403.2 -592.9 to -213.5 Yes **** <0.0001 
  S33Y vs. T41S 160.2 -29.56 to 349.9 No ns 0.2155 
  S33Y vs. T41N 61.81 -127.9 to 251.5 No ns >0.9999 
  S33Y vs. T41P -14.04 -203.8 to 175.7 No ns >0.9999 
  S33Y vs. E14 160.7 -3.625 to 325 No ns 0.0628 
  S33P vs. S33C 21.84 -167.9 to 211.6 No ns >0.9999 
  S33P vs. S33F 17.3 -172.4 to 207 No ns >0.9999 
  S33P vs. S33L 74.92 -114.8 to 264.6 No ns 0.9981 
  S33P vs. G34V -84.71 -274.4 to 105 No ns 0.99 
  S33P vs. G34E -46.89 -236.6 to 142.8 No ns >0.9999 
  S33P vs. G34R -101.1 -290.8 to 88.66 No ns 0.9316 
  S33P vs. S37C -410.1 -622.3 to -198 Yes **** <0.0001 
  S33P vs. S37F -332.5 -522.2 to -142.8 Yes **** <0.0001 
  S33P vs. S37A -332 -544.1 to -119.9 Yes **** <0.0001 
  S33P vs. S37Y -551.4 -763.5 to -339.3 Yes **** <0.0001 
  S33P vs. S45Y 117.1 -72.65 to 306.8 No ns 0.7801 
  S33P vs. S45P 93.2 -96.52 to 282.9 No ns 0.9696 
  S33P vs. S45F 54.64 -135.1 to 244.4 No ns >0.9999 
  S33P vs. S45C 143.2 -68.94 to 355.3 No ns 0.6293 
  S33P vs. T41I -536.4 -726.1 to -346.7 Yes **** <0.0001 
  S33P vs. T41A -399.3 -589 to -209.6 Yes **** <0.0001 
  S33P vs. T41S 164.1 -25.65 to 353.8 No ns 0.1817 
  S33P vs. T41N 65.72 -124 to 255.4 No ns 0.9998 
  S33P vs. T41P -10.13 -199.9 to 179.6 No ns >0.9999 
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  S33P vs. E14 164.6 0.2815 to 328.9 Yes * 0.0491 
  S33C vs. S33F -4.546 -194.3 to 185.2 No ns >0.9999 
  S33C vs. S33L 53.08 -136.6 to 242.8 No ns >0.9999 
  S33C vs. G34V -106.5 -296.3 to 83.17 No ns 0.891 
  S33C vs. G34E -68.73 -258.5 to 121 No ns 0.9995 
  S33C vs. G34R -122.9 -312.6 to 66.82 No ns 0.7031 
  S33C vs. S37C -432 -644.1 to -219.9 Yes **** <0.0001 
  S33C vs. S37F -354.4 -544.1 to -164.6 Yes **** <0.0001 
  S33C vs. S37A -353.8 -566 to -141.7 Yes **** <0.0001 
  S33C vs. S37Y -573.3 -785.4 to -361.2 Yes **** <0.0001 
  S33C vs. S45Y 95.22 -94.5 to 284.9 No ns 0.9619 
  S33C vs. S45P 71.36 -118.4 to 261.1 No ns 0.9991 
  S33C vs. S45F 32.79 -156.9 to 222.5 No ns >0.9999 
  S33C vs. S45C 121.3 -90.78 to 333.4 No ns 0.8735 
  S33C vs. T41I -558.3 -748 to -368.5 Yes **** <0.0001 
  S33C vs. T41A -421.2 -610.9 to -231.4 Yes **** <0.0001 
  S33C vs. T41S 142.2 -47.49 to 331.9 No ns 0.424 
  S33C vs. T41N 43.88 -145.8 to 233.6 No ns >0.9999 
  S33C vs. T41P -31.98 -221.7 to 157.7 No ns >0.9999 
  S33C vs. E14 142.7 -21.56 to 307 No ns 0.1757 
  S33F vs. S33L 57.62 -132.1 to 247.3 No ns >0.9999 
  S33F vs. G34V -102 -291.7 to 87.72 No ns 0.9255 
  S33F vs. G34E -64.19 -253.9 to 125.5 No ns 0.9998 
  S33F vs. G34R -118.4 -308.1 to 71.36 No ns 0.7638 
  S33F vs. S37C -427.4 -639.5 to -215.3 Yes **** <0.0001 
  S33F vs. S37F -349.8 -539.5 to -160.1 Yes **** <0.0001 
  S33F vs. S37A -349.3 -561.4 to -137.2 Yes **** <0.0001 
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  S33F vs. S37Y -568.7 -780.8 to -356.6 Yes **** <0.0001 
  S33F vs. S45Y 99.77 -89.95 to 289.5 No ns 0.9394 
  S33F vs. S45P 75.9 -113.8 to 265.6 No ns 0.9977 
  S33F vs. S45F 37.34 -152.4 to 227.1 No ns >0.9999 
  S33F vs. S45C 125.9 -86.24 to 338 No ns 0.8324 
  S33F vs. T41I -553.7 -743.4 to -364 Yes **** <0.0001 
  S33F vs. T41A -416.6 -606.3 to -226.9 Yes **** <0.0001 
  S33F vs. T41S 146.8 -42.95 to 336.5 No ns 0.3635 
  S33F vs. T41N 48.42 -141.3 to 238.1 No ns >0.9999 
  S33F vs. T41P -27.43 -217.1 to 162.3 No ns >0.9999 
  S33F vs. E14 147.3 -17.02 to 311.6 No ns 0.1378 
  S33L vs. G34V -159.6 -349.3 to 30.1 No ns 0.2205 
  S33L vs. G34E -121.8 -311.5 to 67.91 No ns 0.7181 
  S33L vs. G34R -176 -365.7 to 13.74 No ns 0.1033 
  S33L vs. S37C -485.1 -697.2 to -272.9 Yes **** <0.0001 
  S33L vs. S37F -407.4 -597.1 to -217.7 Yes **** <0.0001 
  S33L vs. S37A -406.9 -619 to -194.8 Yes **** <0.0001 
  S33L vs. S37Y -626.3 -838.5 to -414.2 Yes **** <0.0001 
  S33L vs. S45Y 42.15 -147.6 to 231.9 No ns >0.9999 
  S33L vs. S45P 18.28 -171.4 to 208 No ns >0.9999 
  S33L vs. S45F -20.28 -210 to 169.4 No ns >0.9999 
  S33L vs. S45C 68.25 -143.9 to 280.4 No ns >0.9999 
  S33L vs. T41I -611.3 -801 to -421.6 Yes **** <0.0001 
  S33L vs. T41A -474.2 -664 to -284.5 Yes **** <0.0001 
  S33L vs. T41S 89.15 -100.6 to 278.9 No ns 0.9815 
  S33L vs. T41N -9.2 -198.9 to 180.5 No ns >0.9999 
  S33L vs. T41P -85.05 -274.8 to 104.7 No ns 0.9895 
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  S33L vs. E14 89.66 -74.64 to 254 No ns 0.9148 
  G34V vs. G34E 37.82 -151.9 to 227.5 No ns >0.9999 
  G34V vs. G34R -16.35 -206.1 to 173.4 No ns >0.9999 
  G34V vs. S37C -325.4 -537.5 to -113.3 Yes **** <0.0001 
  G34V vs. S37F -247.8 -437.5 to -58.08 Yes ** 0.0013 
  G34V vs. S37A -247.3 -459.4 to -35.19 Yes ** 0.0075 
  G34V vs. S37Y -466.7 -678.8 to -254.6 Yes **** <0.0001 
  G34V vs. S45Y 201.8 12.05 to 391.5 Yes * 0.0251 
  G34V vs. S45P 177.9 -11.81 to 367.6 No ns 0.0937 
  G34V vs. S45F 139.3 -50.38 to 329.1 No ns 0.4643 
  G34V vs. S45C 227.9 15.77 to 440 Yes * 0.0222 
  G34V vs. T41I -451.7 -641.4 to -262 Yes **** <0.0001 
  G34V vs. T41A -314.6 -504.3 to -124.9 Yes **** <0.0001 
  G34V vs. T41S 248.8 59.06 to 438.5 Yes ** 0.0012 
  G34V vs. T41N 150.4 -39.29 to 340.1 No ns 0.3184 
  G34V vs. T41P 74.57 -115.1 to 264.3 No ns 0.9982 
  G34V vs. E14 249.3 84.99 to 413.6 Yes **** <0.0001 
  G34E vs. G34R -54.17 -243.9 to 135.6 No ns >0.9999 
  G34E vs. S37C -363.2 -575.4 to -151.1 Yes **** <0.0001 
  G34E vs. S37F -285.6 -475.3 to -95.9 Yes **** <0.0001 
  G34E vs. S37A -285.1 -497.2 to -73 Yes *** 0.0008 
  G34E vs. S37Y -504.5 -716.6 to -292.4 Yes **** <0.0001 
  G34E vs. S45Y 164 -25.76 to 353.7 No ns 0.1826 
  G34E vs. S45P 140.1 -49.63 to 329.8 No ns 0.4537 
  G34E vs. S45F 101.5 -88.19 to 291.2 No ns 0.9286 
  G34E vs. S45C 190.1 -22.05 to 402.2 No ns 0.1383 
  G34E vs. T41I -489.5 -679.2 to -299.8 Yes **** <0.0001 
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  G34E vs. T41A -352.4 -542.1 to -162.7 Yes **** <0.0001 
  G34E vs. T41S 211 21.24 to 400.7 Yes * 0.0144 
  G34E vs. T41N 112.6 -77.11 to 302.3 No ns 0.8321 
  G34E vs. T41P 36.76 -153 to 226.5 No ns >0.9999 
  G34E vs. E14 211.5 47.17 to 375.8 Yes ** 0.0016 
  G34R vs. S37C -309.1 -521.2 to -96.97 Yes *** 0.0002 
  G34R vs. S37F -231.5 -421.2 to -41.73 Yes ** 0.0039 
  G34R vs. S37A -230.9 -443.1 to -18.83 Yes * 0.0188 
  G34R vs. S37Y -450.4 -662.5 to -238.3 Yes **** <0.0001 
  G34R vs. S45Y 218.1 28.4 to 407.8 Yes ** 0.0092 
  G34R vs. S45P 194.3 4.537 to 384 Yes * 0.0388 
  G34R vs. S45F 155.7 -34.02 to 345.4 No ns 0.2594 
  G34R vs. S45C 244.2 32.12 to 456.3 Yes ** 0.009 
  G34R vs. T41I -435.4 -625.1 to -245.6 Yes **** <0.0001 
  G34R vs. T41A -298.3 -488 to -108.5 Yes **** <0.0001 
  G34R vs. T41S 265.1 75.41 to 454.8 Yes *** 0.0004 
  G34R vs. T41N 166.8 -22.94 to 356.5 No ns 0.1607 
  G34R vs. T41P 90.93 -98.79 to 280.6 No ns 0.9769 
  G34R vs. E14 265.6 101.3 to 429.9 Yes **** <0.0001 
  S37C vs. S37F 77.63 -134.5 to 289.7 No ns 0.9994 
  S37C vs. S37A 78.13 -154.2 to 310.5 No ns 0.9998 
  S37C vs. S37Y -141.3 -373.6 to 91.07 No ns 0.8008 
  S37C vs. S45Y 527.2 315.1 to 739.3 Yes **** <0.0001 
  S37C vs. S45P 503.3 291.2 to 715.4 Yes **** <0.0001 
  S37C vs. S45F 464.8 252.7 to 676.9 Yes **** <0.0001 
  S37C vs. S45C 553.3 321 to 785.7 Yes **** <0.0001 
  S37C vs. T41I -126.3 -338.4 to 85.84 No ns 0.8285 
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  S37C vs. T41A 10.82 -201.3 to 222.9 No ns >0.9999 
  S37C vs. T41S 574.2 362.1 to 786.3 Yes **** <0.0001 
  S37C vs. T41N 475.9 263.7 to 688 Yes **** <0.0001 
  S37C vs. T41P 400 187.9 to 612.1 Yes **** <0.0001 
  S37C vs. E14 574.7 385 to 764.4 Yes **** <0.0001 
  S37F vs. S37A 0.5038 -211.6 to 212.6 No ns >0.9999 
  S37F vs. S37Y -218.9 -431 to -6.804 Yes * 0.0355 
  S37F vs. S45Y 449.6 259.9 to 639.3 Yes **** <0.0001 
  S37F vs. S45P 425.7 236 to 615.4 Yes **** <0.0001 
  S37F vs. S45F 387.1 197.4 to 576.9 Yes **** <0.0001 
  S37F vs. S45C 475.7 263.6 to 687.8 Yes **** <0.0001 
  S37F vs. T41I -203.9 -393.6 to -14.18 Yes * 0.0221 
  S37F vs. T41A -66.81 -256.5 to 122.9 No ns 0.9997 
  S37F vs. T41S 496.6 306.9 to 686.3 Yes **** <0.0001 
  S37F vs. T41N 398.2 208.5 to 587.9 Yes **** <0.0001 
  S37F vs. T41P 322.4 132.7 to 512.1 Yes **** <0.0001 
  S37F vs. E14 497.1 332.8 to 661.4 Yes **** <0.0001 
  S37A vs. S37Y -219.4 -451.8 to 12.94 No ns 0.0879 
  S37A vs. S45Y 449.1 237 to 661.2 Yes **** <0.0001 
  S37A vs. S45P 425.2 213.1 to 637.3 Yes **** <0.0001 
  S37A vs. S45F 386.6 174.5 to 598.8 Yes **** <0.0001 
  S37A vs. S45C 475.2 242.8 to 707.5 Yes **** <0.0001 
  S37A vs. T41I -204.4 -416.5 to 7.706 No ns 0.0726 
  S37A vs. T41A -67.32 -279.4 to 144.8 No ns >0.9999 
  S37A vs. T41S 496.1 284 to 708.2 Yes **** <0.0001 
  S37A vs. T41N 397.7 185.6 to 609.8 Yes **** <0.0001 
  S37A vs. T41P 321.9 109.8 to 534 Yes **** <0.0001 
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  S37A vs. E14 496.6 306.9 to 686.3 Yes **** <0.0001 
  S37Y vs. S45Y 668.5 456.4 to 880.6 Yes **** <0.0001 
  S37Y vs. S45P 644.6 432.5 to 856.7 Yes **** <0.0001 
  S37Y vs. S45F 606.1 393.9 to 818.2 Yes **** <0.0001 
  S37Y vs. S45C 694.6 462.2 to 927 Yes **** <0.0001 
  S37Y vs. T41I 15.01 -197.1 to 227.1 No ns >0.9999 
  S37Y vs. T41A 152.1 -60.01 to 364.2 No ns 0.5118 
  S37Y vs. T41S 715.5 503.4 to 927.6 Yes **** <0.0001 
  S37Y vs. T41N 617.1 405 to 829.3 Yes **** <0.0001 
  S37Y vs. T41P 541.3 329.2 to 753.4 Yes **** <0.0001 
  S37Y vs. E14 716 526.3 to 905.7 Yes **** <0.0001 
  S45Y vs. S45P -23.87 -213.6 to 165.9 No ns >0.9999 
  S45Y vs. S45F -62.43 -252.1 to 127.3 No ns 0.9999 
  S45Y vs. S45C 26.11 -186 to 238.2 No ns >0.9999 
  S45Y vs. T41I -653.5 -843.2 to -463.8 Yes **** <0.0001 
  S45Y vs. T41A -516.4 -706.1 to -326.7 Yes **** <0.0001 
  S45Y vs. T41S 47 -142.7 to 236.7 No ns >0.9999 
  S45Y vs. T41N -51.35 -241.1 to 138.4 No ns >0.9999 
  S45Y vs. T41P -127.2 -316.9 to 62.52 No ns 0.6418 
  S45Y vs. E14 47.52 -116.8 to 211.8 No ns >0.9999 
  S45P vs. S45F -38.56 -228.3 to 151.2 No ns >0.9999 
  S45P vs. S45C 49.97 -162.1 to 262.1 No ns >0.9999 
  S45P vs. T41I -629.6 -819.3 to -439.9 Yes **** <0.0001 
  S45P vs. T41A -492.5 -682.2 to -302.8 Yes **** <0.0001 
  S45P vs. T41S 70.87 -118.8 to 260.6 No ns 0.9992 
  S45P vs. T41N -27.48 -217.2 to 162.2 No ns >0.9999 
  S45P vs. T41P -103.3 -293.1 to 86.39 No ns 0.9163 
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  S45P vs. E14 71.38 -92.92 to 235.7 No ns 0.9929 
  S45F vs. S45C 88.54 -123.6 to 300.6 No ns 0.9958 
  S45F vs. T41I -591 -780.8 to -401.3 Yes **** <0.0001 
  S45F vs. T41A -454 -643.7 to -264.2 Yes **** <0.0001 
  S45F vs. T41S 109.4 -80.29 to 299.2 No ns 0.8648 
  S45F vs. T41N 11.08 -178.6 to 200.8 No ns >0.9999 
  S45F vs. T41P -64.77 -254.5 to 125 No ns 0.9998 
  S45F vs. E14 109.9 -54.36 to 274.2 No ns 0.6454 
  S45C vs. T41I -679.6 -891.7 to -467.5 Yes **** <0.0001 
  S45C vs. T41A -542.5 -754.6 to -330.4 Yes **** <0.0001 
  S45C vs. T41S 20.9 -191.2 to 233 No ns >0.9999 
  S45C vs. T41N -77.45 -289.6 to 134.7 No ns 0.9994 
  S45C vs. T41P -153.3 -365.4 to 58.81 No ns 0.4962 
  S45C vs. E14 21.41 -168.3 to 211.1 No ns >0.9999 
  T41I vs. T41A 137.1 -52.63 to 326.8 No ns 0.4966 
  T41I vs. T41S 700.5 510.8 to 890.2 Yes **** <0.0001 
  T41I vs. T41N 602.1 412.4 to 791.8 Yes **** <0.0001 
  T41I vs. T41P 526.3 336.6 to 716 Yes **** <0.0001 
  T41I vs. E14 701 536.7 to 865.3 Yes **** <0.0001 
  T41A vs. T41S 563.4 373.7 to 753.1 Yes **** <0.0001 
  T41A vs. T41N 465 275.3 to 654.8 Yes **** <0.0001 
  T41A vs. T41P 389.2 199.5 to 578.9 Yes **** <0.0001 
  T41A vs. E14 563.9 399.6 to 728.2 Yes **** <0.0001 
  T41S vs. T41N -98.35 -288.1 to 91.37 No ns 0.9472 
  T41S vs. T41P -174.2 -363.9 to 15.52 No ns 0.1128 
  T41S vs. E14 0.5144 -163.8 to 164.8 No ns >0.9999 
  T41N vs. T41P -75.85 -265.6 to 113.9 No ns 0.9977 
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  T41N vs. E14 98.86 -65.44 to 263.2 No ns 0.8148 
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